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Abstract 
 
Urinary tract infections (UTIs) belong to the most common bacterial infections worldwide. 
Uropathogenic Escherichia coli (UPEC) are held accountable for majority of the cases. 
Millions of people suffer from UTI each year, with the highest incidence rate reported among 
women. Moreover, woman once affected will most likely experience a recurrent infection. 
High prevalence and recurrence of UTI lead to considerable medical costs. The current 
treatment generally involves antibiotics. However, choosing a proper antibiotic therapy 
becomes more difficult as resistant strains rapidly proliferate. Therefore, the need to develop 
alternative, non-antibiotic strategies is more pressing than ever. 
UPEC express filamentous organelles called type 1 pili (fimbriae), which protrude from the 
bacterial surface and mediate the adhesion to the bladder-epithelial cells. The mannose-
specific adhesin FimH is located on the distal end of the pili. It contains the mannose-specific 
carbohydrate recognition domain (CRD), which binds to highly mannosylated uroplakin 1a 
(UP1a) expressed by urothelial cells leading to the infection. The compounds capable of 
blocking the interaction between FimH and surface-exposed glycans pave the way for a novel 
anti-adhesive strategy to treat and prevent UTI. 
The first part of the thesis addresses the problem of poor oral bioavailability arising from 
high polarity of the FimH antagonists. The strategy involves a prodrug approach, in which 
lipophilic esters are introduced to the parent compounds either on the aglycone’s carboxylic 
acid or the mannose moiety. The absorption potential as well as propensity to hydrolysis by 
esterases of liver or plasma was evaluated. The second part of the thesis emphasizes the 
optimization of the pharmacodynamic properties of FimH antagonists. In the first approach, 
the mannose moiety was modified in order to explore a cavity located at the entrance to 
binding pocket. The obtained antagonists were evaluated in competitive binding assay and by 
isothermal titration calorimetry (ITC) to reveal their thermodynamic binding profile. The 
second approach involved an elongation of the aglycone to allow additional interactions with 
the guanidinium side chain of Arg98. For the evaluation of these antagonists, competitive 
binding assays with the wild type FimH and the R98A mutant was established. 
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1. Introduction 
 
1.1 Urinary tract infection 
 
Urinary tract infections (UTIs) belong to the most widespread infectious diseases, affecting 
millions of people every year.1,2 The high incidence rate results in substantial associated costs 
estimated for US$ 3.5 billion every year in the United States alone.3 The highest morbidity is 
observed among women with 40-50% risk of the onset of the disease at one point in their 
life.4,5 Approximately 25% of the afflicted women will experience a second UTI episode 
within six months after the prior infection.6 However, the elderly, infants and patients with 
diabetes, catheter or spinal cord injuries are even more prone to UTI.7 When UTI is confined 
to the bladder it is referred to as cystitis, whereas an infection located in the kidneys is called 
pyelonephritis.8 UTIs can be further differentiated into uncomplicated and complicated. 
Uncomplicated UTIs involve individuals, who are otherwise healthy with no structural or 
functional abnormalities. However, when urinary tract or host defense is compromised (e.g. 
urinary obstruction, renal transplantation, immunosuppression, catheters) UTIs are classified 
as complicated.9 Symptoms elicited by uncomplicated lower urinary tract infections include 
dysuria, bacteriuria, frequent urination, pyuria and haematuria.3,10 The first-line treatment 
involves 3-to-7-day regimen with nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin 
or the β-lactam pivmecillinam. Fluoroquinolones (e.g. ciprofloxacin, levofloxacin) and 
additional β-lactams (e.g. amoxicillin–clavulanate, cefdinir) belong to the second-line 
treatment.11 However, the choice of the proper treatment becomes increasingly complicated, 
due to antimicrobial resistance.12 It is believed that trimethoprim-sulfamethoxazole may no 
longer be recommended for the treatment of acute uncomplicated cystitis.13 Therefore, novel 
non-antibiotic approaches to treat UTI are urgently needed.  
 
1.1.1 The etiology and the infection cycle 
 
The etiology of UTIs is attributed to uropathogenic Escherichia coli (UPEC) in 80-85% of 
the cases. The second most prevalent uropathogen is Staphylococcus saprophyticus, 
accounting for 5-15% of the diagnosed UTIs. Other less frequent bacterial pathogens include 
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Klebsiella pneumoniae and Proteus mirabilis.10,14,15 The colonization of the host by UPEC 
follows a well-described infection cycle (Figure 1.1).16-19  
 
Figure 1.1. Infection cycle of uropathogenic Escherichia coli (UPEC) in the bladder (adopted from ref. 28). In 
the first step, UPEC bind to the superficial cells of the bladder. Bacteria thereupon invade the cells and rapidly 
replicate in the cytosol to form protective biofilm-like intracellular bacterial communities (IBCs). Mature 
bacteria then escape from the cell to the bladder lumen and spread to another superficial or underlying cells. 
 
The whole process begins with the bacterial adhesion to bladder-epithelial cells (urothelial 
cells), which prevents UPEC from being washed out by micturition. The adhesion results 
from the interaction of the mannose-specific adhesin FimH located at the tip of bacterial type 
1 pili with highly-mannosylated glycoprotein uroplakin 1a (UP1a) expressed on urothelial 
cells.20,21 Attached to the cell surface, UPEC can enter the superficial umbrella cells and start 
to replicate in the cytosol.17,22 This leads to the formation of biofilm-like intracellular 
bacterial communities (IBCs), which protect UPEC from the host immune system or 
exposure to antibiotics.23,24 After IBCs reach a mature state, bacteria is released to the bladder 
in order to reinitiate the infection cycle.18 Moreover, some of these bacteria re-emerge in the 
form of filamentous structures, allowing them to evade neutrophil phagocytosis.25 In response 
to the infection, the superficial cells of the bladder are exfoliated.26 However, that results in 
spreading of UPEC in the environment, since the bacteria is able to escape from dying cells. 
Moreover, exfoliation exposes underlying layer of immature cells, which then can also be 
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infected.18,26 In these cells, bacteria form quiescent intracellular reservoirs (QIRs), which are 
insensitive to antibiotics and can persist for weeks. These reservoirs are therefore the source 
of the pathogen initiating recurrent infections.27,28 
 
1.1.2 Structure and biogenesis of type 1 pilus (fimbria) 
 
Type 1 pili (fimbriae) are expressed by 
essentially all UPEC isolates and a large 
number of other bacteria of 
Enterobacteriaceae family.29,30 E. coli express 
between 100 and 400 of these filamentous 
organelles per each cell.31 The  pilus rod is the 
proximal part of the fimbria. It is 7 nm-wide 
helical structure composed of 500 to 3000 
copies of protein FimA, which is anchored to 
the bacterial outer membrane by means of the 
usher FimD.32,33 The tip fibrillum is the most 
distal 3 nm-wide fragment containing two 
adaptor subunits FimF and FimG followed by a 
single copy of mannose-binding adhesin FimH. 
Upon assembly, the type 1 pili can protrude up 
to 3 µm from the surface of the bacterium.34-36 
 
The biogenesis of the type 1 pili begins in the periplasm via the chaperone/usher pathway 
(Figure 1.2).37-39 It requires the assistance of proteins FimC and FimD. The first one serves as 
a chaperone, whereas the latter forms a channel in the bacterial outer membrane and 
translocates the subunits out of the cell. All fimbrial subunits represent an incomplete 
immunoglobuline (Ig)-like fold devoid of a C-terminal β-strand. The chaperone FimC donates 
the missing β-strand to the subunits in a process called donor-strand complementation 
(DSC).40-42 The chaperone-subunit complex diffuses to FimD, where FimC is replaced by 
amino-terminal extension of the subunit already embedded in a growing pilus. This 
mechanism is known as donor-strand exchange (DSE).43 It was proposed that the correct 
order of the subunits during the assembly of the pili is governed by periplasmic 
 
 
Figure 1.2. Schematic representation of type 1 
pilus biogenesis via chaperone-usher pathway 
(adopted from ref. 42). The periplasmic 
chaperone FimC transports the subunits to the 
FimD usher, which assembles and translocates 
them through the outer membrane. 
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concentrations of a given subunit, affinity of different chaperone-subunit complexes for 
FimD and reaction kinetics of DSE different for each subunit.44,45 Apart from the highest 
affinity of FimC-FimH for the usher, it is also the only complex capable of transforming 
FimD into highly efficient assembly catalyst by inducing its proper conformation.46 
 
1.2 The uropathogenic virulence factor FimH  
 
The adhesin FimH is located at the tip of type 1 pili. It consists of the N-terminal lectin 
domain containing residues 1-156 and the C-terminal pilin domain composed of residues 
160-279, both linked together by a short peptide chain. The lectin domain is folded into a 
jelly roll-like, elongated β barrel, which contains the mannose-binding carbohydrate 
recognition domain (CRD) on its distal end. Similar to other subunits, the pilin domain has 
Ig-like topology with a missing C-terminal β-strand. It is connected to FimG, which donates 
the missing strand thereby stabilizing the structure of the pilin domain.35,40,47 
 
In 1999, the first crystal structure of the chaperone-adhesin complex co-crystallized with 
cyclohexylbutanoyl-N-hydroxyethyl-D-glucamide (C-HEGA) was reported.40 Over the course 
of the following years, the X-ray structures were determined only for the purified lectin 
domain or FimH in the complex with FimC.35,40,48,49 In all of these examples, the lectin 
domain adopted a narrow, elongated high-affinity state. In 2010, Le Trong and co-workers 
solved the first crystal structure of FimH in wide and more compressed low-affinity state.47 
The published research showed also the involvement of the pilin domain in switching 
between high- and low-affinity state.  
 
1.2.1 Allosteric catch bond in FimH adhesion 
 
Adhesive molecular interactions are constantly exposed to a shear stress due cytoskeletal 
contraction or the flow of the biological fluids. Most interactions become weaker and short-
lived under tensile force. This type of interaction is referred to as a slip bond. By contrast, an 
interaction enhanced by mechanical force is called a catch bond (Figure 1.3).50,51 Although 
less common, catch bonds are involved in selectin-mediated adhesion of leukocytes,52,53 
interaction of  actin with myosin54 and FimH-mediated bacterial adhesion.55-57  
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Figure 1.3. Schematic plots illustrating the difference between slip and catch bonds. The catch bond is the 
weakest and the slip bond is the strongest when tensile force is weak. Upon the increase of tensile force, the slip 
bond loses its strength, while the catch bond becomes stronger until the point where it is overpowered by force. 
 
Over a decade ago, Thomas and co-workers provided the first experimental data supporting a 
catch bond mechanism for FimH adhesion.55 Under static conditions, the red blood cells did 
not agglutinate despite the presence of E. coli. By contrast, the same cells subjected to 
rocking formed tight aggregates.55 The following studies reporting on shear force-induced 
differences in cell adhesion and the bond strength between FimH and mannose further 
supported the involvement of the catch bond mechanism in the FimH adhesion.58,59 It was 
also proposed that FimH could adopt two distinct conformations, a high- and a low-affinity 
state conformation.55 An interdomain interaction was shown to regulate the force-induced 
change between these two conformations by an allosteric mechanism.55,60,61  
 
The crystal structure of the full-length FimH protein in the low-affinity state obtained a few 
years later provided a structural basis for a force regulated conformational change (Figure 
1.4).47 When compared to the high-affinity conformation,48 the adhesin in the low-affinity 
state has a wider and more compressed lectin domain leading to a looser binding site. 
Moreover, the pilin domain interacting with the lectin domain forces a large β sheet to twist 
and thereby opens the binding pocket. This allosteric auto-inhibition can be abolished by 
force-induced separation of the two domains. This results in untwisting of the β sheet and 
closing the binding pocket around the ligand. Since the conformational change of the β sheet 
resembles the process of sliding the page in the book before turning it, this process is referred 
to as a “page-turning” mechanism (Figure 1.5).47 
Introduction 
 
6 
 
 
 
Figure 1.4. (A) The crystal structure of the tip fibrillum in the complex with the chaperone FimC (PDB ID: 
3JWN). (B) A compressed and wide lectin FimH in the low-affinity state. (C) The crystal structure of the 
purified lectin domain in the high-affinity state with n-butyl -D-mannoside bound to the FimH-CRD (PDB ID: 
1UWF). The structure is longer than the lectin domain in the low-affinity state by 11 Å and contains the binding 
pocket tightly clamped around the ligand (adopted from ref. 47). 
 
The shear-force enhanced bacterial adhesion has several advantages. Since soluble 
oligosaccharides or natural defense proteins (e.g. Tamm-Horsfall glycoprotein) cannot exert 
any force on the adhesin, they are worse ligands for FimH than surface-exposed glycans.62 
Moreover, short-lived interactions lead to weak rolling adhesion responsible for rapid 
colonization of the surface, whereas a subsequently adopted high-affinity conformation 
allows to establish tight microcolonies.63 Furthermore, a recently proposed kinetic-selection 
model of binding suggests that a higher association rate for the low-affinity state facilitates an 
initiation of binding at high flow.64 By contrast, a slower dissociation rate for the high-
affinity state induced upon binding prevents the detachment of the adhesin. This combination 
of association/dissociation rates for different conformations allows bacteria to reach higher 
effective affinity than the one achieved by each separate state.64 
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Figure 1.5. The illustration of a “page-turning” mechanism (adopted from ref. 47). (A) The bottom left corner 
of the β sheet is pushed upward opening the FimH-CRD in the low-affinity state. (B) The same corner is pushed 
downward tightening the FimH-CRD in the high-affinity state. 
 
1.2.2 The carbohydrate recognition domain (CRD) 
 
The first crystal structure of FimH was 
very important for understanding the 
assembly mechanism, however it did not 
reveal the binding mode of natural ligands 
to FimH.40 Few years later, Hung and co-
workers resolved the crystal structure of the 
FimC-FimH complex co-crystallized with 
-D-mannose providing an invaluable 
insight into the binding mode of a 
physiologically important ligand (PDB ID: 
1KLF).35 The carbohydrate recognition 
domain is a deep and negatively charged pocket, which envelops the mannose exposing only 
the anomeric hydroxyl group of the sugar. The other hydroxyl groups interact with Phe1, 
Asn46, Asp47, Asp54, Gln133, Asn135 and Asp140 forming ten direct hydrogen bonds and 
indirect hydrogen bonds via the water molecule located in the binding site (Figure 1.6).35 The 
entrance to the pocket forms a hydrophobic rim composed of Tyr48, Ile52 and Tyr137, also 
known as the tyrosine gate. Bouckaert et al. further explored hydrophobic interactions 
between aliphatic aglycone and the tyrosine gate showing the significance of these three 
 
 
Figure 1.6. The complex hydrogen bond network 
between the FimH-CRD and -D-mannose (adopted 
from ref. 35). 
 
Introduction 
 
8 
 
amino acids for binding.48 The crystal structures obtained within the next few years enabled a 
rational design of highly potent monovalent FimH antagonists.49,65-71 
 
1.3 FimH antagonists 
 
An emerging antimicrobial resistance in UPEC poses a serious threat to patients. Moreover, it 
accounts for healthcare expenditure reaching billions of dollars each year.3,12,72 Therefore, 
different treatment strategies for UTI are urgently needed. A molecule capable of preventing 
the bacterial adhesion would enable the clearance of the pathogen by the bulk flow of urine. 
Since FimH antagonists do not kill the bacteria, the imposed selection pressure is markedly 
reduced resulting in a low risk of developing resistance.73,74 Moreover, these mannose-based 
molecules show high selectivity for FimH reducing the risk of side effects.75 Therefore, an 
anti-adhesive therapy based on FimH antagonists is a promising alternative to antibiotics.76-78 
Until now, this strategy has been tested in vivo in several studies.49,70,79-84 
 
1.3.1 Development of high-affinity ligands 
 
More than three decades ago, Sharon and co-workers reported several monosaccharides (i.e. 
D-mannose, methyl -D-mannoside, aryl -D-mannosides) and mannose-containing 
oligosaccharides capable of preventing the type 1 pili-mediated yeast agglutination in the 
presence of UPEC.85-89 Since activity of aromatic -D-mannoside 4 was superior to affinity of 
oligosaccharides,85,86 a library of aryl monosaccharides was prepared and tested.88 Based on 
the results, a model of a mannose-binding site surrounded by hydrophobic region was 
proposed without any crystal structure available at that time.89 Over the next years, various 
oligosaccharides were also investigated, which ultimately led to identification of a low 
nanomolar ligand oligomannose-3 (Kd = 20 nM).
88,90 The adhesin FimH was later co-
crystallized with oligomannose-3 to reveal the docking mode of this natural glycan ligand.49 
Nevertheless, the big size and high polarity of oligosaccharides preclude their oral 
administration.91,92 
 
In 2005, Bouckaert et al. made a serendipitous discovery of butyl -D-mannoside (2) co-
crystallized with FimH despite no deliberate addition of that ligand to the protein.48 It was 
postulated, that the Luria-Bertani medium used for growing bacteria during expression of 
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FimH had been the source of alkyl mannoside. The crystal structure revealed that the alkyl 
aglycone forms van der Waals contacts with the tyrosine gate. Further optimization of the 
alkyl aglycone resulted in identification of 30-fold more potent n-heptyl -D-mannoside (3, 
Kd = 5 nM).
48 
 
Over the following decade, a great effort has been made to understand and optimize the 
interactions with the tyrosine gate. Numerous studies focused on mannose-based ligands 
containing aromatic aglycones led to a discovery of low nanomolar FimH antagonists,69,71,93-
95 including biphenyl (e.g. 6-10),65,70,81-83 indolinylphenyl (e.g. 11)84 and squaric acid (e.g. 
5)96 derivatives (Figure 1.7).  
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Figure 1.7. The most prominent examples of FimH antagonists. The structures of each FimH antagonist contain 
a crucial for binding mannose moiety and an aliphatic (1-3) or an aromatic (4-11) aglycone. 
 
In order to explain the improved activity, several aryl mannosides were co-crystallized with 
the FimH protein. It was found that the tyrosine gate could adopt two distinct conformations 
ensuring an optimal π-π stacking with the aglycone. In the closed conformation, the aglycone 
interacts mainly with the side chain of Tyr48, which is rotated towards Tyr137 (Figure 1.8A) 
precluding the aglycone from inserting into the gate.65,67,69-71 By contrast, the open 
conformation comprises the side chains of both tyrosines oriented parallel to each other 
leaving more space for the ligand (Figure 1.8B).66 The π-π stacking with the electron-rich 
tyrosine gate could be further improved by the addition of electron-withdrawing groups to the 
terminal phenyl ring of biphenyl aglycones.65,70,81-83,93 It was also proposed that some of the 
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substituents in meta-position of the outer aromatic ring of the biphenyl aglycone contribute to 
binding by interacting with the nearby Arg98.65 To date, only few molecules were designed 
to reach and establish a salt bridge with Arg98.65,93 However, these antagonists did not show 
the expected improvement in affinity. Apart from modifications on the distal part of the 
aglycone, different hydrophobic substituents in ortho-position of the proximal phenyl ring 
proved to be also beneficial for binding.82,89,93 A prominent example of a highly active 
compound combining this substituent with optimal electron-withdrawing p-cyano group on 
the terminal phenyl ring ( 8) was recently published by Kleeb et al.70 
 
 
Figure 1.8. The crystal structure of 8 (PDB ID: 4CST) and 12 (PDB ID: 4AVK) bound to FimH-CRD with 
tyrosine gate adopting open (A) and close (B) conformation. 
 
Since the mannose moiety forms an optimal hydrogen bond network within the binding site, 
any replacement of the mannose moiety by other hexoses (e.g. fucose, glucose, galactose) or 
removal/substitution of hydroxyl groups weakened the interaction with the binding 
site.48,65,71,97 Moreover, recently published 1-C-branched mannose derivatives showed a 
reduced activity upon addition of bulky groups at anomeric carbon.98 It was proposed that the 
steric clash caused by these groups induced an unfavorable tilted binding mode. However, 
mannoside derivatives containing carbon or nitrogen in place of anomeric oxygen have been 
reported to reach nanomolar affinity.69,94 
 
Multivalent mannosides, which capitalize on the cluster effect improving affinity, form 
another class of nanomolar FimH antagonists.99 To date, numerous multivalent antagonists 
have been described in the literature.100-106 Furthermore, the first in vivo study evaluating 
heptavalent glycoconjugates of heptyl -D-mannoside tethered to β-cyclodextrin showed a 
preventive effect in UTI mouse model.106 Despite high affinity reached by the multivalent 
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ligands, these molecules are too big and too polar to be absorbed in the gastrointestinal tract 
and therefore have to be applied directly to the bladder.91,92 Hence, these antagonists do not 
have a therapeutic potential to treat UTI. 
 
1.3.2 Development of orally available anti-adhesives for the treatment of UTI 
 
The anti-adhesive therapy may require a daily intake of the drug for an extended period of 
time. Therefore, oral administration of FimH antagonists is the most suitable route of 
application. High bioavailability of FimH antagonists can be attained only with FimH 
antagonists exhibiting solubility, lipophilicity and permeability allowing efficient intestinal 
absorption.107,108 Moreover, the renal excretion should be the main route of elimination since 
the target, uropathogenic E. coli, is located in the bladder. Therefore, metabolic stability is a 
further required property.  
 
The main impediment precluding carbohydrate-based drugs from crossing the intestinal 
membrane is the intrinsically high polarity of the sugar moiety, conferred by many hydroxyl 
groups. Reducing polarity by removal of these groups or replacing them by lipophilic 
substituents is not a suitable strategy for FimH antagonists due to a loss of affinity.48,65,71,97 
The lipophilic aglycone can counterbalance high polarity of the sugar moiety, however in 
most of FimH antagonists, the aglycone comprises of lipophilic biphenyl decorated with 
additional polar groups (e.g. carboxylic acid).  
These issues were addressed with an ester prodrug approach.109 In general, prodrugs designed 
to enhance the intestinal absorption enclose lipophilic promoiety masking the polarity of the 
parent compound. Upon absorption, the promoiety is cleaved by hepatic or plasma-borne 
esterases to release the active principle.110 Several carbohydrate derivatives with lipophilic 
promoieties incorporated into the sugar core have been reported to show enhanced cellular 
uptake.111-117 By contrast, Klein et al. implemented the ester prodrug approach to mask polar 
group located on the aglycone ( 6, Figure 1.9).81 The methyl ester 6 was the first reported 
orally available FimH antagonist, which showed preventive effect in the UTI mouse model. 
Nevertheless, low solubility of 6 limits the application of this prodrug.  
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Figure 1.9. The concept of an ester prodrug approach implemented by Klein et al.81 The lipophilic methyl 
promoiety allows efficient intestinal absorption of 6. Upon hydrolysis of the methyl ester in the liver, the active 
principle 7 is excreted to the bladder, where it reaches the target. 
 
The next in vivo study of FimH antagonists included methyl amide-substituted biphenyl 
mannosides (e.g. 10).82 Although the invasion to the bladder was prevented upon an oral 
application of 10, a high oral dose of the antagonist was required. By contrast, Jiang et al. 
reported indolinylphenyl 11 capable of reducing bacterial load in the bladder by 3.7 log units 
after an intravenously injected dose of 1 mg/kg.84 However, the solubility of 11 is too low for 
the oral application. Recently, Kleeb et al. published a series of compounds with bioisosteric 
groups replacing carboxylic acid in antagonist 7.70 Apart from high affinity for FimH, the 
most prominent antagonist 8 showed an excellent PK profile in vivo. Moreover, it reduced the 
bacterial load in the bladder by 2.7 log units 3 h after infection in UTI mouse model. 
 
1.4 The aim of the thesis 
 
The first goal of this thesis was to optimize physicochemical and pharmacokinetic properties 
of lead FimH antagonists. The strategy involved prodrug approaches, with promoieties 
located either on the carboxylic acid of the aglycone or on the sugar moiety. The second goal 
was to establish new interactions with previously unexplored regions of the FimH protein in 
order to improve affinity. The new FimH antagonists targeted either Arg98 or a hydrophobic 
pocket located close to the 2-C position of the mannose moiety. 
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2. Results and Discussion 
 
2.1 Manuscript 1: FimH Antagonists: Ester Prodrugs for Achieving Oral 
Bioavailability 
 
This manuscript describes the optimization of the intestinal absorption potential of FimH 
antagonist by means of an ester prodrug approach. The ester promoieties employed in this 
strategy span from simple aliphatic chains to more complex oxygen- and nitrogen-containing 
heteroalkyl structures. Moreover, enzymatic hydrolysis of these esters via liver- and plasma-
borne esterases is discussed in detail. 
 
 
Contribution to the project: 
Wojciech Schönemann was involved in the design of the ester promoieties as well as the 
chemical synthesis of all compounds described in this manuscript. Furthermore, he is 
responsible for writing the synthetic part. 
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Abstract 
Urinary tract infections by uropathogenic Escherichia coli are among the most prevalent 
infectious diseases requiring antibiotic treatment. Since recurrent antibiotic exposure leads to 
the emergence of antimicrobial resistance, a novel prevention and treatment strategy is 
urgently required. The interaction of FimH, a lectin located at the tip of bacterial pili, with 
mannosylated glycoproteins on the urinary bladder mucosa is the initial step of the infection 
cycle. Biphenyl -D-mannopyranosides with an electron-withdrawing carboxylic acid 
substituent on the terminal aromatic ring of the agylcone were identified as potent antagonists 
of this interaction.  
The present report describes the synthesis and pharmacokinetic evaluation of various ester 
prodrugs that increase the intestinal absorption potential of the biphenyl 
-D-mannopyranoside FimH antagonist. We identified two ester prodrugs with well-balanced 
pharmacokinetic profiles: the 2-(dimethylamino)ethyl ester derivative 5l displaying high 
solubility, moderate membrane permeability, and rapid hydrolysis mediated by the plasma-
borne cholinesterase as well as the 2-ethoxyethyl ester derivative 3g exhibiting moderate 
solubility, high permeability, and prolonged bioactivation by the hepatic carboxylesterase. 
These two compounds will be selected for future in vivo pharmacokinetic studies.  
Introduction 
Urinary tract infections (UTIs), characterized by dysuria, frequent and urgent urination, 
bacteriuria, or pyuria, are among the most frequent bacterial infections. Around 60% of 
women have at least one UTI in their lifetime. Most episodes are caused by uropathogenic 
Escherichia coli (UPEC).[1] UTI requires an antibiotic treatment to tackle the symptoms and 
to prevent potentially devastating complications like pyelonephritis and urosepsis.[2] 
However, recurrent infections with subsequent antibiotic exposure result in antimicrobial 
resistance. This often leads to treatment failure and reduces the range of therapeutic 
options.[3] Therefore, efficient non-antibiotic treatment strategies are urgently needed. 
The pathogenesis of UTI relies on bacterial lectins which recognize carbohydrate ligands 
located on the endothelial cells of the urinary tract.[4] P-piliated UPEC cause pyelonephritis 
by binding to galabiose-containing ligands on the kidney epithelium, while mannose-binding 
type 1 pili promote cystitis by targeting uroplakin 1a on the mucosal surface of the urothelial 
cells of the bladder.[5] The bacterial adhesion prevents rapid clearance of UPEC from the 
urinary tract by the bulk flow of urine and enables the colonization of the host cells.[6] The 
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lectin FimH expressed at the tip of bacterial type 1 pili encloses a carbohydrate recognition 
domain (CRD) which can interact with a mannosylated glycoprotein on the cell surface 
(uroplakin 1a), and a pilin domain regulating the switch between the low and high affinity 
states of the CRD.[7,8]  
The inhibition of the bacteria-cell interaction by FimH antagonists is not inducing a selection 
pressure and is therefore a promising approach to reduce or even avoid the resistance 
problem accompaning the current antibiotic treatment. More than two decades ago, Sharon 
and coworkers investigated various mannosides as antagonists for type 1 fimbriae-mediated 
bacterial adhesion.[9-11] Since then, two different approaches have been explored for the 
further improvement of the anti-adhesive effects. First, multivalent mannosides[12-14] were 
investigated and second, monovalent high-affinity antagonists[15-21] were designed based on 
the structural information obtained from crystal structures of FimH co-crystallized with alkyl 
and aryl -D-mannopyranosides.[15,22-25] Only recently, the first in vivo studies performed in a 
mouse model were published, describing antibacterial effects in the bladder upon oral 
administration of biphenyl -D-mannopyranosides.[18,26] In either of the reported cases, high 
dose (≥ 50 mg/kg body weight) was however necessary to maintain the minimal therapeutic 
concentration in the urine over an extended period of time due to unfavorable 
physicochemical and pharmacokinetic properties of the orally applied antagonists.[18,21]  
In order to reach the urinary bladder, an orally applied FimH antagonist needs to be absorbed 
from the intestinal lumen into the portal vein, to be metabolically stable and survive the first 
liver passage and subsequently to be excreted via the kidneys. Permeability through the 
intestinal mucosa usually improves with increasing lipophilicity.[27,28] By contrast, renal 
excretion is necessary to reach the target in the bladder. However after filtration at the 
glomerulus, hydrophilic compounds are not re-absorpt from the primary urine in the renal 
tubules and therefore they are quickly excreted.[29,30] As a consequence, the minimal 
therapeutic concentration cannot be maintained in the bladder for an extended period of time. 
In this report we present an ester prodrug concept (Figure 1) combining lipophilicity, 
conferred by an alkyl promoiety, and hydrophilicity, provided by the free carboxylate upon 
enzyme-mediated hydrolysis of the ester in hepatocytes or in plasma.[31,32]  
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Figure 1. Ester prodrug concept enabling oral bioavailability and renal excretion for the biphenyl 
-D-mannopyranoside FimH antagonist 1.  
Results and Discussion 
In a previous publication, we described the biphenyl -D-mannopyranoside 1 exhibiting 
nanomolar affinity towards the isolated FimH-CRD and treatment efficacy in a mouse 
disease model.[18] Moreover, we showed that esterification of the polar carboxylate with a 
methyl promoiety ( 2) is a promising approach for achieving oral bioavailability. 
Nevertheless, the levels of the parent compound in plasma detected upon oral administration 
of the prodrug were moderate when compared to the concentrations reached by intravenous 
application. Therefore, we expanded the ester prodrug strategy in order to optimize the oral 
absorption potential. In a first step, we synthesized a set of simple alkyl esters ( 3a-e, Table 
1) and characterized their intestinal absorption potential. Based on these findings we then 
optimized the prodrug by (a) introducing alkyl promoieties containing heteroatoms ( 3f-i, 
k-n) and by (b) replacing the ortho-chloro substituent of the biphenyl aglycone with a 
trifluoromethyl group ( 4, 5l).  
 
Table 1. Ester prodrugs for optimizing oral bioavailability of the biphenyl -D-mannopyranosides 1 and 4.  
O
O
OH
HO
HO
COOR2
R1
OH
 
cpd R1 R2 cpd R1 R2 cpd R1 R2 
1[18] 
2[18] 
3a 
3b 
3c 
3d 
3e 
Cl 
Cl 
Cl 
Cl 
Cl 
Cl 
Cl 
H 
CH3 
CH2CH3 
CH2CH2CH3 
(CH2)3CH3 
CH(CH3)2 
C(CH3)3 
3f 
3g 
3h 
3i 
3k 
3l 
3m 
3n 
Cl 
Cl 
Cl 
Cl 
Cl 
Cl 
Cl 
Cl 
CH2CH2OCH3 
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CH2CH2OCH(CH3)2 
CH2CH2OCH2CH2OCH2CH3 
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NCH2CH2
 
N OCH2CH2
 
4[21] 
5l 
CF3 
CF3 
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CH2CH2N(CH3)2 
Results and discussion 
29 
 
Synthesis 
The synthesis of alkyl and oxygen-containing heteroalkyl esters is depicted in Scheme 1. The 
glycosylation between commercially available 8 and phenol 9 was performed in presence of 
Lewis acid affording -D-mannoside 10 in 62% yield. The boronate ester intermediates 7a-d, 
f, g were obtained by treating acid 6 with thionyl chloride and an excess of corresponding 
alcohol. The esters 7h-j were obtained by Steglich esterification.[33] All boronate ester 
intermediates were purified by MPLC on silica gel and characterized except 7f, 7g and 7i, 
from which only major impurities were removed before using them in the next step. The 
compound 7e was purchased from Frontier Scientific, Inc. Starting from 10, palladium-
mediated Suzuki coupling reactions[34] with 7a-j yielded the biphenyls 11a-j. To avoid 
transesterification reactions, a mixture of chloroform and corresponding alcohol together with 
its alkoxide was used for deacetylation. In the case of more complex alcohols ( 3e-j), bulky 
tert-butanol with potassium tert-butoxide was applied. 
R1: a
b
c
d
e
f
g
h
i
j
OH
O
O
O
O
OAc
k
O
O
OAc
OAc
OAc
AcO
AcO
O
OAc
OAc
AcO
AcO
O
I
O
OR2
OR2
R2O
R2O
O
11a-j, R2 = Ac
8
3a-i, k, R2 = H
9
HO
I
Cl
d)
Cl
10
COOR1
B
O
O
e), f) or g)
COOR1h)
Cl
COOH
B
O
O
a), b) or c)
7a-d, h, j6
 
 
Scheme 1. a) R1-OH, SOCl2, 60 °C, 2-6 h, 42-65% (7a-c); b) R1-OH, DIC, DMAP, DCM, 0 °C  rt, 1-4 h, 43-
69% (7h, j); c) iPrOH, SOCl2, Et3N, CHCl3, 60 °C, 5 h, 32% (7d); d) BF3Et2O, DCM, 4Å MS, 40 °C, 50 h, 
62%; e) 7a-e, 7h or 7j, PdCl2(dppf)CH2Cl2, K3PO4, DMF, 80 °C, 2-6 h, 55-81% (11a-e, h, j); f) i. 6, R1-OH, 
SOCl2, 60 °C, 4-6 h; ii. PdCl2(dppf)CH2Cl2, K3PO4, DMF, 80 °C, 4-5.5 h, 47-52% (11f, g); g) i. 6, R1-OH, 
DIC, DMAP, DCM, 0 °C  rt, 3.5 h; ii. PdCl2(dppf)CH2Cl2, K3PO4, DMF, 80 °C, 5 h, 44% (11i); h) R1-
ONa/R1-OH or t-BuOK/t-BuOH, CHCl3, rt, 2-25 h, 25-69%. 
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The synthesis of nitrogen-containing ester analogs was performed in a different manner to 
avoid possible deactivation of the catalyst[35] during Suzuki coupling reaction. Esterification 
was performed on the unprotected mannosides 1 and 4 and the crude products 3l-n and 5l 
were purified by means of preparative HPLC resulting in moderate yields (Scheme 2). 
 
O
OH
OH
HO
HO
O
COOH
O
OH
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HO
O
COOR1
a)
O
OAc
OAc
OAc
AcO
AcO
8 1 (R2 = Cl)
4 (R2 = CF3)
3l-n (R2 = Cl)
5l (R2 = CF3)
[Ref18, 21]
R1:
N
Nl
m
n
N
O
R2 R2
 
 
Scheme 2. a) R1-OH, COMU, DIPEA, DMF, rt, 4-31 h, 14-53%. 
 
Physicochemical and in vitro pharmacokinetic characterization 
For estimating the oral absorption potential of the various ester prodrugs as well as their 
propensity to enzyme-mediated bioactivation, we conducted aqueous solubility, lipophilicity, 
permeability, and metabolic stability studies (for experimental data refer to Table 2). 
Aqueous solubility was of interest because the orally applied dose needs to be dissolved in 
the intestinal fluids prior to absorption.[36] Lipophilicity was quantified by means of the 
octanol-water distribution coefficient at pH 7.4 (log D7.4).
[37] The parallel artificial membrane 
permeability assay (PAMPA) was performed to estimate the prodrugs’ ability to diffuse 
through the intestinal membranes,[38] while bi-directional permeation studies across a 
colorectal adenocarcinoma (Caco-2) cell monolayer were implemented to reveal active influx 
and efflux processes.[39] Furthermore, the prodrugs were incubated with rat and human liver 
microsomes (RLM, HLM) for estimating their susceptibility to hydrolases localized in the 
endoplasmic reticulum of hepatocytes,[40] while incubations with human plasma were 
performed to investigate the involvement of plasma-borne enzymes in ester hydrolysis.[41] 
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Table 2. Pharmacokinetic parameters of different ester prodrugs of the FimH antagonists 1 and 4. PAMPA, 
parallel artificial membrane permeability assay; Pe, effective permeability; Papp, apparent permeability; RLM, 
rat liver microsomes; HLM, human liver microsomes; n.d., not determined. The Caco-2 assay was performed at 
an initial compound concentration (c0) of 62.5 µM. Microsomal stability was determined with pooled male rat 
liver microsomes (0.125 mg/mL) and pooled human liver microsomes (0.125 mg/mL) at pH 7.4 and 37 °C. 
Plasma stability was determined with human plasma (50%) at pH 7.4 and 37 °C. 
Cpd PAMPA 
log Pe 
[cm/s]/pH 
Caco-2 
Papp [10-6 cm/s] 
log D7.4 Solubility 
[µg/mL]/pH 
RLM 
t1/2 
[min] 
HLM 
t1/2 
[min] 
Plasma 
t1/2 
[min] ab ba 
1[18] no permeation 0.20.0 0.40.0 < -1.5 >3000 / 6.61 --- --- --- 
2[18] -4.6 5.30.6 181 2.32 11.9 / 6.53 3.1 36 >120 
3a -4.50.1 / 7.4 n.d. n.d. n.d. 3.90.1 / 7.4 n.d. n.d. n.d. 
3b -4.50.1 / 7.4 n.d. n.d. n.d. 2.20.5 / 7.4 n.d. n.d. n.d. 
3c -4.6       / 7.4 n.d. n.d. n.d. 0.80.2 / 7.4 n.d. n.d. n.d. 
3d -4.40.1 / 7.4 n.d. n.d. n.d. 141 / 7.4 n.d. n.d. n.d. 
3e -4.40.1 / 7.4 n.d. n.d. n.d. 3.80.6 / 7.4 n.d. n.d. n.d. 
3k -6.60.1 / 7.4 0.60.1 9.60.6 1.80.1 >160     / 7.4 >120 >120 >120 
3f -4.90.0 / 7.4 4.50.4 181 2.30.0 1214    / 7.4 4.1 47 57 
3g -4.90.2 / 7.4 111 191 2.70.0 13714 / 7.4 5.9 101 66 
3h -4.50.1 / 7.4 8.30.7 364 3.10.1 906 / 7.4 1.9 16 57 
3i -5.10.1 / 7.4 4.60.6 367 2.10.1 1476 / 7.4 5.1 33 33 
3l 
-6.40.0 / 5.0 
-6.20.1 / 7.4 
0.90.1 270 1.60.0 
>160 / 3.0 
>160 / 7.4 
>120 >120 6.2 
3m 
-5.50.0 / 5.0 
-5.10.0 / 7.4 
1.00.3 332 2.40.1 
798 / 3.0 
574 / 7.4 
49 >120 3.7 
3n 
-6.30.2 / 5.0 
-5.60.0 / 7.4 
0.60.2 355 2.20.1 
>120 / 3.0 
>120 / 7.4 
32 >120 86 
4 
-8.41.3 / 5.0 
-8.61.6 / 7.4 
n.d. n.d. -0.80.1 
151 / 3.0 
>200 / 7.4 
--- --- --- 
5l 
-6.70.2 / 5.0 
-6.40.0 / 7.4 
1.6 37 1.70.0 
>160 / 3.0 
>160 / 7.4 
80 n.d. 17 
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Oral absorption. As previously reported, low aqueous solubility (< 20 µg/mL) is a primary 
drawback constraining oral absorption of the methyl ester 2.[18,42] Moreover, carrier-mediated 
efflux at the apical enterocyte membrane – revealed by the bi-directional Caco-2 permeation 
assay – probably interferes with the intestinal uptake of the prodrug, in spite of promising 
membrane permeability suggested by PAMPA (log Pe = -4.6).
[43,44] Therefore, we expanded 
the alkyl promoiety with the aim to increase solubility and permeability.  
In the first step, esters with simple alkyl promoieties (3a-e) were synthesized. They trend 
towards slightly higher effective permeability (log Pe), as detected by PAMPA. However, 
replacing the methyl promoiety with an ethyl, propyl, butyl, isopropyl, or tert-butyl group 
further reduced the aqueous solubility of the prodrug and, as a consequence, its intestinal 
absorption potential.[36]  
In order to counteract decreasing aqueous solubility, we introduced ethyl promoieties 
functionalized with oxygenated or nitrogenated substituents.[45] These esters (3f-i, k-n) were 
indeed more soluble than the initial methyl ester 2 and the prodrugs 3a-e. Moreover, the 2-
ethoxyethyl ester 3g and the 2-isopropoxyethyl ester 3h displayed a higher log D7.4 than the 
methyl ester, suggesting an increase in membrane permeability. On the other hand, the 
tertiary amines present in the compounds 3l and 3n induced a decrease in log D7.4 but a 
strong increase in aqueous solubility. The moderate lipophilicity of the 
2-(dimethylamino)ethyl ester 3l could in turn be slightly raised by replacing the ortho-chloro 
substituent with a trifluoromethyl moiety on the aromatic ring of the biphenyl aglycone 
adjacent to the anomeric position ( 5l). Effective permeability deduced from PAMPA 
(log Pe) correlated with log D7.4, such that the most lipophilic ester 3h showed optimal log Pe 
for membrane permeation (-4.5).[43] In the case of the esters 3l-n and 5l bearing an amine 
functional group, we observed moreover a strong dependence of log Pe on the pH of the 
compound solution in the donor compartment of the PAMPA.  
A bi-directional Caco-2 permeability screening at low initial compound concentrations in the 
donor chamber (c0 = 62.5 µM) classified all heteroalkyl esters as apparent substrates of efflux 
transporters.[44] Passive diffusion driven by the concentration gradient across the cell 
monolayer and active efflux given for intrinsic carrier substrates are considered as key 
determinants of the apparent net flux.[46] Accordingly, moderately permeable aminoalkyl 
esters, such as compound 3l, diffused slowly but were strongly recognized by the efflux 
carriers, resulting in a high efflux ratio (ba/ab). Since 3l is well soluble in aqueous 
medium, the initial concentration (c0) in the donor chambers could however be expanded to 
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825 µM, which increased the gradient and apparently saturated the transporter activity 
(Figure 2). As a result, apparent permeability (Papp, ab) in the range for successful oral 
absorption was achieved. 
In contrast to the 2-aminoethyl esters, the highly permeable esters 3f-h diffused more rapidly, 
which led to a lower efflux ratio and promising Papp, ab under the screening conditions 
(c0 = 62.5 µM). However, for the ester 3h exhibiting the least favorable efflux ratio among 
those esters, the attempt to saturate the transporters was not successful due to insufficient 
aqueous solubility (90 µg/mL).  
 
Figure 2. Apparent permeability (Papp) of ester 3l through a Caco-2 cell monolayer. The assay was performed at 
different initial compound concentrations in the donor compartment (c0), ranging from 100 µM to 825 µM. Papp 
(ab), permeability in the absorptive direction; Papp (ba), permeability in the secretory direction.  
 
Enzyme-mediated bioactivation. Besides solubility and permeability, propensity to enzyme-
mediated bioactivation was a key feature of our ester prodrug concept.[31] Hydrolysis of the 
ester bond can be mediated by plasma-borne enzymes or by isozymes of the carboxlyesterase 
(CES) superfamily associated to the endoplasmic reticulum of various tissues.[41,47] The 
isozyme hCE1, highly expressed in hepatocytes but scarcely observed in enterocytes, and the 
isozyme hCE2, present in both hepatocytes and enterocytes, have been identified as major 
human CES.[40] Since the prodrug approach might only be successful when hydrolysis takes 
place in the bloodstream or in the liver and not in the small intestines or in the enterocytes 
during absorption, high chemical stability of the ester bond and substrate specificity for 
plasma-borne hydrolases or hCE1 was aspired. 
Incubations of the esters 3f-i, k-n, and 5l in buffer without active enzyme (pH 7.4, 37 °C) 
showed a negligible degradation within one hour, suggesting high chemical stability of the 
prodrugs. With regard to the enzyme-mediated bioactivation, we identified different esterases 
to be involved in the conversion of the oxygen-containing esters 3f-i, k and the amine-
bearing esters 3l-n and 5l to the active parent compounds.  
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When we incubated the oxyethyl esters 3f-h, k (initial concentration, c0 = 2 µM in TRIS-HCl 
0.1 M, pH 7.4) with RLM (0.125 mg/mL, total incubation time = 60 min), we observed the 
previously described relationship between the lipophilicity of the ester and its propensity to 
hydrolysis by microsome-associated hydrolases.[48,49] The 2-hydroxyethyl ester 3k, i.e. the 
least lipophilic representative among the oxyethyl esters, showed stability during the entire 
incubation time (t1/2 > 120 min). By contrast, the 2-methoxyethyl ester 3f, 2-ethoxyethyl ester 
3g, and 2-isopropoxyethyl ester 3h were all susceptible to degradation by microsome-
associated enzymes, with the most lipophilic 3h showing the shortest metabolic half-life. 
Nonetheless, the observed high rates of biotransformation by murine hydrolases did not 
correlate with the turnover by human enzymes. In fact, the incubations with HLM under 
similar assay conditions revealed important species differences in the observed half-lives (see 
Table 2), which need to be considered when predicting the rates of bioconversion in human 
from in vivo animal experiments.[50]  
 
 
 
 
 
 
 
  
Figure 3. Human liver microsome (HLM) mediated hydrolysis of ester prodrug 2, 3f, 3g, and 3h in presence of 
loperamide hydrochloride (12), a specific inhibitor of the human carboxylesterase isotype 2 (hCE2). The bars 
represent the accumulation of the parent compound 1 in the incubation with inhibitor (1 µM, 10 µM, 100 µM) 
relative to the accumulation in the control experiment without loperamide (blank). 
 
When bis(4-nitrophenyl) phosphate (BNPP, 1 mM) – an inhibitor of all CES isozymes – was 
added to the microsomal incubations of the esters 3f-h, a strong decrease in the rates of 
hydrolysis was observed. These results suggest that enzymes of the CES superfamily are the 
main contributors to the bioactivation of these prodrugs.[40] Otherwise, treating the HLM with 
loperamide (1 – 100 µM) – a specific inhibitor of the human CES isotype 2 (hCE2) – did not 
affect the rates of hydrolysis (Figure 3), which attributes the observed enzymatic turnover 
primarily to the hCE1 isozyme.[51]  
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In contrast to the 2-oxyethyl esters, all 2-aminoethyl ester prodrugs 3l-n and 5l showed low 
susceptibility to hydrolysis by microsome-associated esterases. Indeed, the cationic tertiary 
amine present in these esters is supposed to establish strong interactions with negatively 
charged residues in the active site gorge of the CES and, as a consequence, to inhibit the 
hydrolytic activity.[49] By contrast, the 2-(dimethylamino)ethyl esters 3l, 5l, and the 
2-(piperidin-1-yl)ethyl ester 3m were rapidly cleaved by plasma-borne enzymes. Since the 
2-aminoethyl carboxylate present in these prodrugs is structurally related to choline esters, 
we postulated that they were recognized by the butyrylcholinesterase (BChE) present in 
human plasma.[52,53] The metabolic turnover could indeed be inhibited by the specific 
cholinesterase inhibitor neostigmine bromide (13, Figure 4B), which confirms the strong 
contribution of BChE to the observed hydrolysis (Figure 4A).[54] Against our expectations, 
the 2-morpholinoethyl promoiety in 3n, known from marketed ester prodrugs, e.g. 
micophenolate mofetil (14, Figure 4B),[55] was scarcely cleaved by microsomal or plasma-
associated enzymes. 
 A      B 
 
 
 
 
  
Figure 4. (A) Hydrolysis of the 2-(dimethylamino)ethyl ester 3l and the 2-(piperidin-1-yl)ethyl ester 3m by 
plasma-associated esterases in presence of the specific butyrylcholinesterase inhibitor neostigmine bromide 
(0.01 - 10 µM). The activity was calculated by dividing the metabolic t1/2 observed in presence of the inhibitor 
neostigmine by the metabolic t1/2 of the control experiment without inhibitor. (B) A chemical structure of 
neostigmine bromide (13) and micophenolate mofetil (14). 
 
In summary, the prodrug approach proved successful to mask the polar character of the 
carboxylic acid and hence to increase permeability of the biphenyl -D-mannopyranoside 1. 
As opposed to merely aliphatic motifs present in 3a-e, the oxyalkyl promoieties in 3f-h 
enhanced both permeability and solubility. Nonetheless, aqueous solubility was still 
insufficient to reach concentrations necessary for efflux transporter saturation. Moreover, we 
suspect that, despite hydrolysis by hepatic CES, further metabolic modifications within the 
hepatocytes (e.g. glucuronidation of the free acid) or hepatobiliary excretion may take place 
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and constrain the systemic availability of the active principle.[31] Otherwise, the 2-aminoethyl 
derivatives showed high aqueous solubility, compensating for moderate permeability and 
providing a promising overall absorption potential. Furthermore, the well soluble esters 3l 
and 5l displayed high propensity to hydrolysis by plasma-borne enzymes, which suggests 
rapid and quantitative conversion of the prodrug to the polar active principle within the 
bloodstream and thus low compound loss during the first pass through the liver.[31] 
With regard to the rate of enzyme-mediated bioactivation, rapid conversion, such as observed 
for the prodrugs 3h, 3l or 5l, is not necessarily advantageous, since it favors rapid compound 
clearance from circulation, i.e. high initial concentrations in the bladder but only short-acting 
therapeutic effects. We therefore hypothesize that the slightly prolonged metabolic t1/2 of the 
prodrug 3g would allow maintaining the minimal therapeutic concentration in the urine for a 
longer period of time, thus reducing the dosing frequency.  
 
Summary and Conclusion 
Although described as potent and selective FimH antagonists, biaryl -D-mannosides bearing 
carboxylic acid on the terminal aromatic ring have physicochemical profile unfavorable for 
an oral therapy. In a former publication, we introduced an ester prodrug approach rendering 
the biphenyl mannoside 1 orally available. The goal of the present study was to optimize the 
properties of the promoiety in order to enhance the intestinal uptake and the delivery of the 
pharmacologically active parent compound to the therapeutic target in the urinary bladder.  
Introducing alkyl promoieties (i.e. ethyl, propyl, isopropyl, butyl, isopropyl, or tert-butyl) 
was unsuccessful due to markedly reduced aqueous solubility of the final molecules. By 
contrast, alkyl promoieties functionalized with oxygenated or nitrogenated substituents 
proved advantageous for masking the polar carboxylic acid substituent of the biphenyl 
aglycone and at the same time for raising the aqueous solubility of the prodrug. With regard 
to enzymatic bioactivation, we identified different esterases responsible for the hydrolysis of 
the alkoxyethyl esters and the aminoethyl derivatives. Whereas the class of the alkoxyethyl 
esters was recognized by the ER-associated CES expressed in hepatocytes, the aminoethyl 
derivatives were rapidly cleaved by the plasma-borne BChE, which implies immediate 
availability of the active principle in the bloodstream and lower non-renal clearance by phase 
II metabolic reactions or hepatobiliary excretion.  
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With respect to all ADME parameters determined in vitro (Table 2), the prodrugs 3g and 5l 
showed the most promising profiles. The 2-(dimethylamino)ethyl ester 5l displayed high 
solubility, moderate permeability, and rapid hydrolysis mediated by the cholinesterase, which 
can lower the risk of non-renal clearance but also shorten the dosing interval of the treatment. 
On the other hand, the 2-ethoxyethyl ester 3g exhibited moderate solubility, high 
permeability, and a slightly prolonged t1/2, which may be beneficial in terms of dose regimen 
but also may increase the propensity to hepatic clearance. In order to evaluate the advantages 
and drawbacks of these two prodrugs, in vivo pharmacokinetic studies in mice should be 
conducted as a next step. 
 
Experimental Section 
 
Chemistry 
General methods: NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, HMBC). Chemical shifts are expressed in ppm using residual CHCl3, 
CHD2OD or HDO as references. Optical rotations were measured using Perkin-Elmer 
Polarimeter 341. Electron spray ionization mass spectra (ESI-MS) were obtained on a Waters 
micromass ZQ Mass Spectrometer. The LC-HRMS analysis were carried out using a Agilent 
1100 LC equipped with a photodiode array detector and a Micromass QTOF I equipped with 
a 4 GHz digital-time converter. Reactions were monitored by TLC using glass plates coated 
with silica gel 60 F254 (Merck) and visualized by using UV light and/or by charring with a 
molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and 
ammonium molybdate tetrahydrate in aqueous 10% H2SO4). MPLC separations were carried 
out on a CombiFlash Companion or Rf from Teledyne Isco equipped with RediSep normal-
phase. LC-MS separations were carried out on a Waters system equipped with sample 
manager 2767, pump 2525, PDA 2996, column SunFireTM Prep C18 OBD
TM (5 m, 19 x 150 
mm), and Micromass ZQ. All compounds used for biological assays are at least of 95% 
purity based on HPLC analytical results. Commercially available reagents were purchased 
from Aldrich, Alfa Aesar, Acros Organics or Frontier Scientific. Solvents were purchased 
from Sigma-Aldrich or Acros and were dried prior to use where indicated. Methanol 
(MeOH), ethanol (EtOH), n-propanol (PrOH), isopropanol (i-PrOH), n-butanol (BuOH) and 
tert-butanol (t-BuOH) were dried by storing with activated molecular sieves 3Å or 4Å for at 
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least one day. Dichloromethane (DCM) was dried by filtration over Al2O3 (Fluka, type 5016 
A basic) and stored over activated molecular sieves 4Å . Molecular sieves 3Å and 4Å were 
activated in vacuo at 200 °C for 30 min immediately before use. 
 
General procedure A for Suzuki coupling reaction. A round-bottom flask was charged 
with 10, boronate 6 or 7 and K3PO4, then evacuated and flushed with argon. Anhydrous DMF 
(0.5-4 mL) was added and the mixture was degassed in an ultrasonic bath for 10 min 
followed by the addition of PdCl2(dppf)CH2Cl2. The reaction was stirred at 80 °C under 
argon until completion (2-6 h). After cooling to rt, the mixture was diluted with EtOAc (30-
50 mL) and washed with satd aq NaHCO3 (2 x 20 mL) and H2O (2 x 20 mL). The organic 
layer was dried over Na2SO4, concentrated in vacuo and purified by MPLC on silica gel to 
afford 11a-j. 
 
General procedure B for deacetylation. To a solution of protected mannoside 11 in a 
mixture of dry alcohol and chloroform, freshly prepared sodium alkoxide or potassium tert-
butoxide was added. The mixture was stirred at rt under argon until completion (2-25 h). 
Then, the mixture was neutralized with Amberlyst-15 (H+) ion-exchange resin, filtered and 
concentrated in vacuo. The crude product was purified by MPLC on silica gel to afford 3a-i, 
k. 
 
General procedure C for esterification of compounds 1 and 4. To a solution of 1 or 4, the 
corresponding alcohol and DIPEA in DMF was added COMU. The mixture was stirred at rt 
under argon until completion (4-31 h) and then concentrated in vacuo. The residue was 
dissolved in MeOH (1 mL) or MeCN (1 mL), passed through a nylon membrane syringe 
filter (pore size 0.45 m) and purified by LC-MS (H2O/MeCN + 0.2% HCO2H) to afford 3l-
n and 5l as solids after lyophilization from H2O. 
 
4-Ethoxycarbonylphenylboronic acid pinacol ester (7a). A round-bottom flask was 
charged with 6 (60 mg, 0.235 mmol), evacuated and flushed with argon. Then, dry EtOH (0.6 
mL) and SOCl2 (41 L, 0.282 mmol, 2.4 eq) were added. The mixture was stirred at 60 °C 
for 2 h. The reaction mixture was concentrated in vacuo and purified by MPLC on silica gel 
(petroleum ether/EtOAc, 9:1) to afford 7a (43 mg, 66%) as a colorless oil. Analytical data are 
in accordance with literature data.[56] 
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4-Propoxycarbonylphenylboronic acid pinacol ester (7b). Prepared according to the 
procedure for 7a from 6 (39 mg, 0.152 mmol) with SOCl2 (12 L, 0.152 mmol, 1.0 eq) in dry 
PrOH (0.3 mL). After stirring for 6 h, the reaction mixture was diluted with EtOAc (40 mL) 
and washed with satd aq NaHCO3 (20 mL). The organic layer was dried over Na2SO4, 
concentrated in vacuo and purified by MPLC on silica gel (petroleum ether/EtOAc, 9:1) to 
afford 7b (23 mg, 52%) as a colorless oil. 1H NMR (500 MHz, CDCl3): δ = 7.95 (d, J = 8.2 
Hz, 2H, Ar-H), 7.79 (d, J = 8.2 Hz, 2H, Ar-H), 4.21 (t, J = 6.7 Hz, 2H, OCH2), 1.76-1.69 (m, 
2H, CH2), 1.28 (s, 12H, 2 C(CH3)2), 0.96 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (125 MHz, 
CDCl3): δ = 166.92 (CO), 134.84, 132.91, 128.76 (6C, Ar-C), 84.36 (2C, 2 C(CH3)2), 66.82 
(OCH2), 25.08 (4C, 2 C(CH3)2), 22.31 (CH2), 10.72 (CH3); elemental analysis: Calcd (%) for 
C16H23BO4: C 66.23, H 7.99, found: C 66.15, H 8.01. 
 
4-Butoxycarbonylphenylboronic acid pinacol ester (7c). Prepared according to the 
procedure for 7a from 6 (47 mg, 0.188 mmol) with SOCl2 (17 L, 0.232 mmol, 1.2 eq) in dry 
BuOH (0.4 mL). After stirring for 6 h, the mixture was concentrated in vacuo and purified by 
MPLC on silica gel (petroleum ether/EtOAc, 9:1) to afford 7c (37 mg, 65%) as a colorless 
oil. 1H NMR (500 MHz, CDCl3): δ = 7.94 (d, J = 8.2 Hz, 2H, Ar-H), 7.79 (d, J = 8.1 Hz, 2H, 
Ar-H), 4.25 (t, J = 6.7 Hz, 2H, OCH2), 1.71-1.66 (m, 2H, CH2), 1.44-1.37 (m, 2H, CH2), 1.28 
(s, 12H, 2 C(CH3)2), 0.91 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (125 MHz, CDCl3): δ = 166.93 
(CO), 134.84, 132.91, 128.75 (6C, Ar-C), 84.36 (2C, 2 C(CH3)2), 65.13 (OCH2), 30.97 
(CH2), 25.08 (4C, 2 C(CH3)2), 19.47 (CH2), 13.97 (CH3); ESI-MS: m/z: Calcd for 
C17H25BNaO4 [M+Na]
+: 327.17, found: 326.98. 
 
4-Isopropoxycarbonylphenylboronic acid pinacol ester (7d). To a solution of 6 (39 mg, 
0.152 mmol) in CHCl3 (1 mL) was added SOCl2 (28 L, 0.380 mmol, 2.5 eq). The reaction 
mixture was stirred at 60 °C under argon. Dry i-PrOH (1 mL) and Et3N (23 L, 0.167 mmol, 
1.1 eq) were added after 2 h. When the reaction was complete (2.5 h), the mixture was 
concentrated in vacuo and the residue purified by MPLC on silica gel (petroleum 
ether/EtOAc, 9:1) to afford 7d (14 mg, 32%) as a colorless oil. 1H NMR (500 MHz, CDCl3): 
δ = 7.94 (d, J = 8.2 Hz, 2H, Ar-H), 7.78 (d, J = 8.1 Hz, 2H, Ar-H), 5.18 (hept, J = 6.3 Hz, 1H, 
OCH), 1.71-1.66 (m, 2H, CH2), 1.44-1.37 (m, 2H, CH2), 1.31-1.29 (m, 18H, 2 C(CH3)2, 
CH(CH3)2); 
13C NMR (125 MHz, CDCl3): δ = 166.37 (CO), 134.79, 133.33, 128.74 (6C, Ar-
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C), 84.36 (2C, 2 C(CH3)2), 68.67 (OCH), 25.10 (4C, 2 C(CH3)2), 22.16 (2C, CH(CH3)2); ESI-
MS: m/z: Calcd for C16H23BNaO4 [M+Na]
+: 313.16, found: 312.99. 
 
4-(2-Isopropoxyethoxycarbonyl)phenylboronic acid pinacol ester (7h). To a solution of 6 
(100 mg, 0.391 mmol) in dry DCM (2 mL) under argon were added 2-isopropoxyethanol (91 
L, 0.782 mmol, 2.0 eq) and a catalytic amount of DMAP (4 mg, 0.033 mmol, 0.08 eq). 
Then, DIC (91 L, 0.587 mmol, 1.5 eq) was added at 0 °C, the reaction was allowed to reach 
rt and stirred for 1 h. The reaction mixture was diluted with EtOAc (40 mL) and washed with 
0.1 N HCl (10 mL), satd aq NaHCO3 (20 mL) and H2O (20 mL). The organic layer was dried 
over Na2SO4, concentrated in vacuo and purified by MPLC on silica gel (DCM/MeOH, 99:1) 
to afford 7h (70 mg, 53%) as a colorless oil. 1H NMR (500 MHz, CDCl3): δ = 8.03 (d, J = 8.3 
Hz, 2H, Ar-H), 7.86 (d, J = 8.1 Hz, 2H, Ar-H), 4.46-4.43 (m, 2H, COCH3), 3.77-3.75 (m, 2H, 
CH2O), 3.66 (hept, J = 6.1 Hz, 1H, OCH), 1.35 (s, 12H, 2 C(CH3)2), 1.18 (d, J = 6.1 Hz, 6H, 
CH(CH3)2); 
13C NMR (125 MHz, CDCl3): δ = 166.78 (CO), 134.76, 132.52, 128.82 (6C, Ar-
C), 84.30 (2C, 2 C(CH3)2), 72.20 (OCH), 66.09 (CH2O), 64.71 (COCH2), 25.02 (4C, 2 
C(CH3)2), 22.19 (2C, CH(CH3)2); elemental analysis: Calcd (%) for C18H27BO5: C 64.69, H 
8.14, found: C 65.05, H 8.21. 
 
4-(2-Acetoxyethoxycarbonyl)phenylboronic acid pinacol ester (7j). Prepared according to 
the procedure for 7h from 6 (100 mg, 0.403 mmol) and 2-hydroxyethyl acetate[57] (0.150 mL) 
with DIC (94 L, 0.605 mmol, 1.5 eq) and DMAP (4 mg, 0.033 mmol, 0.08 eq) in dry DCM 
(2 mL) to afford 7j (71 mg, 53%) as a colorless oil. 1H NMR (500 MHz, CD3OD): δ = 8.00 
(d, J = 8.2 Hz, 2H, Ar-H), 7.84 (d, J = 8.2 Hz, 2H, Ar-H), 4.53-4.51 (m, 2H, CH2), 4.43-4.41 
(m, 2H, CH2), 2.06 (s, 3H, COCH3), 1.36 (s, 12H, 2 C(CH3)2); 
13C NMR (125 MHz, 
CD3OD): δ = 172.63, 167.70 (2 CO), 135.69, 129.64 (6C, Ar-C), 85.53 (2C, 2 C(CH3)2), 
64.17, 63.44 (2 OCH2), 25.20 (4C, 2 C(CH3)2), 20.66 (COCH3); ESI-MS: m/z: Calcd for 
C17H23BNaO6 [M+Na]
+: 357.15, found: 357.04. 
 
2-Chloro-4-iodophenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (10). To a 
suspension of 8 (1.33 g, 3.42 mmol), phenol 9 (1.04 g, 4.10 mmol, 1.2 eq) and activated 
molecular sieves 4 Å (1.40 g) in dry DCM (10 mL), BF3Et2O (1.67 mL, 13.7 mmol, 4.0 eq) 
was added dropwise at rt under argon. After 22 h of stirring at 40 °C, a second portion of 
BF3Et2O (0.42 mL, 3.42 mmol, 1.0 eq) was added. The mixture was stirred at 40 °C for 28 h 
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and then filtered through Celite and the filtrate was diluted with EtOAc (100 mL), washed 
with satd aq NaHCO3 (2 x 50 mL), H2O (50 mL) and brine (20 mL). The organic layer was 
dried over Na2SO4 and concentrated in vacuo. The residue was purified by MPLC on silica 
gel (petroleum ether/EtOAc, 9:1) to afford 10 (1.25 g, 62%) as a white solid. Analytical data 
are with accordance with the literature data.[20] 
 
Ethyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-4-
carboxylate (11a). Prepared according to general procedure A from 10 (83 mg, 0.142 mmol) 
and 7a (43 mg, 0.156 mmol, 1.1 eq) with K3PO4 (93 mg, 0.411 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (3.4 mg, 4.2 mol, 0.03 eq) in anhydrous DMF (0.5 mL). Purified by 
MPLC on silica gel (petroleum ether/EtOAc, 7:3). Yield: 62 mg (62%) as colorless oil. [α]
  
D
20 
+66.4 (c 1.00, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 8.02 (d, J = 8.4 Hz, 2H, Ar-H), 7.59 
(d, J = 2.2 Hz, 1H, Ar-H), 7.51 (d, J = 8.4 Hz, 2H, Ar-H), 7.39 (dd, J = 2.2, 8.6 Hz, 1H, Ar-
H), 7.18 (d, J = 8.6 Hz, 1H, Ar-H), 5.58-5.54 (m, 2H, H-1, H-3), 5.48 (dd, J = 1.8, 3.4 Hz, 
1H, H-2), 5.33 (t, J = 10.1 Hz, 1H, H-4), 4.32 (q, J = 7.1 Hz, 2H, OCH2), 4.22 (dd, J = 5.3, 
12.3 Hz, 1H, H-6a), 4.12 (ddd, J = 2.1, 5.2, 10.1 Hz, 1H, H-5), 4.03 (dd, J = 2.2, 12.4 Hz, 1H, 
H-6b), 2.14, 2.00, 1.97, 1.96 (4 s, 12H, 4 COCH3), 1.34 (t, J = 7.1 Hz, 3H, CH3); 
13C NMR 
(125 MHz, CDCl3): δ = 170.61, 170.10, 169.92, 169.91, 166.45 (5 CO), 151.27, 143.48, 
136.33, 130.36, 129.79, 129.44, 126.83, 126.64, 125.03, 117.39 (12C, Ar-C), 96.79 (C-1), 
69.99 (C-5), 69.47 (C-2), 68.92 (C-3), 65.96 (C-4), 62.25 (C-6), 61.22 (OCH2), 21.02, 20.86, 
20.84, 20.82 (4 COCH3), 14.51 (CH3); elemental analysis: Calcd (%) for C29H31ClO12: C 
57.38, H 5.15, found: C 57.62, H 5.32. 
 
Propyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-4-
carboxylate (11b). Prepared according to general procedure A from 10 (35 mg, 0.060 mmol) 
and 7b (19 mg, 0.065 mmol, 1.1 eq) with K3PO4 (39 mg, 0.179 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (2.3 mg, 2.8 mol, 0.05 eq) in DMF (0.5 mL). Purified by MPLC on 
silica gel (petroleum ether/EtOAc, 1:0-0:1). Yield: 26 mg (70%) as colorless oil. [α]
  
D
20 +68.2 
(c 0.87, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 8.03 (d, J = 8.4 Hz, 2H, Ar-H), 7.60 (d, J 
= 2.2 Hz, 1H, Ar-H), 7.52 (d, J = 8.4 Hz, 2H, Ar-H), 7.39 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 
7.19 (d, J = 8.5 Hz, 1H, Ar-H), 5.57 (dd, J = 3.5, 10.1 Hz, 1H, H-3), 5.54 (d, J = 1.5 Hz, 1H, 
H-1), 5.49 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.34 (t, J = 10.1 Hz, 1H, H-4), 4.25-4.21 (m, 3H, 
H-6a, OCH2), 4.12 (ddd, J = 2.1, 5.2, 10.1 Hz, 1H, H-5), 4.03 (dd, J = 2.2, 12.3 Hz, 1H, H-
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6b), 2.15, 2.01, 1.98, 1.97 (4 s, 12H, 4 COCH3), 1.78-1.71 (m, 2H, CH2), 0.98 (t, J = 7.4 Hz, 
3H, CH3); 
13C NMR (125 MHz, CDCl3): δ = 170.66, 170.16, 169.97, 169.96, 166.57 (5 CO), 
151.32, 143.54, 136.40, 130.41, 129.86, 129.49, 126.90, 126.68, 125.09, 117.43 (12C, Ar-C), 
96.84 (C-1), 70.03 (C-5), 69.52 (C-2), 68.96 (C-3), 66.85 (OCH2), 66.01 (C-4), 62.29 (C-6), 
22.33 (CH2), 21.07, 20.90, 20.88, 20.86 (4 COCH3), 10.72 (CH3); ESI-MS: m/z: Calcd for 
C30H37ClNO12 [M+NH4]
+: 638.20, found: 638.07. 
 
Butyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-4-
carboxylate (11c). Prepared according to general procedure A from 10 (52 mg, 0.090 mmol) 
and 7c (30 mg, 0.099 mmol, 1.1 eq) with K3PO4 (59 mg, 0.270 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (3.9 mg, 4.5 mol, 0.05 eq) in DMF (0.5 mL). Purified by MPLC on 
silica gel (petroleum ether/EtOAc, 7:3). Yield: 33 mg (58%) as pink oil. [α]
  
D
20 +105.1 (c 1.10, 
CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 8.03 (d, J = 8.4 Hz, 2H, Ar-H), 7.61 (d, J = 2.2 Hz, 
1H, Ar-H), 7.54 (d, J = 8.4 Hz, 2H, Ar-H), 7.41 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.19 (d, J = 
8.6 Hz, 1H, Ar-H), 5.57 (dd, J = 3.5, 10.1 Hz, 1H, H-3), 5.54 (d, J = 1.6 Hz, 1H, H-1), 5.49 
(dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.34 (t, J = 10.1 Hz, 1H, H-4), 4.28 (t, J = 6.6 Hz, 2H, OCH2), 
4.22 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.12 (ddd, J = 2.2, 5.2, 10.1 Hz, 1H, H-5), 4.04 (dd, J = 
2.2, 12.3 Hz, 1H, H-6b), 2.15, 2.01, 1.98, 1.97 (4 s, 12H, 4 COCH3), 1.73-1.67 (m, 2H, CH2), 
1.46-1.39 (m, 2H, CH2), 0.92 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (125 MHz, CDCl3): δ = 
170.67, 170.17, 169.98, 169.97, 166.58 (5 CO), 151.33, 143.54, 136.41, 130.42, 129.87, 
129.50, 126.90, 126.68, 125.09, 117.44 (12C, Ar-C), 96.85 (C-1), 70.04 (C-5), 69.53 (C-2), 
68.96 (C-3), 66.02 (C-4), 65.16 (OCH2), 62.30 (C-6), 31.00 (CH2), 21.07, 20.91, 20.88, 20.87 
(4 COCH3), 19.49 (CH2),  13.98 (CH3); HRMS: m/z: Calcd for C31H35ClNaO12 [M+Na]
+: 
657.1715, found: 657.1711. 
 
Isopropyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-4-
carboxylate (11d). Prepared according to general procedure A from 10 (26 mg, 0.044 mmol) 
and 7d (14 mg, 0.048 mmol, 1.1 eq) with K3PO4 (29 mg, 0.132 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (1.5 mg, 1.8 mol, 0.04 eq) in DMF (0.5 mL). Purified by MPLC on 
silica gel (petroleum ether/EtOAc, 7:3). Yield: 22 mg (81%) as colorless oil. [α]
  
D
20 +57.5 (c 
1.05, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 8.02 (d, J = 8.5 Hz, 2H, Ar-H), 7.61 (d, J = 
2.2 Hz, 1H, Ar-H), 7.53 (d, J = 8.5 Hz, 2H, Ar-H), 7.40 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.19 
(d, J = 8.3 Hz, 1H, Ar-H), 5.57 (dd, J = 3.5, 10.1 Hz, 1H, H-3), 5.54 (d, J = 1.6 Hz, 1H, H-1), 
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5.49 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.34 (t, J = 10.1 Hz, 1H, H-4), 5.20 (hept, J = 6.3 Hz, 1H, 
OCH), 4.22 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.12 (ddd, J = 2.2, 5.2, 10.1 Hz, 1H, H-5), 4.03 
(dd, J = 2.3, 12.2 Hz, 1H, H-6b), 2.15, 2.01, 1.98, 1.97 (4 s, 12H, 4 COCH3), 1.38 (d, J = 6.3 
Hz, 6H, CH(CH3)2); 
13C NMR (125 MHz, CDCl3): δ = 170.67, 170.17, 169.98, 169.97, 
166.00 (5 CO), 151.30, 143.44, 136.46, 130.39, 130.26, 129.49, 126.84, 126.68, 125.08, 
117.43 (12C, Ar-C), 96.84 (C-1), 70.03 (C-5), 69.52 (C-2), 68.97 (C-3), 68.71 (OCH), 66.02 
(C-4), 62.30 (C-6), 22.17 (2C, CH(CH3)2), 21.07, 20.91, 20.88, 20.87 (4 COCH3); HRMS: 
m/z: Calcd for C30H33ClNaO12 [M+Na]
+: 643.1558, found: 643.1554. 
 
tert-Butyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-4-
carboxylate (11e). Prepared according to general procedure A from 10 (27 mg, 0.047 mmol) 
and 4-tert-butyloxycarbonylphenyl boronic pinacol ester (7e, 16 mg, 0.052 mmol, 1.1 eq) 
with K3PO4 (31 mg, 0.141 mmol, 3.0 eq) and PdCl2(dppf)CH2Cl2 (1.6 mg, 1.9 mol, 0.04 
eq) in DMF (0.5 mL). Purified by MPLC on silica gel (petroleum ether/EtOAc, 7:3). Yield: 
22 mg (74%) as colorless oil. [α]
  
D
20 +64.9 (c 1.09, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 
7.97 (d, J = 8.4 Hz, 2H, Ar-H), 7.59 (d, J = 2.2 Hz, 1H, Ar-H), 7.49 (d, J = 8.4 Hz, 2H, Ar-
H), 7.38 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.18 (d, J = 8.8 Hz, 1H, Ar-H), 5.57 (dd, J = 3.5, 
10.1 Hz, 1H, H-3), 5.55 (d, J = 1.5 Hz, 1H, H-1), 5.49 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.34 (t, 
J = 10.1 Hz, 1H, H-4), 4.22 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.12 (ddd, J = 2.1, 5.3, 10.1 Hz, 
1H, H-5), 4.03 (dd, J = 2.2, 12.3 Hz, 1H, H-6b), 2.15, 2.01, 1.98, 1.97 (4 s, 12H, 4 COCH3), 
1.54 (s, 9H, C(CH3)3); 
13C NMR (125 MHz, CDCl3): δ = 170.68, 170.18, 169.99, 169.98, 
165.68 (5 CO), 151.26, 143.16, 136.55, 131.39, 130.30, 129.48, 126.77, 126.67, 125.08, 
117.45 (12C, Ar-C), 96.86 (C-1), 81.40 (C(CH3)3), 70.04 (C-5), 69.54 (C-2), 68.98 (C-3), 
66.04 (C-4), 62.31 (C-6), 28.43 (3C, C(CH3)3), 21.09, 20.92, 20.90, 20.88 (4 COCH3); ESI-
MS: m/z: Calcd for C31H35ClNaO12 [M+Na]
+: 657.17, found: 657.13. 
 
2-Methoxyethyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chloro-biphenyl-
4-carboxylate (11f). 4-(2-Methoxyethoxycarbonyl)phenylboronic acid pinacol ester (7f) was 
prepared according to the procedure for 7a from 6 (25 mg, 0.104 mmol) with SOCl2 (11 L, 
0.151 mmol, 1.5 eq) in 2-methoxyethanol (0.4 mL). The reaction mixture was concentrated in 
vacuo after 4 h. The crude product was used directly in the coupling reaction according to 
general procedure A with 10 (55 mg, 0.095 mmol), K3PO4 (61 mg, 0.285 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (3.1 mg, 3.8 mol, 0.04 eq) in DMF (1 mL). Purified by MPLC on silica 
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gel (petroleum ether/EtOAc, 3:2). Yield: 32 mg (52% over two steps) as colorless oil. [α]
  
D
20 
+60.9 (c 1.26, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 8.05 (d, J = 8.4 Hz, 2H, Ar-H), 7.60 
(d, J = 2.2 Hz, 1H, Ar-H), 7.52 (d, J = 8.4 Hz, 2H, Ar-H), 7.39 (dd, J = 2.2, 8.6 Hz, 1H, Ar-
H), 7.19 (d, J = 8.9 Hz, 1H, Ar-H), 5.56 (dd, J = 3.5, 10.1 Hz, 1H, H-3), 5.54 (d, J = 1.5 Hz, 
1H, H-1), 5.49 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.34 (t, J = 10.1 Hz, 1H, H-4), 4.43-4.42 (m, 
2H, CH2), 4.22 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.12 (ddd, J = 2.2, 5.2, 10.1 Hz, 1H, H-5), 
4.03 (dd, J = 2.2, 12.3 Hz, 1H, H-6b), 3.68-3.67 (m, 2H, CH2), 3.37 (s, 3H, OCH3), 2.14, 
2.01, 1.98, 1.97 (4 s, 12H, 4 COCH3); 
13C NMR (125 MHz, CDCl3): δ = 170.58, 170.07, 
169.89, 169.88, 166.39 (5 CO), 151.26, 143.64, 136.25, 130.51, 129.41, 129.30, 126.81, 
126.60, 125.00, 117.34 (12C, Ar-C), 96.74 (C-1), 70.69 (CH2), 69.95 (C-5), 69.42 (C-2), 
68.87 (C-3), 65.92 (C-4), 64.24 (CH2), 62.20 (C-6), 59.19 (OCH3), 20.98, 20.82, 20.79, 20.78 
(4 COCH3); ESI-MS: m/z: Calcd for C30H33ClNaO13 [M+Na]
+: 659.15, found: 659.12. 
 
2-Ethoxyethyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chloro-biphenyl-4-
carboxylate (11g). 4-(2-Ethoxyethoxycarbonyl)phenylboronic acid pinacol ester (7g) was 
prepared according to the procedure for 7a from 6 (40 mg, 0.161 mmol) with SOCl2 (35 L, 
0.484 mmol, 3.0 eq) in 2-ethoxyethanol (0.6 mL). After 6 h, the reaction mixture was diluted 
with DCM (40 mL) and washed with H2O (4 x 30 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo. The crude product was used directly in the coupling 
reaction according to general procedure A with 10 (47 mg, 0.081 mmol), K3PO4 (53 mg, 
0.242 mmol, 3.0 eq) and PdCl2(dppf)CH2Cl2 (3.3 mg, 4.1 mol, 0.05 eq) in DMF (2 mL). 
Purified by MPLC on silica gel (petroleum ether/EtOAc, 1:0-0:1). Yield: 25 mg (47% over 
two steps) as colorless oil. [α]
  
D
20 +54.5 (c 1.15, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 
8.12 (d, J = 8.4 Hz, 2H, Ar-H), 7.67 (d, J = 2.2 Hz, 1H, Ar-H), 7.59 (d, J = 8.4 Hz, 2H, Ar-
H), 7.46 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.27-7.25 (m, 1H, Ar-H), 5.64 (dd, J = 3.5, 10.1 Hz, 
1H, H-3), 5.62 (d, J = 1.7 Hz, 1H, H-1), 5.56 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.41 (t, J = 10.1 
Hz, 1H, H-4), 4.50-4.48 (m, 2H, CH2), 4.30 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.20 (ddd, J = 
2.2, 5.2, 10.1 Hz, 1H, H-5), 4.11 (dd, J = 2.2, 12.2 Hz, 1H, H-6b), 3.80-3.78 (m, 2H, CH2), 
3.60 (q, J = 7.0 Hz, 2H, OCH2CH3), 2.22, 2.08, 2.05, 2.04 (4 s, 12H, 4 COCH3), 1.24 (t, J = 
7.0 Hz, 3H, CH3); 
13C NMR (125 MHz, CDCl3): δ = 170.59, 170.09, 169.91, 169.89, 166.43 
(5 CO), 151.28, 143.62, 136.29, 130.52, 129.43, 129.42, 126.83, 126.62, 125.02, 117.35 
(12C, Ar-C), 96.77 (C-1), 69.96 (C-5), 69.45 (C-2), 68.89 (C-3), 68.56 (CH2), 66.85 
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(OCH2CH3), 65.94 (C-4), 64.49 (CH2), 62.22 (C-6), 21.00, 20.84, 20.81, 20.80 (4 COCH3), 
15.30 (CH3); ESI-MS: m/z: Calcd for C31H35ClNaO13 [M+Na]
+: 673.17, found: 673.19. 
 
2-Isopropoxyethyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chloro-
biphenyl-4-carboxylate (11h). Prepared according to general procedure A from 10 (105 mg, 
0.180 mmol) and 7h (60 mg, 0.180 mmol, 1.0 eq) with K3PO4 (118 mg, 0.540 mmol, 3.0 eq) 
and PdCl2(dppf)CH2Cl2 (7.3 mg, 9.0 mol, 0.05 eq) in DMF (2 mL). Purified by MPLC on 
silica gel (petroleum ether/EtOAc, 1:0-0:1). Yield: 67 mg (56%) as colorless oil. [α]
  
D
20 +55.6 
(c 1.10, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 8.11 (d, J = 8.4 Hz, 2H, Ar-H), 7.67 (d, J 
= 2.2 Hz, 1H, Ar-H), 7.59 (d, J = 8.4 Hz, 2H, Ar-H), 7.46 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 
7.26 (d, J = 8.4 Hz, 1H, Ar-H), 5.63 (dd, J = 3.5, 10.1 Hz, 1H, H-3), 5.61 (d, J = 1.3 Hz, 1H, 
H-1), 5.55 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.47-4.45 (m, 2H, 
CH2), 4.29 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.20 (ddd, J = 2.1, 5.2, 10.0 Hz, 1H, H-5), 4.10 
(dd, J = 2.1, 12.2 Hz, 1H, H-6b), 3.78-3.76 (m, 2H, CH2), 3.67 (hept, J = 6.1 Hz, 1H, OCH), 
2.21, 2.07, 2.05, 2.04 (4 s, 12H, 4 COCH3), 1.22 (d, J = 6.1 Hz, 6H, CH(CH3)2); 
13C NMR 
(125 MHz, CDCl3): δ = 170.59, 170.09, 169.91, 169.89, 166.43 (5 CO), 151.28, 143.59, 
136.30, 130.49 129.49, 129.44, 126.83, 126.61, 125.03, 117.36 (12C, Ar-C), 96.78 (C-1), 
72.20 (OCH), 69.97 (C-5), 69.45 (C-2), 68.89 (C-3), 66.12 (CH2), 65.95 (C-4), 64.76 (CH2), 
62.22 (C-6), 22.21 (2C, CH(CH3)2), 21.00, 20.84, 20.81, 20.80 (4 COCH3); ESI-MS: m/z: 
Calcd for C32H37ClNaO13 [M+Na]
+: 687.18, found: 687.23. 
 
2-(2-Ethoxyethoxy)ethyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-
chlorobiphenyl-4-carboxylate (11i). 4-(2-(2-Ethoxyethoxy)ethoxycarbonyl)phenyl-boronic 
acid pinacol ester (7i) was prepared according to the procedure for 7h from 6 (75 mg, 0.196 
mmol) and 2-(2-ethoxyethoxy)ethanol (40 L, 0.196 mmol, 1.0 eq) with DIC (54 L, 0.235 
mmol, 1.2 eq) and DMAP (2 mg, 0.016 mmol, 0.08 eq) in DCM (2 mL). The major 
impurities were removed by MPLC on silica gel (DCM/MeOH, 99:1) and the product was 
used directly in the coupling reaction according to general procedure A with 10 (79 mg, 
0.135 mmol), K3PO4 (89 mg, 0.405 mmol, 3.0 eq) and PdCl2(dppf)CH2Cl2 (5.5 mg, 6.8 
mol, 0.05 eq) in DMF (2 mL). Purified by MPLC on silica gel (petroleum ether/EtOAc, 
3:2). Yield: 60 mg (44% over two steps) as colorless oil. [α]
  
D
20 +58.6 (c 1.15, CHCl3); 
1H 
NMR (500 MHz, CDCl3): δ = 8.06-8.04 (m, 2H, Ar-H), 7.60 (d, J = 2.2 Hz, 1H, Ar-H), 7.53-
7.51 (m, 2H, Ar-H), 7.39 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.19 (m, 1H, Ar-H), 5.57 (dd, J = 
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3.5, 10.1 Hz, 1H, H-3), 5.54 (d, J = 1.7 Hz, 1H, H-1), 5.49 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 
5.34 (t, J = 10.1 Hz, 1H, H-4), 4.45-4.43 (m, 2H, CH2), 4.22 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 
4.12 (ddd, J = 2.2, 5.2, 10.1 Hz, 1H, H-5), 4.03 (dd, J = 2.2, 12.3 Hz, 1H, H-6b), 3.80-3.78 
(m, 2H, CH2), 3.65-3.63 (m, 2H, CH2), 3.56-3.54 (m, 2H, CH2), 3.47 (q, J = 7.0 Hz, 2H, 
OCH2CH3), 2.15, 2.01, 1.98, 1.97 (4 s, 12H, 4 COCH3), 1.14 (t, J = 7.0 Hz, 3H, CH3); 
13C 
NMR (125 MHz, CDCl3): δ = 170.60, 170.10, 169.91, 169.90, 166.40 (5 CO), 151.28, 
143.63, 136.28, 130.52, 129.44, 129.40, 126.83, 126.62, 125.02, 117.35 (12C, Ar-C), 96.77 
(C-1), 70.92, 70.00 (2C, 2 CH2), 69.96 (C-5), 69.45 (C-2), 69.39 (CH2), 68.89 (C-3), 66.86 
(OCH2CH3), 65.94 (C-4), 64.37 (CH2), 62.22 (C-6), 21.00, 20.84, 20.82, 20.80 (4 COCH3), 
15.29 (CH3); ESI-MS: m/z: Calcd for C33H39ClNaO14 [M+Na]
+: 717.19, found: 717.27. 
 
2-Acetoxyethyl 4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chloro-biphenyl-
4-carboxylate (11j). Prepared according to general procedure A from 10 (120 mg, 0.205 
mmol) and 7j (69 mg, 0.205 mmol, 1.0 eq) with K3PO4 (135 mg, 0.618 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (8.4 mg, 10.3 mol, 0.05 eq) in DMF (2 mL). Purified by MPLC on 
silica gel (petroleum ether/EtOAc, 3:2). Yield: 79 mg (58%) as colorless oil. [α]
  
D
20 +43.9 (c 
0.75, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 8.11 (d, J = 8.4 Hz, 2H, Ar-H), 7.67 (d, J = 
2.2 Hz, 1H, Ar-H), 7.60 (d, J = 8.4 Hz, 2H, Ar-H), 7.46 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.27 
(m, 1H, Ar-H), 5.64 (dd, J = 3.5, 10.1 Hz, 1H, H-3), 5.62 (d, J = 1.7 Hz, 1H, H-1), 5.56 (dd, J 
= 1.9, 3.4 Hz, 1H, H-2), 5.41 (t, J = 10.1 Hz, 1H, H-4), 4.54-4.53 (m, 2H, CH2), 4.45-4.43 
(m, 2H, CH2), 4.30 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.19 (ddd, J = 2.2, 5.2, 10.1 Hz, 1H, H-
5), 4.11 (dd, J = 2.2, 12.3 Hz, 1H, H-6b), 2.22, 2.11, 2.08, 2.05, 2.04 (5 s, 15H, 5 COCH3); 
13C NMR (125 MHz, CDCl3): δ = 171.01, 170.61, 170.12, 169.93, 169.90, 166.19 (6 CO), 
151.35, 143.86, 136.21, 130.53, 129.46, 129.05, 126.93, 126.64, 125.07, 117.37 (12C, Ar-C), 
96.79 (C-1), 69.99 (C-5), 69.46 (C-2), 68.90 (C-3), 65.95 (C-4), 62.97, 62.33 (2C, 2 CH2), 
62.23 (C-6), 21.02, 21.00, 20.85, 20.83, 20.82 (5 COCH3); HRMS: m/z: Calcd for 
C31H33ClNaO14 [M+Na]
+: 687.1457, found: 687.1450. 
 
Ethyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3a). Prepared 
according to general procedure B from 11a (18 mg, 0.030 mmol) with 1 M EtONa/EtOH 
(160 L) in EtOH/CHCl3 (4 mL, 1:1). Purified by MPLC on silica gel (DCM/MeOH, 17:3). 
Yield: 9 mg (69%) as a white solid. [α]
  
D
20 +105.0 (c 0.60, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 8.07 (d, J = 8.5 Hz, 2H, Ar-H), 7.73 (d, J = 2.3 Hz, 1H, Ar-H), 7.70 (d, J = 8.5 
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Hz, 2H, Ar-H), 7.59 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.49 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, 
J = 1.6 Hz, 1H, H-1), 4.38 (q, J = 7.1 Hz, 2H, OCH2), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 
4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.80-3.71 (m, 3H, H-4, H-6a, H-6b), 3.65 (ddd, J = 2.4, 
5.4, 9.8 Hz, 1H, H-5), 1.40 (t, J = 7.1 Hz, 3H, CH3); 
13C NMR (125 MHz, CD3OD): δ = 
167.86 (CO), 153.35, 145.15, 136.26, 131.15, 130.50, 129.76, 127.79, 127.74, 125.38, 118.61 
(12C, Ar-C), 100.73 (C-1), 76.02 (C-5), 72.40 (C-3), 71.84 (C-2), 68.22 (C-4), 62.66 (C-6), 
62.19 (OCH2), 14.61 (CH3); HRMS: m/z: Calcd for C21H23ClNaO8 [M+Na]
+: 461.0979, 
found: 461.0972. 
 
Propyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3b). Prepared 
according to general procedure B from 11b (22 mg, 0.035 mmol) with 1 M PrONa/PrOH 
(150 L) in PrOH/CHCl3 (2 mL, 1:1). Purified by MPLC on silica gel (DCM/MeOH, 17:3). 
Yield: 9 mg (56%) as a white solid. [α]
  
D
20 +90.0 (c 0.90, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 8.08 (d, J = 8.5 Hz, 2H, Ar-H), 7.74 (d, J = 2.3 Hz, 1H, Ar-H), 7.72 (d, J = 8.5 
Hz, 2H, Ar-H), 7.59 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.47 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, 
J = 1.5 Hz, 1H, H-1), 4.29 (t, J = 6.6 Hz, 2H, OCH2), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 
4.02 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-4, H-6a, H-6b), 3.65 (ddd, J = 2.4, 
5.5, 9.9 Hz, 1H, H-5), 1.85-1.78 (m, 2H, CH2), 1.06 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (125 
MHz, CD3OD): δ = 167.91 (CO), 153.35, 145.16, 136.28, 131.14, 130.47, 129.76, 127.80, 
127.76, 125.37, 118.61 (12C, Ar-C), 100.73 (C-1), 76.02 (C-5), 72.40 (C-3), 71.84 (C-2), 
68.22 (C-4), 67.74 (OCH2), 62.66 (C-6), 23.18 (CH2), 10.80 (CH3); HRMS: m/z: Calcd for 
C22H25ClNaO8 [M+Na]
+: 475.1136, found: 475.1131. 
 
Butyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3c). Prepared 
according to general procedure B from 11c (33 mg, 0.052 mmol) with 1 M BuONa/BuOH 
(200 L) in BuOH/CHCl3 (3 mL, 2:1). An additional portion of 1 M BuONa/BuOH (200 L) 
was added after 2 h. Purified by MPLC on silica gel (DCM/MeOH, 9:1). Yield: 9 mg (37%) 
as a white solid. [α]
  
D
20 +78.5 (c 0.95, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.07 (d, J = 
8.5 Hz, 2H, Ar-H), 7.74 (d, J = 2.2 Hz, 1H, Ar-H), 7.71 (d, J = 8.5 Hz, 2H, Ar-H), 7.60 (dd, J 
= 2.3, 8.6 Hz, 1H, Ar-H), 7.47 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, J = 1.3 Hz, 1H, H-1), 4.34 
(t, J = 6.5 Hz, 2H, OCH2), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 3.5, 9.5 Hz, 1H, 
H-3), 3.80-3.71 (m, 3H, H-4, H-6a, H-6b), 3.65 (ddd, J = 2.4, 5.5, 9.8 Hz, 1H, H-5), 1.81-
1.75 (m, 2H, CH2), 1.55-1.48 (m, 2H, CH2), 1.01 (t, J = 7.4 Hz, 3H, CH3); 
13C NMR (125 
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MHz, CD3OD): δ = 167.91 (CO), 153.36, 145.17, 136.29, 131.15, 130.48, 129.77, 127.80, 
127.76, 125.38, 118.61 (12C, Ar-C), 100.73 (C-1), 76.02 (C-5), 72.40 (C-3), 71.84 (C-2), 
68.22 (C-4), 65.99 (OCH2), 62.66 (C-6), 31.94, 20.33 (2 CH2), 14.08 (CH3); HRMS: m/z: 
Calcd for C23H27ClNaO8 [M+Na]
+: 489.1292, found: 489.1291. 
 
Isopropyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3d). Prepared 
according to general procedure B from 11d (21 mg, 0.034 mmol) with 1 M i-PrONa/i-PrOH 
(200 L) in i-PrOH/CHCl3 (1.5 mL, 2:1). An additional portion of 0.5 M i-PrONa/i-PrOH 
(500 L) was added after 6.5 h. Purified by MPLC on silica gel (DCM/MeOH, 9:1). Yield: 
9.5 mg (62%) as a white solid. [α]
  
D
20 +89.4 (c 0.90, MeOH); 1H NMR (500 MHz, CD3OD): δ 
= 8.06 (d, J = 8.5 Hz, 2H, Ar-H), 7.73 (d, J = 2.3 Hz, 1H, Ar-H), 7.70-7.69 (m, 2H, Ar-H), 
7.61 (dd, J = 2.3, 8.7 Hz, 1H, Ar-H), 7.47 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, J = 1.6 Hz, 1H, 
H-1), 5.23 (hept, J = 6.3 Hz, 1H, OCH), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 
9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-4, H-6a, H-6b), 3.64 (ddd, J = 2.4, 5.4, 9.8 Hz, 1H, H-
5), 1.38 (d, J = 6.3 Hz, 6H, CH(CH3)2); 
13C NMR (125 MHz, CD3OD): δ = 167.38 (CO), 
153.34, 145.07, 136.31, 131.10, 130.85, 129.76, 127.78, 127.70, 125.37, 118.61 (12C, Ar-C), 
100.73 (C-1), 76.02 (C-5), 72.40 (C-3), 71.84 (C-2), 69.87 (OCH), 68.22 (C-4), 62.66 (C-6), 
22.14 (2C, CH(CH3)2); HRMS: m/z: Calcd for C22H25ClNaO8 [M+Na]
+: 475.1136, found: 
475.1132. 
 
tert-Butyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3e). Prepared 
according to general procedure B from 11e (17 mg, 0.027 mmol) with t-BuOK (49 mg, 0.441 
mmol, 16 eq) in t-BuOH/CHCl3 (2 mL, 3:1). Purified by MPLC on silica gel (DCM/MeOH, 
9:1). Yield: 8 mg (63%) as a colorless solid. [α]
  
D
20 +82.4 (c 0.40, MeOH); 1H NMR (500 
MHz, CD3OD): δ = 8.01 (d, J = 8.5 Hz, 2H, Ar-H), 7.73 (d, J = 2.2 Hz, 1H, Ar-H), 7.67 (d, J 
= 8.5 Hz, 2H, Ar-H), 7.59 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.47 (d, J = 8.7 Hz, 1H, Ar-H), 
5.61 (d, J = 1.3 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.2 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 
1H, H-3), 3.81-3.71 (m, 3H, H-4, H-6a, H-6b), 3.64 (ddd, J = 2.4, 5.4, 9.6 Hz, 1H, H-5), 1.61 
(s, 9H, C(CH3)3); 
13C NMR (125 MHz, CD3OD): δ = 167.13 (CO), 153.29, 144.78, 136.39, 
131.99, 131.02, 129.74, 127.76, 127.60, 125.36, 118.61 (12C, Ar-C), 100.74 (C-1), 82.35 
(C(CH3)3), 76.01 (C-5), 72.40 (C-3), 71.84 (C-2), 68.22 (C-4), 62.66 (C-6), 28.43 (3C, 
C(CH3)3); HRMS: m/z: Calcd for C23H27ClNaO8 [M+Na]
+: 489.1292, found: 489.1286. 
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2-Methoxyethyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3f). 
Prepared according to general procedure B from 11f (16 mg, 0.025 mmol) with t-BuOK (56 
mg, 0.502 mmol, 20 eq) in t-BuOH/CHCl3 (6 mL, 5:1). An additional portion of t-BuOH (3 
mL) was added after 17 h and additional portions of t-BuOK were added after 17 h (40 eq) 
and 22 h (8 eq). Purified by MPLC on silica gel (DCM/MeOH, 9:1). Yield: 3 mg (25%) as a 
white wax. [α]
  
D
20 +92.3 (c 0.30, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.10 (d, J = 8.5 
Hz, 2H, Ar-H), 7.75 (d, J = 2.3 Hz, 1H, Ar-H), 7.72 (d, J = 8.5 Hz, 2H, Ar-H), 7.61 (dd, J = 
2.3, 8.6 Hz, 1H, Ar-H), 7.48 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, J = 1.6 Hz, 1H, H-1), 4.48-
4.46 (m, 2H, CH2), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 
3.80-3.71 (m, 5H, CH2, H-4, H-6a, H-6b), 3.64 (ddd, J = 2.3, 5.4, 9.7 Hz, 1H, H-5), 3.43 (s, 
3H, OCH3); 
13C NMR (125 MHz, CD3OD): δ = 167.75 (CO), 153.38, 145.30, 136.27, 
131.29, 130.19, 129.78, 127.82, 127.77, 125.39, 118.62 (12C, Ar-C), 100.73 (C-1), 76.03 (C-
5), 72.40 (C-3), 71.84 (C-2), 71.65 (CH2), 68.22 (C-4), 65.17 (CH2), 62.66 (C-6), 59.18 
(OCH3); HRMS: m/z: Calcd for C22H25ClNaO9 [M+Na]
+: 491.1085, found: 491.1080. 
 
2-Ethoxyethyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3g). 
Prepared according to general procedure B from 11g (12.5 mg, 0.019 mmol) with t-BuOK 
(51 mg, 0.432 mmol, 23 eq) in t-BuOH/CHCl3 (6 mL, 5:1). An additional portion of t-BuOK 
(23 eq) was added after 19 h. Purified by MPLC on silica gel (DCM/MeOH, 9:1). Yield: 6 
mg (67%) as a colorless solid. [α]
  
D
20 +70.1 (c 0.55, MeOH); 1H NMR (500 MHz, CD3OD): δ 
= 8.11-8.09 (m, 2H, Ar-H), 7.74 (d, J = 2.3 Hz, 1H, Ar-H), 7.72-7.71 (m, 2H, Ar-H), 7.60 
(dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.47 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, J = 1.6 Hz, 1H, H-1), 
4.47-4.45 (m, 2H, CH2), 4.12 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-
3), 3.81-3.71 (m, 5H, H-4, H-6a, H-6b, CH2), 3.65 (m, 1H, H-5), 3.61 (q, J = 7.0 Hz, 2H, 
OCH2CH3), 1.22 (t, J = 7.0 Hz, 3H, CH3); 
13C NMR (125 MHz, CD3OD): δ = 167.77 (CO), 
153.37, 145.27, 136.27, 131.28, 130.22, 129.78, 127.82, 127.76, 125.38, 118.61 (12C, Ar-C), 
100.73 (C-1), 76.02 (C-5), 72.40 (C-3), 71.84 (C-2), 69.56 (CH2), 68.22 (C-4), 67.67 
(OCH2CH3), 65.40 (CH2), 62.22 (C-6), 15.44 (CH3); ESI-MS: m/z: Calcd for C23H27ClNaO9 
[M+Na]+: 505.1241, found: 505.1234. 
 
2-Isopropoxyethyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3h). 
Prepared according to general procedure B from 11h (48 mg, 0.072 mmol) with t-BuOK (42 
mg, 0.361 mmol, 5.0 eq) in t-BuOH/CHCl3 (5.5 mL, 10:1). Additional portions of t-BuOK 
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were added every 30 min (5.0 eq, 5.0 eq and 1.0 eq). Purified by MPLC on silica gel 
(DCM/MeOH, 9:1). Yield: 24 mg (67%) as a white solid. [α]
  
D
20 +74.6 (c 0.30, MeOH); 1H 
NMR (500 MHz, CD3OD): δ = 8.09 (d, J = 8.5 Hz, 2H, Ar-H), 7.74 (d, J = 2.2 Hz, 1H, Ar-
H), 7.71 (d, J = 8.5 Hz, 2H, Ar-H), 7.60 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.47 (d, J = 8.7 Hz, 
1H, Ar-H), 5.61 (d, J = 1.4 Hz, 1H, H-1), 4.45-4.43 (m, 2H, CH2), 4.12 (dd, J = 1.8, 3.2 Hz, 
1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.69 (m, 6H, CH2, H-4, H-6a, H-6b, 
OCH), 3.65 (ddd, J = 2.3, 5.4, 9.7 Hz, 1H, H-5), 1.08 (d, J = 6.1 Hz, 6H, CH(CH3)2); 
13C 
NMR (125 MHz, CD3OD): δ = 167.79 (CO), 153.37, 145.26, 136.26, 131.26, 130.62, 129.77, 
127.81, 127.76, 125.38, 118.61 (12C, Ar-C), 100.73 (C-1), 76.02 (C-5), 73.45 (OCH), 72.40 
(C-3), 71.83 (C-2), 68.21 (C-4), 67.22 (CH2), 65.70 (CH2), 62.66 (C-6), 22.38 (2C, 
CH(CH3)2); HRMS: m/z: Calcd for C24H29ClNaO9 [M+Na]
+: 519.1398, found: 519.1395. 
 
2-(2-Ethoxyethoxy)ethyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate 
(3i). Prepared according to general procedure B from 11i (14 mg, 0.020 mmol) with t-BuOK 
(4 mg, 0.034 mmol, 1.7 eq) in t-BuOH (2 mL). An additional portion of t-BuOK (1.7 eq) was 
added after 2.5 h. Purified by MPLC on silica gel (DCM/MeOH, 9:1). Yield: 4.2 mg (40%) 
as a white wax. [α]
  
D
20 +76.4 (c 0.40, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.11-8.09 
(m, 2H, Ar-H), 7.74 (d, J = 2.3 Hz, 1H, Ar-H), 7.72-7.70 (m, 2H, Ar-H), 7.60 (dd, J = 2.3, 
8.6 Hz, 1H, Ar-H), 7.48 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, J = 1.7, 1H, H-1), 4.49-4.46 (m, 
2H, CH2), 4.12 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.86-3.84 
(m, 2H, CH2), 3.80-3.69 (m, 5H, H-6a, H-6b, H-4, OCH2), 3.65 (ddd, J = 2.4, 5.4, 9.8 Hz, 
1H, H-5), 3.62-3.60 (m, 2H, CH2), 3.53 (q, J = 7.0 Hz, 2H, OCH2CH3), 1.17 (t, J = 7.0 Hz, 
3H, CH3); 
13C NMR (125 MHz, CD3OD): δ = 167.76 (CO), 153.37, 145.27, 136.26, 131.30, 
130.24, 129.77, 127.81, 127.75, 125.38, 118.61 (12C, Ar-C), 100.73 (C-1), 76.02 (C-5), 
72.40 (C-3), 71.84 (C-2), 71.68, 70.92, 70.22 (3C, CH2), 68.22 (C-4), 67.62 (CH2),  65.35 
(OCH2CH3), 62.66 (C-6), 15.41 (CH3); HRMS: m/z: Calcd for C25H31ClNaO10 [M+Na]
+: 
549.1503, found: 549.1498. 
 
2-Hydroxyethyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3k). 
Prepared according to general procedure B from 11j (36 mg, 0.054 mmol) with t-BuOK (32 
mg, 0.271 mmol, 5.0 eq) in t-BuOH/CHCl3 (5.5 mL, 10:1). Additional portions of t-BuOK 
(10 eq) were added after 2 h and 24 h. Purified by MPLC on silica gel (DCM/MeOH, 9:1). 
Yield: 8 mg (32%) as a white wax. [α]
  
D
20 +79.5 (c 0.65, MeOH); 1H NMR (500 MHz, 
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CD3OD): δ = 8.13 (d, J = 8.5 Hz, 2H, Ar-H), 7.74 (d, J = 2.3 Hz, 1H, Ar-H), 7.71 (d, J = 8.5 
Hz, 2H, Ar-H), 7.60 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.47 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, 
J = 1.6 Hz, 1H, H-1), 4.41-4.39 (m, 2H, CH2), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J 
= 3.4, 9.5 Hz, 1H, H-3), 3.89-3.87 (m, 2H, CH2), 3.80-3.71 (m, 3H, H-4, H-6a, H-6b), 3.65 
(ddd, J = 2.4, 5.4, 9.7 Hz, 1H, H-5); 13C NMR (125 MHz, CD3OD): δ = 167.93 (CO), 153.36, 
145.23, 136.29, 131.35, 130.29, 129.77, 127.80, 127.72, 125.38, 118.62 (12C, Ar-C), 100.73 
(C-1), 76.02 (C-5), 72.40 (C-3), 71.83 (C-2), 68.22 (C-4), 67.63 (CH2), 62.66 (C-6), 61.16 
(CH2); HRMS: m/z: Calcd for C21H23ClNaO9 [M+Na]
+: 477.0928, found: 477.0921. 
 
2-(Dimethylamino)ethyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate 
(3l). Prepared according to general procedure C from 1 (19 mg, 0.044 mmol) and 2-
(dimethylamino)ethanol (13 L, 0.132 mmol, 3.0 eq) with DIPEA (23  L, 0.132 mmol, 3.0 
eq) and COMU (39 mg, 0.088 mmol, 2.0 eq) in DMF (2 mL). Purified by preparative LC-MS 
(RP-18, H2O/MeCN, 19:1-3:7, + 0.2% HCOOH). Yield: 8.2 mg (39%) as a white solid. [α]
  
D
20 
+62.7 (c 0.75, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.15 (d, J = 8.4 Hz, 2H, Ar-H), 
7.75-7.73 (m, 3H, Ar-H), 7.60 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.48 (d, J = 8.7 Hz, 1H, Ar-
H), 5.61 (d, J = 1.5 Hz, 1H, H-1), 4.69-4.67 (m, 2H, CH2), 4.11 (dd, J = 1.8, 3.3 Hz, 1H, H-
2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.80-3.71 (m, 3H, H-4, H-6a, H-6b), 3.64 (ddd, J = 
2.4, 5.5, 9.7 Hz, 1H, H-5), 3.57-3.55 (m, 2H, CH2), 2.97 (s, 6H, N(CH3)2); 
13C NMR (125 
MHz, CD3OD): δ = 167.18 (CO), 153.46, 145.69, 136.03, 131.54, 129.77, 129.38, 127.83, 
125.41, 118.61 (12C, Ar-C), 100.69 (C-1), 76.03 (C-5), 72.39 (C-3), 71.82 (C-2), 68.21 (C-
4), 62.66 (C-6), 60.42, 57.65 (2 CH2), 44.16 (2C, N(CH3)2); HRMS: m/z: Calcd for 
C23H29ClNO8 [M+H]
+: 482.1582, found: 482.1578. 
 
2-Piperidinoethyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3m). 
Prepared according to general procedure C from 1 (46 mg, 0.112 mmol) and 1-(2-
hydroxyethyl)piperidine (59 L, 0.448 mmol, 4.0 eq) with DIPEA (58  L, 0.336 mmol, 3.0 
eq) and COMU (99 mg, 0.224 mmol, 2.0 eq) in DMF (4 mL). Purified by preparative LC-MS 
(RP-18, H2O/MeCN, 19:1-1:19, + 0.2% HCOOH). Yield: 7.8 mg (13%) as a yellowish solid. 
[α]
  
D
20 +64.3 (c 0.25, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.12 (d, J = 8.4 Hz, 2H, Ar-
H), 7.75-7.73 (m, 3H, Ar-H), 7.61 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.48 (d, J = 8.7 Hz, 1H, 
Ar-H), 5.62 (d, J = 1.4 Hz, 1H, H-1), 4.62-4.60 (m, 2H, CH2), 4.12 (dd, J = 1.8, 3.2 Hz, 1H, 
H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-4, H-6a, H-6b), 3.64 (ddd, J = 
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2.4, 5.5, 9.6 Hz, 1H, H-5), 3.23 (m, 2H, CH2N), 3.02 (br s, 4H, 2 NCH2), 1.81-1.76 (m, 4H, 2 
CH2), 1.62-1.60 (m, 2H, (CH2)2CH2); 
13C NMR (125 MHz, CD3OD): δ = 167.23 (CO), 
153.47, 145.69, 136.03, 131.49, 129.78, 129.44, 127.86, 127.83, 125.42, 118.62 (12C, Ar-C), 
100.70 (C-1), 76.04 (C-5), 72.40 (C-3), 71.82 (C-2), 68.22 (C-4), 62.67 (C-6), 60.19 (CH2), 
57.01 (CH2N), 54.93 (2 NCH2), 24.31 (2C, 2 CH2), 22.65 ((CH2)2CH2); HRMS: m/z: Calcd 
for C26H33ClNO8 [M+H]
+: 522.1895, found: 522.1889. 
 
2-Morpholinoethyl 3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxylate (3n). 
Prepared according to general procedure C from 1 (20 mg, 0.049 mmol) and 4-(2-
hydroxyethyl)morpholine (18 L, 0.147 mmol, 3.0 eq) with DIPEA (25 L, 0.146 mmol, 3.0 
eq) and COMU (42 mg, 0.095 mmol, 2.0 eq) in DMF (2 mL). The major impurities were 
removed by MPLC on silica gel (DCM/MeOH, 8:2) followed by purification by preparative 
LC-MS (RP-18, H2O/MeCN, 19:1-1:19, + 0.2% HCOOH). Yield: 3.2 mg (13%) as a 
yellowish solid. [α]
  
D
20 +72.5 (c 0.35, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.12 (d, J = 
8.4 Hz, 2H, Ar-H), 7.75-7.72 (m, 3H, Ar-H), 7.61 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.48 (d, J 
= 8.7 Hz, 1H, Ar-H), 5.61 (d, J = 1.4 Hz, 1H, H-1), 4.59-4.57 (m, 2H, OCH2), 4.12 (dd, J = 
1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 7H, 2 CH2O, H-4, 
H-6a, H-6b), 3.64 (ddd, J = 2.3, 5.4, 9.6 Hz, 1H, H-5), 3.13-3.11 (m, 2H, CH2N), 2.92 (m, 
4H, 2 NCH2); 
13C NMR (125 MHz, CD3OD): δ = 167.53 (CO), 153.43, 145.47, 136.17, 
131.37, 129.93, 129.78, 127.81, 125.41, 118.62 (12C, Ar-C), 100.72 (C-1), 76.04 (C-5), 
72.40 (C-3), 71.83 (C-2), 68.22 (C-4), 66.78 (2C, 2 CH2O), 62.67 (C-6), 61.95 (OCH2), 57.94 
(CH2N), 54.55 (2C, 2 NCH2); HRMS: m/z: Calcd for C25H31ClNO9 [M+H]
+: 524.1687, 
found: 524.1684. 
 
2-(Dimethylamino)ethyl 3’-trifluoromethyl-4’-(-D-mannopyranosyloxy)-biphenyl-4-
carboxylate (5l). Prepared according to general procedure C from 4[21] (60 mg, 0.135 mmol) 
and 2-(dimethylamino)ethanol (82 L, 0.810 mmol, 6.0 eq) with DIPEA (69 L, 0.405 
mmol, 3.0 eq) and COMU (119 mg, 0.270 mmol, 2.0 eq) in DMF (4 mL). Purified by 
preparative LC-MS (RP-18, H2O/MeCN, 19:1-1:19, + 0.2% HCOOH). Yield: 37 mg (53%) 
as a white solid. [α]
  
D
20 +80.9 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.17 (d, J = 
8.4 Hz, 2H, Ar-H), 7.91-7.89 (m, 2H, Ar-H), 7.76 (d, J = 8.4 Hz, 2H, Ar-H), 7.61 (d, J = 8.4 
Hz, 1H, Ar-H), 5.66 (d, J = 1.2 Hz, 1H, H-1), 4.66-4.64 (m, 2H, OCH2), 4.06 (dd, J = 1.8, 3.3 
Hz, 1H, H-2), 3.94 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-4, H-6a, H-6b), 3.58 
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(ddd, J = 2.3, 5.6, 9.6 Hz, 1H, H-5), 3.45-3.43 (m, 2H, CH2N), 2.87 (s, 6H, N(CH3)2); 
13C 
NMR (125 MHz, CD3OD): δ = 167.23 (CO), 155.61, 145.55, 134.59, 133.46, 131.58, 129.67, 
127.89, 126.46, 126.41, 126.07, 123.90, 121.00, 120.76, 120.51, 117.83 (13C, Ar-C, CF3), 
100.27 (C-1), 76.13 (C-5), 72.24 (C-3), 71.73 (C-2), 68.11 (C-4), 62.68 (C-6), 60.95 (OCH2), 
57.79 (CH2N), 44.41 (2C, N(CH3)2); HRMS: m/z: Calcd for C24H29F3NO8 [M+H]
+: 516.1845, 
found: 516.1840. 
 
Physicochemical and in vitro pharmacokinetic studies 
 
Materials: Dimethyl sulfoxide (DMSO), 1-propanol, 1-octanol, Dulbecco’s Modified 
Eagle’s Medium (DMEM) high glucose, Penicillin-Streptomycin (solution stabilized, with 
10’000 units Penicillin and 10 mg Streptomycin/mL), L-glutamine solution (200 mM), 
magnesium chloride, bis(4-nitrophenyl) phosphate (BNPP), Loperamide hydrochloride, and 
Neostigmine bromide were purchased from Sigma-Aldrich (St. Louis, MI, USA). PRISMA 
HT universal buffer, GIT-0 Lipid Solution, and Acceptor Sink Buffer were ordered from pIon 
(Woburn, MA, USA). MEM non-essential amino acids solution 10 mM (100X), fetal bovine 
serum (FBS), and DMEM without sodium pyruvate and phenol red were bought from 
Invitrogen (Carlsbad, CA, USA). Acetonitrile (MeCN) and methanol (MeOH) were ordered 
from Acros Organics (Geel, Belgium). Human plasma was purchased from Biopredic 
(Rennes, France). Pooled male rat liver microsomes (Sprague Dawley), and pooled human 
liver microsomes were ordered from BD Bioscience (Woburn, MA, USA). The Caco-2 cells 
were kindly provided by Prof G. Imanidis, FHNW, Muttenz, Switzerland and originated from 
the American Type Culture Collection (Rockville, MD, USA).  
 
Aqueous solubility. Solubility was determined in a 96-well format using the µSOL Explorer 
solubility analyzer (pIon, version 3.4.0.5). For each compound, measurements were 
performed at two pH values (3.0, 7.4) in triplicate. Six wells of a deep well plate, i.e. three 
wells per pH value, were filled with 300 µL of PRISMA HT universal buffer adjusted to 
pH 3.0 or 7.4 by adding the requested amount of NaOH (0.5 M). Aliquots (3 µL) of a 
compound stock solution (40-100 mM in DMSO) were added and thoroughly mixed. The 
final sample concentration was 0.4-1.0 mM, the residual DMSO concentration was 1.0% 
(v/v) in the buffer solutions. After 15 h, the solutions were filtrated (0.2 µm 96-well filter 
plates) using a vacuum to collect manifold (Whatman Ltd., Maidstone, UK) to remove any 
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precipitates. Equal amounts of filtrate and 1-propanol were mixed and transferred to a 96-
well plate for UV/Vis detection (190 to 500 nm, SpectraMax 190, Molecular Devices, Silicon 
Valley, CA, USA). The amount of material dissolved was calculated by comparison with 
UV/Vis spectra obtained from reference samples, which were prepared by dissolving 
compound stock solution in a 1:1 mixture of buffer and 1-propanol (final concentrations 
0.067-0.167 mM).  
 
log D7.4 determination. The in silico prediction tool ALOGPS
[58] was used to estimate the 
log P values of the compounds. Depending on these values, the compounds were classified 
into three categories: hydrophilic compounds (log P below zero), moderately lipophilic 
compounds (log P between zero and one) and lipophilic compounds (log P above one). For 
each category, two different ratios (volume of 1-octanol to volume of buffer) were defined as 
experimental parameters (Table 3).  
Table 3. Compound classification based on estimated log P values. 
compound type log P ratios (1-octanol: buffer) 
hydrophilic  < 0 30:140, 40:130 
moderately lipophilic 0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
 
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol were mixed and shaken 
vigorously for 5 min to saturate the phases. The mixture was left until separation of the two 
phases occurred, and the buffer was retrieved. Stock solutions of the test compounds were 
diluted with buffer to a concentration of 1 µM. For each compound, six determinations, i.e. 
three determinations per 1-octanol:buffer ratio, were performed in different wells of a 96-well 
plate. The respective volumes of buffer containing analyte (1 µM) were pipetted to the wells 
and covered by saturated 1-octanol according to the chosen volume ratio. The plate was 
sealed with aluminium foil, shaken (1350 rpm, 25 °C, 2 h) on a Heidoph Titramax 1000 
plate-shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) and 
centrifuged (2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). 
The aqueous phase was transferred to a 96-well plate for analysis by liquid chromatography-
mass spectrometry (LC-MS, see below).  
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The log D7.4 coefficients were calculated from the 1-octanol:buffer ratio (o:b), the initial 
concentration of the analyte in buffer (1 µM), and the concentration of the analyte in buffer 
(cB) with Equation 1:  
 
The average of the three log D7.4 values per 1-octanol:buffer ratio was calculated. If the two 
means obtained for a compound did not differ by more than 0.1 units, the results were 
accepted.  
 
Parallel artificial membrane permeability assay (PAMPA). Effective permeability 
(log Pe) was determined in a 96-well format with the PAMPA.
[38] For each compound, 
measurements were performed at two pH values (5.0, 7.4) in quadruplicate. Eight wells of a 
deep well plate, i.e. four wells per pH-value, were filled with 650 µL of PRISMA HT 
universal buffer adjusted to pH 5.0 or 7.4 by adding the requested amount of NaOH (0.5 M). 
Samples (150 µL) were withdrawn from each well to determine the blank spectra by UV-
spectroscopy (190 to 500 nm, SpectraMax 190). Then, analyte dissolved in DMSO (10 mM) 
was added to the remaining buffer to yield 50 µM solutions. To exclude precipitation, the 
optical density was measured at 650 nm, with 0.01 being the threshold value. Solutions 
exceeding this threshold were filtrated. Afterwards, samples (150 µL) were withdrawn to 
determine the reference spectra. Further 200 µL was transferred to each well of the donor 
plate of the PAMPA sandwich (pIon, P/N 110 163). The filter membranes at the bottom of 
the acceptor plate were infused with 5 µL of GIT-0 Lipid Solution and 200 µL of Acceptor 
Sink Buffer was filled into each acceptor well. The sandwich was assembled, placed in the 
GutBoxTM, and left undisturbed for 16 h. Then, it was disassembled and samples (150 µL) 
were transferred from each donor and acceptor well to UV-plates. Quantification was done 
by UV/Vis-spectroscopy. Effective permeability (log Pe) was calculated from the compound 
flux deduced from the UV/Vis spectra, the filter area, and the initial sample concentration in 
the donor well with the aid of the PAMPA Explorer Software (pIon, version 3.5). 
 
Colorectal adenocarcinoma (Caco-2) cell permeation assay. Caco-2 cells were cultivated 
in tissue culture flasks (BD Biosciences, Franklin Lakes, NJ, USA) with DMEM high 
glucose medium, containing L-glutamine (2 mM), nonessential amino acids (0.1 mM), 
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Penicillin (100 U/mL), Streptomycin (100 µg/mL), and fetal bovine serum (10%). The cells 
were kept at 37 °C in humidified air containing 5% CO2, and the medium was changed every 
second day. When approximately 90% confluence was reached, the cells were split in a 1:10 
ratio and distributed to new tissue culture flasks. At passage numbers between 60 and 65, 
they were seeded at a density of 5.3 x 105 cells per well to Transwell 6-well plates (Corning 
Inc., Corning, NY, USA) with 2.5 mL of culture medium in the basolateral and 2 mL in the 
apical compartment. The medium was renewed on alternate days. Permeation experiments 
were performed between days 19 and 21 post seeding. Previously to the experiment, the 
integrity of the Caco-2 monolayers was evaluated by measuring the transepithelial electrical 
resistance (TEER) with an Endohm tissue resistance instrument (World Precision Instruments 
Inc., Sarasota, FL, USA). Only wells with TEER values higher than 250 Ω cm2 were used. 
To inhibit carboxylesterase activity, the Caco-2 cell monolayers were pre-incubated with 
bis(4-nitrophenyl) phosphate (BNPP, 200 µM) dissolved in transport medium (DMEM 
without sodium pyruvate and phenol red) for 40 min.[59] Experiments were performed in the 
apical-to-basolateral (absorptive) and basolateral-to-apical (secretory) directions in triplicate. 
Transport medium was withdrawn from the donor compartments of three wells and replaced 
by the same volume of compound stock solutions (in DMSO) to reach an initial sample 
concentration of 62.5 µM, 100 µM, 200 µM, 400 µM, or 825 µM. The Transwell plate was 
shaken (600 rpm, 37 °C) on a Heidolph Titramax 1000 plate-shaker. Samples (40 µL) were 
withdrawn from the donor and acceptor compartments 30 min after initiation of the 
experiment and the concentrations were determined by LC-MS (see below). Apparent 
permeability (Papp) was calculated according to Equation 2: 
 
where dQ/dt is the compound flux (mol s-1), A the surface area of the monolayer (cm2), and 
c0 the initial concentration in the donor compartment (mol cm
-3).[44] After the experiment, 
TEER values were assessed again for each well and results from wells with values below 
250 Ω cm2 were discarded.  
 
In vitro metabolism: microsomal stability  
Metabolic stability study. Incubations were performed in triplicate in a 96-well format on an 
Eppendorf Thermomixer Comfort. The reaction mixture (270 µL) consisting of liver 
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microsomes (0.139 µg/mL), TRIS-HCl buffer (0.1 M, pH 7.4) and MgCl2 (2 mM) was 
preheated (37 °C, 500 rpm, 10 min), and the incubation was initiated by adding 30 µL of 
compound solution (20 µM) in TRIS-HCl buffer. The final concentration of the compound 
was 2 µM, and the microsomal concentration was 0.125 mg/mL. At the beginning of the 
experiment (t = 0 min) and after an incubation time of 5, 10, 20, 40, and 60 min, samples 
(40 µL) were transferred to 120 µL of ice-cooled MeCN or MeOH and centrifuged 
(3600 rpm, 4 °C, 10 min). Then, 80 µL of supernatant was transferred to a 96-well plate for 
LC-MS analysis (see below). The metabolic half-life (t1/2) was calculated from the slope of 
the linear regression from the log percentage remaining compound versus incubation time 
relationship. Control experiments were performed in parallel by preincubating the 
microsomes with the specific carboxylesterase inhibitor BNPP (1 mM) for 5 min before 
addition of the compound solution.[40]  
Inhibition study. Test compounds were dissolved in DMSO to 1 mM and then diluted with 
TRIS-HCl buffer (0.1 M, pH 7.4) containing MgCl2 (2 mM) to a concentration of 6 µM. 
Loperamide hydrochloride was dissolved in DMSO to 20 mM, 2 mM, and 0.2 mM and then 
diluted with TRIS-HCl buffer containing MgCl2 to a concentration of 750 µM, 75 µM, and 
7.5 µM. Human liver microsomes were suspended in TRIS-HCl buffer containing MgCl2 to a 
concentration of 30 µg/mL. Compound solution (100 µL) and microsome suspension 
(200 µL) mixed with Loperamide solution or blank buffer (50 µL) were preheated (37 °C, 
500 rpm, 15 min) in separate wells of a 96-well plate. The incubation was initiated by 
transferring 200 µL of microsome suspension containing Loperamide to the compound 
solution. The final compound concentration was 2 µM, the microsomal concentration was 
20 µg/ml, and the Loperamide concentration was 100 µM, 10 µM, 1 µM, and 0 µM (blank). 
At the beginning of the experiment (t = 0 min) and after an incubation time of 10, 20, 30, 45, 
and 60 min, samples (20 µL) were transferred to 60 µL of ice-cooled MeOH and analysed by 
LC-MS (see below). The metabolic turnover was assessed as accumulation of product 1 
versus incubation time.  
 
In vitro metabolism: plasma stability 
Metabolic stability study. Incubations were performed in triplicates in a 96-well format 
according to the procedure described by Di et al.[60] Human plasma was centrifuged (4 °C, 
3000 rpm, 10 min) to remove particulates before use. Compounds were dissolved in DMSO 
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to 80 µM and then diluted with phosphate buffer (0.1 M, pH 7.4) to a concentration of 8 µM. 
Plasma (156 µL) was mixed with phosphate buffer (84 µL) and preheated (37 °C, 500 rpm, 
10 min). The incubation was initiated by adding 80 µL of compound solution. The final 
compound concentration was 2 µM and the plasma concentration was 50% in buffer pH 7.4. 
At the beginning of the experiment (t = 0 min) and after an incubation time of 15, 30, 60, and 
120 min, samples (50 µL) were transferred to 150 µL of ice-cooled MeOH, frozen (-20 °C, 
10 min) and centrifuged (3600 rpm, 4 °C, 10 min). The supernatant (80 µL) was transferred 
to a 96-well plate for LC-MS analysis (see below). The metabolic half-life (t1/2) was 
calculated from the slope of the linear regression from the log percentage remaining 
compound versus incubation time relationship. To monitor non-enzymatic compound 
degradation, incubations in absence of human plasma were run in parallel.  
Inhibition study. Human plasma and test compound were processed as described above. 
Neostigmine bromide was dissolved in DMSO to 10 mM, 3 mM, 1 mM, 0.3 mM, 0.1 mM, 
0.03 mM, and 0.01 mM and then diluted with phosphate buffer (0.1 M, pH 7.4) to a 
concentration of 80 µM, 24 µM, 8 µM, 2.4 µM, 0.8 µM, 0.24 µM, and 0.08 µM. Human 
plasma (156 µL) mixed with phosphate buffer (44 µL) was preheated (37 °C, 500 rpm, 
10 min). Then, Neostigmine bromide solution or blank buffer (40 µL) was added for 
preincubation (37 °C, 500 rpm, 5 min). The incubation was initiated by adding 80 µL of 
compound solution. The final compound concentration was 2 µM, the plasma concentration 
was 50% in buffer pH 7.4, and the Neostigmine bromide concentration was 10 µM, 3 µM, 
1 µM, 0.3 µM, 0.1 µM, 0.03 µM, 0.01 µM, and 0 µM (blank). At the beginning of the 
experiment (t = 0 min) and after an incubation time of 5, 10, 30, and 60 min, samples (50 µL) 
were transferred to 150 µL of ice-cooled MeOH, frozen (-20 °C, 10 min), and centrifuged 
(3600 rpm, 4 °C, 10 min). The supernatant (80 µL) was transferred to a 96-well plate for LC-
MS analysis (see below). Metabolic activity was calculated from the slope of the linear 
regression from the log percentage remaining compound versus incubation time relationship. 
 
LC-MS measurements. Analyses were performed using a 1100/1200 Series HPLC System 
coupled to a 6410 Triple Quadrupole mass detector (Agilent Technologies, Inc., Santa Clara, 
CA, USA) equipped with electrospray ionization. The system was controlled with the Agilent 
MassHunter Workstation Data Acquisition software (version B.01.04). The column used was 
an Atlantis® T3 C18 column (2.1 x 50 m) with a 3-µm particle size (Waters Corp., Milford, 
MA, USA). The mobile phase consisted of eluent A: H2O containing 0.1% formic acid (for 1, 
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3f-i, 3l-n, 4, and 5l), or 10 mM ammonium acetate, pH 5.0 in 95:5 H2O:MeCN (for 2, 3a-e, 
3k); and eluent B: MeCN containing 0.1% formic acid. The flow rate was maintained at 0.6 
mL/min. The gradient was ramped from 95% A/5% B to 5% A/95% B over 1 min, and then 
hold at 5% A/95% B for 0.1 min. The system was then brought back to 95% A/5% B, 
resulting in a total duration of 4 min. MS parameters such as fragmentor voltage, collision 
energy, polarity were optimized individually for each drug, and the molecular ion was 
followed for each compound in the multiple reaction monitoring mode. The concentrations of 
the analytes were quantified by the Agilent Mass Hunter Quantitative Analysis software 
(version B.01.04).  
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NMR spectra and HPLC traces to document purity of the test compounds. 
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2.2 Paper 2: Prodruggability of Carbohydrates – Oral FimH Antagonists 
 
This manuscript focuses on improving membrane permeability of 4’-(methylsulfonyl)-
biphenyl-4-yl -D-mannopyranoside by means of an ester prodrug approach. Various 
lipophilic acyl groups are incorporated into the sugar moiety masking the polar hydroxyl 
group 6-OH. Moreover, the propensity of the prodrugs to the enzyme-mediated hydrolysis 
was studied in detail. 
 
 
 
 
Contribution to the project: 
Wojciech Schönemann was involved in the design of the prodrugs and their chemical 
synthesis together with the master student Philipp Dätwyler who he supervised. Furthermore, 
he was responsible for reviewing of the manuscript and writing the synthetic part. 
 
 
 
 
 
This paper was published in the Canadian Journal of Chemistry. 
 
Schönemann, W.*; Kleeb, S.*; Dätwyler, P.; Schwardt, O.; Ernst, B. Prodruggability of 
carbohydrates — oral FimH antagonists. Can. J. Chem. 2016, 94, 909-919. 
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2.3 Chapter 3: Antagonists Targeting the Arg98 Residue of FimH 
Adhesin   
 
The following chapter describes our approach to establish a stable interaction with Arg98 of 
the FimH protein using elongated fragments attached via amide bond to the terminal ring of 
biaryl mannosides. The involvement of Arg98 to binding was evaluated by comparing 
activities of obtained antagonists towards the wild type and R98A mutant of FimH. 
Furthermore, the physicochemical properties of the new antagonists were determined.  
  
  
  
  
Contribution to the project:  
Wojciech Schönemann designed and synthesized all, previously not reported, FimH 
antagonists described in this chapter. Furthermore, he is responsible for the writing of the 
entire chapter. 
Dr. Simon Kleeb and Dr. Jacqueline Bezençon determined physicochemical properties of 
new FimH antagonists. Dr. Said Rabbani measured affinity of new FimH antagonists in 
competitive binding assay. 
 
 
 
 
 
 
 
 
 
Abbreviations: UPEC, uropathogenic Escherichia coli; UTI, urinary tract infection; CRD, 
carbohydrate-recognition domain; P, octanol-water partition coefficient; Papp, apparent 
permeability; Pe, effective permeability; PAMPA, parallel artificial membrane permeability 
assay. 
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Introduction 
Urinary tract infections (UTIs) are among the most common bacterial infections worldwide. 
Millions of people suffer from UTI, in particular women.[1] More than 25% suffering from 
UTI will experience a recurrent infection within six months.[2] This makes UTIs a serious 
medical and economical issue.[3] Uropathogenic Escherichia coli (UPEC) are the most 
prevalent causative factor of UTI accounting for 70-95% of the reported cases.[4] The 
frequent use of antimicrobials led to increased antibiotic-resistance making alternative 
treatment strategies a pressing need.[5]  
UPEC employ adhesin FimH located on the tip of their type 1 pili to attach to urothelia cells 
of the host and to induce the infection.[6,7] In addition, adherent bacteria cannot be removed 
from the bladder by the bulk flow of urine. The high-mannosylated glycoprotein uroplakin 1a 
(UP1a) expressed on urothelial cells is a natural ligand for the carbohydrate recognition 
domain (CRD) of FimH.[8] Therefore, carbohydrate mimetics capable of blocking the 
adherence of UPEC can be employed as anti-adhesive drugs substituting antibiotics in the 
treatment of UTI. 
Almost three decades ago, Sharon and co-workers reported several aryl mannosides capable 
of inhibiting yeast agglutination in the presence of E. coli.[9-11] In the following decades, 
numerous high-affinity monovalent[12-23] and multivalent[24-30] FimH antagonists were 
synthesized. All FimH antagonists consist of a mannose moiety interacting with a negatively 
charged pocket of FimH-CRD and a lipophilic aglycone interacting with so called tyrosine 
gate composed of Tyr48, Ile52 and Tyr137. It was postulated that Arg98 could also 
contribute to the binding in the case of biphenyl -D-mannosides bearing an appropriate 
substituent in meta-position of the outer phenyl ring by forming hydrogen bonds or a salt 
bridge with the guanidine of Arg98 (Figure 1A).[16] However, in a first published example 
with a methyl carboxylate directly linked to the meta-position of the outer aromatic ring of 
the biphenyl aglycone ( 1) the geometry of the hydrogen bond deduced from the crystal 
structure (PDB ID: 3MCY) is unfavorable to form a strong interaction. Moreover, a 
carboxylic acid located in the same position being capable of establishing strong electrostatic 
interactions reduced the affinity.  
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Figure 1. A) Crystal structure of 1 co-crystallized with the FimH lectin domain (PDB ID: 3MCY);[12] B) 
Binding mode of amino acid derivative 2g stabilized by a salt bridge with Arg98 as observed in MD 
simulation.[31] 
This obviously contradictive result encouraged us to investigate the role of Arg98 in binding 
FimH antagonists in more detail. Pang et al. previously reported on biphenyl mannosides 
containing an elongated carboxylate side chain in para-position designed to reach Arg98.[20] 
However, this modification led to a reduction of the affinity. To establish stable interactions 
with Arg98, we expanded this approach by introducing linear amino acids of different lengths 
in meta- and para-position (e.g. 2g, Figure 1B) as well as substituting a terminal phenyl by 
pyrrole ring. Moreover, we replaced carboxylate by other groups capable of accepting 
hydrogen bond, i.e. pyridine derivatives and hydroxyl-bearing fragments (Figure 2). The 
antagonists most successful in the binding assay with wild type FimH were also tested with 
the R98A mutant. Since all antagonists bind to wild type FimH with nanomolar affinity, we 
evaluated physicochemical properties of these compounds or their ester prodrugs in order to 
estimate their potential use as orally bioavailable drugs. 
 
Figure 2. Modifications of the aglycone of a FimH antagonist introduced in order to establish new interactions 
with Arg98. 
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Results and Discussion 
Synthesis 
Commercially available boronates 4 and 9 were coupled with corresponding protected amino 
acids using COMU reagent to yield the boronate amide intermediates 5b-d and 10b-d, 
respectively. The boronate derivatives underwent directly Suzuki cross-coupling reaction[32] 
with peracetylated mannoside 3 [21] affording the protected biphenyl mannosides 6b-d and 
11b-d in moderate yields (Scheme 1). In order to avoid transesterification on the aglycone, a 
mixture of the corresponding alcohol and alkoxide in chloroform were used for deprotection 
( 7b-d, 12b-d). Additionally, compound 6b underwent transesterification with 
MeONa/MeOH to obtain methyl ester 7a. Saponification of the resulting prodrugs 7a, 7c, 7d 
and 12b-d gave the test compounds 8f-h and 2e, g, h, respectively.  
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Scheme 1. i) R4-NH2HCl, COMU, DIPEA, DMF or MeCN, rt, 3-20 h; ii) PdCl2(dppf)CH2Cl2, K3PO4, DMF, 
80 °C, 3-21 h, 34-66%; iii) MeONa/MeOH, EtONa/EtOH or t-BuOK/t-BuOH, CHCl3, rt, 1.5-35 h, 42-65%; iv) 
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1. aq. NaOH, MeOH, rt, 2-6 h; 2. Amberlyst-15 (H+), 43-61% for 2e, 2g, 2h, 8g, 8h; v) aq. NaOH, MeOH, rt, 
0.5 h, 86% for 8f. 
 
A similar strategy was applied to the synthesis of 18e and 20f (Scheme 2). First, 9 was 
coupled with glycine tert-butyl ester followed by a Suzuki coupling reaction with 13[21] and 
14[20] to yield 15b and 16b, respectively. Deacetylation was achieved with potassium tert-
butoxide in tert-butanol. These reaction conditions resulted in the formation of tert-butyl 
ester prodrugs 17b and 19b as well as active principles 18e and 20f. The ester cleavage might 
have occurred via E2 elimination of isobutylene by potassium tert-butoxide. 
Transesterification of 19b with MeONa/MeOH gave methyl ester 19a in moderate yield. 
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Scheme 2. i) R4-NH2HCl, COMU, DIPEA, DMF, rt, 3-7 h; ii) PdCl2(dppf)CH2Cl2, K3PO4, DMF, 80 °C, 19-20 
h, 49-72%; iii) 1. t-BuOK/t-BuOH, rt, 1.5-3 h; 2. Amberlyst-15 (H+), 36-44% for 17b, 18e, 19b; iv) 1. t-
BuOK/t-BuOH, rt, 1.5-3 h; 2. Amberlyst-15 (H+); 3. 0.5 M NaOH, 31% for 20f; v) MeONa/MeOH, rt, 1.5 h, 
65%. 
 
The synthesis of pyrrole-containing analogue of 2e and 2g is depicted in Scheme 3. 
Commercially available pyrrole 21 was coupled with mannoside 3[21] in copper-diamine-
catalyzed N-arylation[33] followed by reprotection of the sugar moiety by acetylation to give 
22 in a good yield. After treatment with MeONa/MeOH followed by an aqueous solution of 
sodium hydroxide, fully deprotected 23 was obtained. The compound 23 was then coupled 
with glycine tert-butyl ester and β-alanine tert-butyl ester by means of COMU reagent to 
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afford 24b and 24c. Subsequently, the ester prodrugs were saponified to yield test compounds 
25e and 25g. 
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Scheme 3. i) 1. CuI, trans-1,2-diaminocyclohexane, K3PO4, 1,4-dioxane, 100 °C, 19 h; 2. Ac2O, pyridine, 60 
°C, 2 h, 88%; ii) 1. MeONa/MeOH, rt, 1.5 h; 2. aq. NaOH, MeOH, rt, 15.5 h; 3. AcOH, 26%; iii) R4-NH2HCl, 
COMU, DIPEA or TEA, DMF, rt, 16 h, 45-52%; iv) 1. aq. NaOH, MeOH, rt, 16 h; 2. AcOH, 63%. 
 
In order to study different hydrogen bond acceptors in meta-position, additional amide 
derivatives were synthesized (Scheme 4). Previously described 26[34] was treated with 
corresponding amines and COMU reagent. The crude products were purified by preparative 
HPLC. The desired test compounds 27i-l were obtained in moderate to good yields. 
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Scheme 4. i) R4-NH2 or R4-NHHCl, COMU, DIPEA or TEA, DMF, rt, 5-15 h, 55-83%. 
 
Binding affinity 
The binding properties of the amino acid-substituted biaryl -D-mannopyranosides 2e, 2g, 
2h, 8f-h, 18e, 20f, 25e, 25g and the amide derivatives 27i-l were determined in a cell-free 
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competitive binding assay with the wild type FimH-CRD (Table 1).[35] Subsequently, the 
affinities of the most active antagonists (2e & 2g) were measured in the binging assay with 
the R98A mutant of FimH-CRD (Table 2). 
 
Cell-free competitive binding assay. The activities of all antagonists were measured twice 
in duplicate for each concentration. n-Heptyl -D-mannopyranoside (28) was used as the 
reference compound each time in parallel with a new batch of antagonists to ensure 
comparability. The affinities are referred to the activity of 28 as rIC50. Affinity data for the 
wild type FimH-CRD are summarized in Table 1, those for R98A mutant of FimH-CRD in 
Table 2. 
 
Table 1. Binding affinities of FimH antagonists for the FimH-CRD. The IC50 values were determined by the 
cell-free competitive binding assay.[35] The rIC50 values are quotient of the IC50 of the compound of interest and 
the IC50 of the reference compound 28. The rIC50 values below 1.0 indicate antagonists, which are more active 
than the reference 28 and rIC50 above 1.0 that they are less active than the reference 28. 
 
Entry Compd 
O
OH
OH
HO
HO
O
R2
R1
 
IC50 [nM] rIC50 
R1 R2 
1 28 
O
OH
OH
HO
HO
O  
44.0-104.0 1 
2 29[34] Cl ONa
O
 
12.3 0.19 
3 8f Cl HN
O
ONa
O
 
14.2 0.32 
4 8g Cl HN
O
OH
O  
22.2 0.40 
5 8h Cl 
H
N
O
OH
O
 
29.5 0.54 
6 2e Cl NH
O
OH
O  
13.6 0.21 
7 2g Cl N
H
O
OH
O
 
12.6 0.20 
8 2h Cl N
H
O
OH
O  
26.4 0.48 
9 18e H N
H
O
OH
O  
80.1 0.98 
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10 20f CF3 NH
O
ONa
O  
31.9 0.31 
11 25e Cl 
N
O
HN
OH
O  
71.0 1.20 
12 25g Cl 
N
O
HN
OH
O
 
48.4 0.81 
13 27i Cl N
H
O
OH
 
53.1 0.89 
14 27j Cl N
O
OH
 
48.1 0.81 
15 27k Cl N
H
O N
 
32.5 0.55 
16 27l Cl N
H
O
N  
41.0 0.69 
 
All antagonists substituted with amino acid fragments in meta- ( 2e, 2g, 2h) and para- 
( 8f-h) position of the terminal phenyl ring showed affinities in a low nanomolar range. 
The glycine derivatives 2e and 8f were the most active in meta- and para-series, respectively. 
However, no improvement in affinity compared to a derivative without an amino acid 
fragment ( 29) could be detected. In the case of para-substitution, we observed a constant 
drop in affinity in parallel to the elongation of the amino acid moiety.  By contrast, meta-
substituted antagonists did not follow exactly the same trend. Thus, exchanging glycine 
( 8f) by β-alanine ( 8g) in para-position resulted in a slight reduction of the affinity, 
whereas the same exchange in meta-position (2e  2g) was not detrimental. Although the 
difference is rather small, this result may suggest additional interactions between 2g and the 
protein.  
To improve activity of 2e, we modified the ortho-substitution of the phenyl ring adjacent to 
the anomeric position by either removing the chloro substituent ( 18e) or replacing it by a 
trifluoromethyl group ( 20f). In previous studies, this strategy proved to be beneficial when 
CF3 was applied.
[19,20] However, in our case, both modifications were deleterious for binding 
to FimH. 
The replacement of the terminal phenyl ring by pyrrole ( 25e & 25g) was not advantageous 
either, decreasing the affinity several times compared to their counterparts 2e and 2g.  
Reducing the carboxylic acid in 2e to the alcohol ( 27i) and rigidifying the aliphatic chain 
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( 27j) as well as substituting the amino acid fragment with the pyridine ring ( 27k & 27l) 
resulted in worse binding. 
Han et al. reported an enhanced activity of the antagonist bearing a methyl ester in meta-
position ( 1).[16] The beneficial effect was partly attributed to the formation of the hydrogen 
bond with Arg98. In order to establish if Arg98 is involved in the binding of 1 and our 
strongest antagonists 2e and 2g, we determined the affinities of these compounds for the 
R98A mutant of FimH compared to the wild type (Table 2). For all compounds, no 
significant difference in the affinity for the wild type and the R98A mutant was observed. 
Therefore, the contribution of Arg98 to the binding of tested FimH antagonists can be 
excluded. Noteworthy is the fact that these amino acid fragments did not change the affinity 
compared to the reference 29 until the longest amino acid was introduced ( 2h). 
Table 2. Binding affinities of FimH antagonists to the wild type and R98A mutant of FimH-CRD. 
 
Physicochemical and in vitro pharmacokinetic characterization. 
Despite the lack of improvement in affinity, the synthesized antagonists still bind to FimH-
CRD in the low nanomolar range and the introduced modifications may beneficially 
influence parameters relevant for oral bioavailability. In order to estimate their absorption 
potential, we measured aqueous solubility[36], lipophilicity[37] and permeability by an artificial 
membrane permeability assay (PAMPA).[38] The obtained results are summarized in Table 3. 
 
 
Entry Compd 
O
OH
OH
HO
HO
O
R2
R1
 
WT R98A 
R1 R2 IC50 [nM] IC50 [nM] 
1 1 H OMe
O
 
30.6 30.4 
2 2e Cl N
H
O
OH
O  
13.6 13.4 
3 2g Cl N
H
O
OH
O
 
12.6 12.5 
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Table 3. Structural and physicochemical properties of ester prodrugs and amide derivatives. 
 
Entry Compd 
O
OH
OH
HO
HO
O
R2
R1
 
log D7.4 a 
Solubilityb 
[µg/ml]/pH 
PAMPAc 
log Pe 
[log cm/s]/pH 
R1 R2 
1 7a Cl HN
O
O
O
 
1.7 ± 0.1 > 120 / 7.4 -10 / 7.4 
2 7b Cl HN
O
O
O
 
2.6 ± 0.0 128 ± 3 / 7.4 -6.5 ± 0.1 / 7.4 
3 7c Cl HN
O
O
O  
2.7 ± 0.1 151 ± 5 / 7.4 -6.5 ± 0.1 / 7.4 
4 7d Cl HN
O
O
O
 
2.2 ± 0.1 119 ± 3 / 7.4 -9.5 ± 1.0 / 7.4 
5 12b Cl N
H
O
O
O  
2.4 ± 0.1 300 ± 8 / 7.4 -6.4 ± 0.1 / 7.4 
6 12c Cl N
H
O
O
O
 
2.6 ± 0.1 256 ± 11 / 7.4 -6.3 ± 0.1 / 7.4 
7 12d Cl N
H
O
O
O  
2.1 ± 0.2 > 400 / 7.4 -7.7 ± 1.6 / 7.4 
8 17b H N
H
O
O
O  
2.0 ± 0.1 321  10 / 7.4 -9.3  1.3 / 7.4 
9 19a CF3 NH
O
O
O  
1.7 ± 0.1 > 360 / 7.4 -10 / 7.4 
10 19b CF3 NH
O
O
O  
2.8 ± 0.0 224  6 / 7.4 -8.2  2.1 / 7.4 
11 24b Cl 
N
O
HN
O
O  
2.1 ± 0.0 249 ± 22 / 7.4 -10 / 7.4 
12 24c Cl 
N
O
HN
O
O
 
2.2 ± 0.0 181 ± 17 / 7.4 -10 / 7.4 
13 27i Cl NH
O
OH
 
0.9 ± 0.1 336 ± 33 / 7.4 -9.4 ± 1.2 / 7.4 
14 27j Cl N
O
OH
 
0.8 ± 0.0 261  20 / 7.4 -10 / 7.4 
15 27k Cl N
H
O N
 
2.4 ± 0.1 
118 ± 8 / 3.0 
53 ± 11 / 7.4 
-10 / 5.0 
-9.5 ± 1.0 / 7.4 
16 27l Cl NH
O
N  
1.8 ± 0.1 
306 ± 17 / 3.0 
192 ± 20 / 7.4 
-10 / 5.0 
-10 / 7.4 
 
The indicated values represent the mean  standard deviation (SD) of replicate determinations. 
a Octanol-water distribution coefficients (log D7.4) were determined by a miniaturized shake-flask procedure at 
pH 7.4 in sextuplicate.[37] 
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b Kinetic aqueous solubility was measured in 96-well format at pH 3.0 and 7.4 in triplicate using the µSOL 
Explorer solubility analyzer.[36] 
c Pe = effective permeability: diffusion through an artificial membrane was determined at pH 5.0 and 7.4 by the 
parallel artificial membrane permeability assay (PAMPA) in quadruplicate.[38] 
 
All para-substituted derivatives (7a-d, Table 3, entries 1-4) showed moderate solubility (> 
119 µg/ml). Concerning lipophilicity, the tert-butyl ester prodrugs (7b & 7c) reached one of 
the highest values in the series. The elevated lipophilicity correlates with improved 
permeability as determined with PAMPA. Although tert-butyl ester markedly increased 
diffusion rate through the membrane (log Pe -6.5), these prodrugs are still poorly 
permeable.[39] 
 
After shifting the amide group to meta-position ( 12b-d, entries 5-7), aqueous solubility 
was noticeably increased compared to their para-substituted analogues. By contrast, no big 
changes in lipophilicity and permeability could be observed. Nevertheless, prodrug 12c had 
effective permeability in a range predicted for moderate permeation (log Pe > -6.3
[39]).  
 
For a further modification of the aglycone, the terminal phenyl ring was replaced by pyrroles 
( 24b & 24c, entries 11 & 12). In addition, the esterified amino acid fragments were 
substituted by various metabolically stable groups ( 27i-l, entries 13-16). Unfortunately, all 
of these FimH antagonists exhibited very poor absorption potential.  
 
Conclusions 
 
In summary, we synthesized a series of biphenyl mannoside derivatives substituted with 
different amino acid fragments in meta- and para-position of the terminal phenyl ring, either 
in the acid or ester form. In addition, we obtained pyrrole-substituted analogues of the amino 
acid derivatives. Finally, we replaced the carboxylic acid fragments by metabolically stable 
groups linked to the biphenyl aglycone via amide bond in meta-position. All of the 
antagonists showed affinities in a nanomolar range. However, only glycine and β-alanine 
derivatives (2e, 2g, 8f, 8g) were particularly active. We tested 2e, 2g and previously reported 
1 in the competitive binding assay against R98A FimH mutant in order to elucidate the 
influence of Arg98 on binding. We did not observe any difference in the affinities of these 
antagonists between the wild type and the R98A mutant. This indicates no beneficial 
interaction of Arg98 with these antagonists and calls into question the importance of this 
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amino acid for binding. The antagonists 2e and 2g will be co-crystallized with the FimH 
lectin domain to verify if the high affinity results from the interaction with other side chains 
of the protein. 
We also determined the physicochemical properties of the ester prodrugs and the 
metabolically stable amide derivatives. We observed that meta-position is more favorable for 
solubility than para-position. Unfortunately, almost all measured compounds showed poor 
permeability in the PAMPA. Only prodrug 12c reached the moderate permeability. This, 
together with high solubility and the high affinity of the active principle, makes 12c the best 
candidate for the orally available drug. 
 
Experimental section 
 
General methods: NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, HMBC). Chemical shifts are expressed in ppm using residual CHCl3, 
CHD2OD or HDO as references. Optical rotations were measured using Perkin-Elmer 
Polarimeter 341. Electron spray ionization mass spectra (ESI-MS) were obtained on a Waters 
micromass ZQ Mass Spectrometer. The LC-HRMS analysis were carried out using a Agilent 
1100 LC equipped with a photodiode array detector and a Micromass QTOF I equipped with 
a 4 GHz digital-time converter. Reactions were monitored by TLC using glass plates coated 
with silica gel 60 F254 (Merck) and visualized by using UV light and/or by charring with a 
molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and 
ammonium molybdate tetrahydrate in aqueous 10% H2SO4). MPLC separations were carried 
out on a CombiFlash Companion or Rf from Teledyne Isco equipped with RediSep normal-
phase or RP-18 flash columns. LC-MS separations were carried out on a Waters system 
equipped with sample manager 2767, pump 2525, PDA 2996, column SunFireTM Prep C18 
OBDTM (5 m, 19 x 150 mm), and Micromass ZQ. Size-exclusion chromatography was per- 
formed on Bio-Gel P-2 Gel (45–90 mm) from Bio-Rad (Reinach, Switzerland). All 
compounds used for biological assays are at least of 96% purity based on HPLC analytical 
results. Commercially available reagents were purchased from Sigma-Aldrich, Alfa Aesar, 
Acros Organics or Combi-Blocks. Solvents were purchased from Sigma-Aldrich or Acros 
Organics and were dried prior to use where indicated. Methanol (MeOH), ethanol (EtOH) 
and tert-butanol (t-BuOH) were dried by storing with activated molecular sieves 3Å or 4Å 
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for at least one day. Dichloromethane (DCM) was dried by filtration over Al2O3 (Fluka, type 
5016 A basic). Molecular sieves 4Å were activated in vacuo at 200 °C for 30 min 
immediately before use. 
 
General procedure A. To a solution of 4 or 9 and C-protected amino acid in anhydrous 
DMF or MeCN under argon, DIPEA and COMU were added. After stirring for 3-20 h, the 
mixture was diluted with EtOAc (20 mL) and washed with 1 N HCl (2 x 5 mL), satd aq 
NaHCO3 (2 x 10 mL) and brine (10 mL). The organic layer was dried over Na2SO4, 
concentrated in vacuo and co-evaporated with toluene (2 x 10 mL). The crude product was 
mixed with 3[21], 13[21] or 14[20] and dissolved in anhydrous DMF under argon. Then, K3PO4 
and PdCl2(dppf)CH2Cl2 were added and the reaction was stirred at 80 °C until completion 
(3-21 h). The mixture was diluted with EtOAc (20 mL) and washed with H2O (2 x 20 mL). 
The organic layer was dried over Na2SO4, concentrated in vacuo and co-evaporated with 
toluene (2 x 10 mL). The residue was purified by MPLC on silica gel to yield 6b-d, 11b-d, 
15b and 16b. 
 
General procedure B. The protected mannoside was dissolved in a mixture of dry alcohol 
under argon and a freshly prepared solution of sodium alkoxide or potassium tert-butoxide 
was added. The reaction was stirred at rt until completion (1.5-35 h). Then, the mixture was 
neutralized with Amberlyst-15 (H+) ion-exchange resin, filtered and concentrated in vacuo. 
The residue was purified by MPLC on silica gel to give 7a-d, 12b-d, 17b, 18e, 19a, 19b and 
20f. 
 
General procedure C. To a solution of 7b-d, 12b-d, 24b or 24c in MeOH, 0.2-1.0 M aq 
NaOH was added. The reaction was stirred at rt until completion (0.5-16 h). The mixture was 
acidified to pH 3-4 with Amberlyst-15 (H+) ion-exchange resin, filtered and concentrated in 
vacuo. The residue was purified by MPLC (RP-18) to yield 2e, 2g, 2h, 8g, 8h and 25e, 25g. 
 
General procedure D. To a mixture of 23 or 26[34] and H-Gly-OtBuHCl, H--Ala-
OtBuHCl or the corresponding amine in anhydrous DMF were added DIPEA or TEA and 
COMU. The reaction was stirred for 5-16 h under argon. Then, the mixture was concentrated 
in vacuo and co-evaporated with xylene (10 mL). The residue was dissolved in MeOH (1 
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mL) or MeCN (1 mL) and passed through a nylon membrane syringe filter (pore size 0.45 
m) and purified by LC-MS (H2O/MeCN, + 0.2% HCO2H) to yield 24b, 24c and 27i-l. 
 
tert-Butyl [4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-4-
carbonyl]-glycinate (6b). Prepared according to general procedure A from 4 (50 mg, 0.199 
mmol) and H-Gly-OtBuHCl, (34 mg, 0.199 mmol, 1.0 eq) with DIPEA (104 L, 0.605 
mmol, 3.0 eq) and COMU (86 mg, 0.199 mmol, 1.0 eq) in MeCN (2 mL), followed by 
reaction with 3[21] (108 mg, 0.184 mmol), K3PO4 (117 mg, 0.540 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (6.0 mg, 7.4 mol, 0.04 eq) in DMF (2 mL). Purified by MPLC on silica 
gel (petroleum ether/EtOAc, 7:3-0:1). Yield: 56 mg (44% over two steps) as colorless oil. 
[α]
  
D
20 +50.5 (c 1.00, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.88 (d, J = 8.3 Hz, 2H, Ar-
H), 7.66 (d, J = 2.2 Hz, 1H, Ar-H), 7.59 (d, J = 8.4 Hz, 2H, Ar-H), 7.45 (dd, J = 2.2, 8.6 Hz, 
1H, Ar-H), 7.24 (m, 1H, Ar-H), 6.67 (t, J = 4.7 Hz, 1H, NH), 5.64 (dd, J = 3.5, 10.0 Hz, 1H, 
H-3), 5.61 (d, J = 1.6 Hz, 1H, H-1), 5.56 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.41 (t, J = 10.1 Hz, 
1H, H-4), 4.30 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.19 (ddd, J = 2.2, 5.3, 10.3 Hz, 1H, H-5), 
4.16 (d, J = 4.7 Hz, 2H, NHCH2) 4.10 (dd, J = 2.2, 12.3 Hz, 1H, H-6b), 2.22, 2.08, 2.05, 2.04 
(4 s, 12H, 4 COCH3), 1.45 ppm (s, 9H, C(CH3)3); 
13C NMR (125 MHz, CDCl3): δ = 170.62, 
170.11, 169.92, 169.41, 166.88 (6 CO), 151.21, 142.50, 136.29, 133.09, 129.38, 127.89, 
127.10, 126.56, 125.04, 117.39 (12C, Ar-C), 96.80 (C-1), 82.83 (C(CH3)3), 69.97 (C-5), 
69.47 (C-2), 68.91 (C-3), 65.97 (C-4), 62.24 (C-6), 42.72 (NHCH2), 28.24 (3C, C(CH3)3), 
21.02, 20.85, 20.82 ppm (4C, 4 COCH3); ESI-MS: m/z: Calcd for C33H38ClNNaO13 
[M+Na]+: 714.19, found: 714.24. 
 
tert-Butyl 3-[4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-4-
carboxamido]-propanoate (6c). Prepared according to general procedure A from 4 (51 mg, 
0.199 mmol) and H--Ala-OtBuHCl (42 mg, 0.218 mmol, 1.1 eq) with DIPEA (102 L, 
0.594 mmol, 3.0 eq) and COMU (131 mg, 0.297 mmol, 1.5 eq) in DMF (2 mL), followed by 
reaction with 3[21] (105 mg, 0.180 mmol), K3PO4 (118 mg, 0.540 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (8.8 mg, 10.8 mol, 0.06 eq) in DMF (3 mL). Purified by MPLC on 
silica gel (petroleum ether/EtOAc, 6:4). Yield: 58 mg (46% over two steps) as colorless oil. 
[α]
  
D
20 +60.0 (c 1.06, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.82 (d, J = 8.2 Hz, 2H, Ar-
H), 7.64 (d, J = 2.1 Hz, 1H, Ar-H), 7.57 (d, J = 8.2 Hz, 2H, Ar-H), 7.43 (dd, J = 2.1, 8.6 Hz, 
1H, Ar-H), 7.24 (d, J = 8.6 Hz, 1H, Ar-H), 6.96 (t, J = 5.7 Hz, 1H, NH), 5.62 (dd, J = 3.5, 
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10.1 Hz, 1H, H-3), 5.60 (d, J = 1.2 Hz, 1H, H-1), 5.54 (dd, J = 1.8, 3.2 Hz, 1H, H-2), 5.39 (t, 
J = 10.1 Hz, 1H, H-4), 4.28 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.18 (ddd, J = 2.0, 5.2, 10.0 Hz, 
1H, H-5), 4.09 (dd, J = 2.0, 12.2 Hz, 1H, H-6b), 3.70 (app dd, J = 5.8, 11.5 Hz, 2H, NHCH2), 
2.56 (t, J = 5.8 Hz, 2H, CH2CO), 2.20, 2.06, 2.04, 2.02 (4 s, 12H, 4 COCH3), 1.46 ppm (s, 
9H, C(CH3)3); 
13C NMR (125 MHz, CDCl3): δ = 172.42 (CH2CO), 170.56, 170.06, 169.88, 
169.86 (4 CO), 166.86 (CONH), 151.12, 142.20, 136.29, 133.61, 129.30, 127.73, 127.02, 
126.49, 124.97, 117.37 (12C, Ar-C), 96.75 (C-1), 81.41 (C(CH3)3), 69.93 (C-5), 69.42 (C-2), 
68.87 (C-3), 65.92 (C-4), 62.20 (C-6), 35.66 (NHCH2), 35.13 (CH2CO), 28.24 (3C, C(CH3)3), 
20.97, 20.81, 20.78, 20.77 ppm (4 COCH3); HRMS: m/z: Calcd for C34H40ClNNaO13 
[M+Na]+: 728.2086, found: 728.2085; elemental analysis: Calcd (%) for C34H40ClNO13: C 
57.83, H 5.71, N 1.98 found: C 57.68, H 5.89, N 2.06. 
 
Ethyl 4-[4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-4-
carboxamido]-butanoate (6d). Prepared according to general procedure A from 4 (51 mg, 
0.199 mmol) and ethyl 4-aminobutyrate hydrochloride (37 mg, 0.218 mmol, 1.1 eq) with 
DIPEA (102 L, 0.594 mmol, 3.0 eq) and COMU (131 mg, 0.297 mmol, 1.5 eq) in DMF (2 
mL), followed by reaction with 3[21] (105 mg, 0.180 mmol), K3PO4 (118 mg, 0.540 mmol, 3.0 
eq) and PdCl2(dppf)CH2Cl2 (8.8 mg, 10.8 mol, 0.06 eq) in DMF (3 mL). Purified by MPLC 
on silica gel (petroleum ether/EtOAc, 1:1). Yield: 43 mg (34% over two steps) as colorless 
oil. [α]
  
D
20 +60.5 (c 0.86, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.85 (d, J = 8.2 Hz, 2H, 
Ar-H), 7.64 (d, J = 2.1 Hz, 1H, Ar-H), 7.57 (d, J = 8.3 Hz, 2H, Ar-H), 7.44 (dd, J = 2.1, 8.6 
Hz, 1H, Ar-H), 7.24 (d, J = 8.6 Hz, 1H, Ar-H), 6.75 (t, J = 5.0 Hz, 1H, NH), 5.62 (dd, J = 
3.5, 10.1 Hz, 1H, H-3), 5.60 (d, J = 1.1 Hz, 1H, H-1), 5.54 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 
5.39 (t, J = 10.1 Hz, 1H, H-4), 4.28 (dd, J = 5.3, 12.3 Hz, 1H, H-6a), 4.18 (ddd, J = 2.1, 5.2, 
10.0 Hz, 1H, H-5), 4.15-4.08 (m, 3H, OCH2, H-6b), 3.52 (app dd, J = 6.3, 12.0 Hz, 2H, 
NHCH2), 2.45 (t, J = 6.9 Hz, 2H, CH2CO), 2.20, 2.06, 2.04, 2.03 (4 s, 12H, 4 COCH3), 1.97 
(p, J = 6.8 Hz, 2H, CH2), 1.23 ppm (t, J = 7.1 Hz, 3H, CH3); 
13C NMR (125 MHz, CDCl3): δ 
= 174.08 (CH2CO), 170.57, 170.07, 169.89, 169.87 (4 CO), 167.08 (CONH), 151.12, 142.13, 
136.30, 133.57, 129.30, 127.72, 126.99, 126.48, 124.97, 117.37 (12C, Ar-C), 96.76 (C-1), 
69.93 (C-5), 69.42 (C-2), 68.88 (C-3), 65.92 (C-4), 62.20 (C-6), 60.84 (OCH2), 40.01 
(NHCH2), 32.25 (CH2CO), 24.41 (CH2), 20.97, 20.81, 20.79, 20.78 (4 COCH3), 14.30 ppm 
(CH3); ESI-MS: m/z: Calcd for C33H39ClNO13 [M+H]
+: 692.21, found: 692.21. 
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Methyl [3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carbonyl]-glycinate (7a). 
Prepared according to general procedure B from 6b (55 mg, 0.079 mmol) using 1 M MeONa/ 
MeOH (500 L) in dry MeOH (2 mL). Purified by MPLC on silica gel (DCM/MeOH, 19:3). 
Yield: 16 mg (42%) as colorless oil. [α]
  
D
20 +81.2 (c 0.98, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 7.93 (d, J = 8.5 Hz, 2H, Ar-H), 7.72 (d, J = 2.3 Hz, 1H, Ar-H), 7.70 (d, J = 8.5 
Hz, 2H, Ar-H), 7.58 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.46 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, 
J = 1.6 Hz, 1H, H-1), 4.14 (s, 2H, NHCH2), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 
3.4, 9.5 Hz, 1H, H-3), 3.81-3.74 (m, 6H, H-4, H-6a, H-6b, OCH3), 3.65 ppm (ddd, J = 2.4, 
5.4, 9.7 Hz, 1H, H-5); 13C NMR (125 MHz, CD3OD): δ = 171.97, 170.10 (2 CO), 153.23, 
144.03, 136.38, 133.76, 129.68, 129.14, 127.77, 127.71, 125.36, 118.64 (12C, Ar-C), 100.74 
(C-1), 76.01 (C-5), 72.40 (C-3), 71.84 (C-2), 68.22 (C-4), 62.66 (C-6), 52.67 (OCH3), 42.41 
ppm (NHCH2); HRMS: m/z: Calcd for C22H24ClNNaO9 [M+Na]
+: 504.1037, found: 
504.1037. 
 
tert-Butyl [3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carbonyl]-glycinate (7b). 
Prepared according to general procedure B from 6b (145 mg, 0.210 mmol) using t-BuOK (75 
mg, 0.630 mmol, 3.0 eq) in dry t-BuOH/CHCl3 (4 mL, 3:1). An additional portion of t-BuOH 
(4 mL) was added after 18 h and additional portions of t-BuOK (12 eq) were added after 18, 
22 and 23 h. Purified by MPLC on silica gel (DCM/MeOH, 19:3). Yield: 63 mg (57%) as a 
white solid. [α]
  
D
20 +80.0 (c 0.44, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.93 (d, J = 8.4 
Hz, 2H, Ar-H), 7.73 (d, J = 2.2 Hz, 1H, Ar-H), 7.70 (d, J = 8.4 Hz, 2H, Ar-H), 7.59 (dd, J = 
2.2, 8.6 Hz, 1H, Ar-H), 7.47 (d, J = 8.7 Hz, 1H, Ar-H), 5.61 (d, J = 1.4 Hz, 1H, H-1), 4.12 
(dd, J = 1.8, 3.2 Hz, 1H, H-2), 4.03 (br s, 2H, NHCH2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 
3.81-3.71 (m, 3H, H-4, H-6a, H-6b), 3.65 (ddd, J = 2.3, 5.3, 9.5 Hz, 1H, H-5), 1.50 ppm (s, 
9H, C(CH3)3); 
13C NMR (125 MHz, CD3OD): δ = 170.67, 170.10 (2 CO), 153.23, 143.98, 
136.43, 133.98, 129.69, 129.11, 127.78, 127.72, 125.37, 118.65 (12C, Ar-C), 100.75 (C-1), 
82.89 (C(CH3)3), 76.01 (C-5), 72.40 (C-3), 71.84 (C-2), 68.22 (C-4), 62.66 (C-6), 43.35 
(NHCH2), 28.31 ppm (3C, C(CH3)3); HRMS: m/z: Calcd for C25H30ClNNaO9 [M+Na]
+: 
546.1507, found: 546.1505. 
 
tert-Butyl 3-[3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxamido]-
propanoate (7c). Prepared according to general procedure B from 6c (45 mg, 0.064 mmol) 
with t-BuOK (23 mg, 0.191 mmol, 3.0 eq) in dry t-BuOH (5 mL). An additional portion of t-
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BuOK (3.0 eq) was added after 1 h. Purified by MPLC on silica gel (DCM/MeOH, 9:1). 
Yield: 22 mg (65%) as colorless oil. [α]
  
D
20 +79.8 (c 1.05, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 7.87 (d, J = 8.5 Hz, 2H, Ar-H), 7.71 (d, J = 2.3 Hz, 1H, Ar-H), 7.67 (d, J = 8.5 
Hz, 2H, Ar-H), 7.57 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.45 (d, J = 8.7 Hz, 1H, Ar-H), 5.60 (d, 
J = 1.6 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 
3.81-3.71 (m, 3H, H-4, H-6a, H-6b), 3.67-3.61 (m, 3H, H-5, NHCH2), 2.59 (t, J = 6.9 Hz, 
2H, CH2CO), 1.45 ppm (s, 9H, C(CH3)3); 
13C NMR (125 MHz, CD3OD): δ = 172.87 (CO), 
169.74 (CONH), 153.18, 143.74, 136.41, 134.38, 129.65, 128.96, 127.72, 127.68, 125.34, 
118.63 (12C, Ar-C), 100.73 (C-1), 81.96 (C(CH3)3), 75.99 (C-5), 72.39 (C-3), 71.83 (C-2), 
68.21 (C-4), 62.65 (C-6), 37.15 (NHCH2), 36.17 (CH2CO), 28.33 ppm (3C, C(CH3)3); 
HRMS: m/z: Calcd for C26H32ClNNaO9 [M+Na]
+: 560.1663, found: 560.1653. 
 
Ethyl 4-[3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxamido]-butanoate 
(7d). Prepared according to general procedure B from 6d (43 mg, 0.062 mmol) using 1 M 
EtONa/EtOH (400 L) in dry EtOH (6 mL). Purified by MPLC on silica gel (DCM/MeOH, 
9:1).  Yield: 21 mg (64%) as colorless oil. [α]
  
D
20 +79.6 (c 1.05, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 7.78 (d, J = 8.4 Hz, 2H, Ar-H), 7.71 (d, J = 2.2 Hz, 1H, Ar-H), 7.67 (d, J = 8.4 
Hz, 2H, Ar-H), 7.57 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.45 (d, J = 8.7 Hz, 1H, Ar-H), 5.60 (d, 
J = 1.4 Hz, 1H, H-1), 4.13-4.09 (m, 3H, H-2, OCH2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 
3.81-3.71 (m, 3H, H-4, H-6a, H-6b), 3.65 (ddd, J = 2.3, 5.4, 9.7 Hz, 1H, H-5), 3.44 (t, J = 6.9 
Hz, 2H, NHCH2), 2.42 (t, J = 7.3 Hz, 2H, CH2CO), 1.94 (p, J = 7.2 Hz, 2H, CH2), 1.24 ppm 
(t, J = 7.1 Hz, 3H, CH3); 
13C NMR (125 MHz, CD3OD): δ = 175.04 (CO), 169.85 (CONH), 
153.17, 143.67, 136.44, 134.48, 129.64, 128.97, 127.70, 127.67, 125.34, 118.63 (12C, Ar-C), 
100.73 (C-1), 75.99 (C-5), 72.40 (C-3), 71.83 (C-2), 68.22 (C-4), 62.66 (C-6), 61.57 (OCH2), 
40.35 (NHCH2), 32.55 (CH2CO), 25.82 (CH2), 14.49 ppm (CH3); HRMS: m/z: Calcd for 
C25H30ClNNaO9 [M+Na]
+: 546.1507, found: 546.1507. 
 
Sodium [3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carbonyl]-glycinate (8f). To 
a solution of 7a (8 mg, 0.017 mmol) in MeOH, 0.2 M aq. NaOH (10 mL) was added. The 
reaction was stirred at rt until completion (0.5 h). The mixture was neutralized to pH 8 with 
Amberlyst-15 (H+) ion-exchange resin, filtered and concentrated in vacuo. The crude product 
was purified by MPLC on RP-18 (H2O/MeOH, 19:1-1:19) followed by size-exclusion 
chromatography (P-2 gel, H2O). Yield: 7 mg (86%) as a white solid. [α]
  
D
20 +54.6 (c 0.70, 
Results and discussion 
95 
 
H2O); 
1H NMR (500 MHz, D2O): δ = 7.79 (d, J = 8.5 Hz, 2H, Ar-H), 7.59 (d, J = 2.2 Hz, 1H, 
Ar-H), 7.54 (d, J = 8.5 Hz, 2H, Ar-H), 7.45 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.26 (d, J = 8.7 
Hz, 1H, Ar-H), 5.65 (d, J = 1.5 Hz, 1H, H-1), 4.22 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.11 (dd, J 
= 3.5, 9.5 Hz, 1H, H-3), 3.97 (s, 2H, NHCH2), 3.79-3.71 ppm (m, 4H, H-4, H-5, H-6a, H-6b); 
13C NMR (125 MHz, D2O): δ = 176.71, 169.55 (2 CO), 160.97, 150.49, 141.87, 134.82, 
131.96, 128.51, 127.70, 126.55, 126.45, 123.91, 117.59 (12C, Ar-C), 98.48 (C-1), 73.86 (C-
5), 70.42 (C-3), 69.74 (C-2), 66.44 (C-4), 60.58 (C-6), 43.81 ppm (NHCH2); HRMS: m/z: 
Calcd for C21H21ClNNa2O9 [M+Na]
+: 512.0700, found: 512.0696. 
 
3-[3’-Chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxamido]-propanoic acid 
(8g). Prepared according to general procedure C from 7c (13 mg, 0.024 mmol) with 0.4 M aq. 
NaOH (10 mL). Purified by MPLC on RP-18 (H2O/MeOH, 19:1-1:19). Yield: 6 mg (52%) as 
a white solid. [α]
  
D
20 +85.4 (c 0.60, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.88 (d, J = 8.4 
Hz, 2H, Ar-H), 7.72 (d, J = 2.2 Hz, 1H, Ar-H), 7.68 (d, J = 8.4 Hz, 2H, Ar-H), 7.58 (dd, J = 
2.3, 8.6 Hz, 1H, Ar-H), 7.46 (d, J = 8.7 Hz, 1H, Ar-H), 5.60 (d, J = 1.5 Hz, 1H, H-1), 4.12 
(dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.70 (m, 3H, H-4, H-
6a, H-6b), 3.66-3.64 (m, 3H, H-5, NHCH2), 2.64 ppm (t, J = 6.9 Hz, 2H, CH2CO); 
13C NMR 
(125 MHz, CD3OD): δ = 175.66 (CO), 169.80 (CONH), 153.19, 143.74, 136.46, 134.41, 
129.66, 128.98, 127.72, 127.69, 125.35, 118.64 (12C, Ar-C), 100.75 (C-1), 76.00 (C-5), 
72.40 (C-3), 71.84 (C-2), 68.22 (C-4), 62.66 (C-6), 37.24 (NHCH2), 35.25 ppm (CH2CO); 
HRMS: m/z: Calcd for C22H24ClNNaO9 [M+Na]
+: 504.1037, found: 504.1029. 
 
4-[3’-Chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carboxamido]-butanoic acid (8h). 
Prepared according to general procedure C from 7d (7 mg, 0.013 mmol) with 0.2 M aq. 
NaOH (10 mL). Purified by MPLC on RP-18 (H2O/MeOH, 19:1-1:19). Yield: 4 mg (61%) as 
colorless oil. [α]
  
D
20 +91.1 (c 0.60, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.89 (d, J = 8.4 
Hz, 2H, Ar-H), 7.72 (d, J = 2.2 Hz, 1H, Ar-H), 7.68 (d, J = 8.4 Hz, 2H, Ar-H), 7.58 (dd, J = 
2.2, 8.6 Hz, 1H, Ar-H), 7.47 (d, J = 8.7 Hz, 1H, Ar-H), 5.60 (d, J = 1.4 Hz, 1H, H-1), 4.12 
(dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-4, H-
6a, H-6b), 3.65 (ddd, J = 2.3, 5.3, 9.7 Hz, 1H, H-5), 3.45 (t, J = 6.9 Hz, 2H, NHCH2), 2.40 (t, 
J = 7.3 Hz, 2H, CH2CO), 1.94 ppm (p, J = 7.1 Hz, 2H, CH2); 
13C NMR (125 MHz, CD3OD): 
δ = 177.63 (CO), 169.89 (CONH), 153.19, 143.68, 136.50, 134.55, 129.66, 128.99, 127.72, 
127.68, 125.35, 118.65 (12C, Ar-C), 100.76 (C-1), 76.01 (C-5), 72.40 (C-3), 71.85 (C-2), 
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68.23 (C-4), 62.66 (C-6), 40.54 (NHCH2), 32.77 (CH2CO), 25.99 ppm (CH2); HRMS: m/z: 
Calcd for C23H26ClNNaO9 [M+Na]
+: 518.1194, found: 518.1188. 
 
tert-Butyl [4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-3-
carbonyl]-glycinate (11b). Prepared according to general procedure A from 9 (50 mg, 0.198 
mmol) and H-Gly-OtBuHCl (37 mg, 0.218 mmol, 1.1 eq) with DIPEA (102 L, 0.594 
mmol, 3.0 eq) and COMU (131 mg, 0.297 mmol, 1.5 eq) in DMF (2 mL), followed by 
reaction with 3[21] (105 mg, 0.180 mmol), K3PO4 (118 mg, 0.540 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (8.8 mg, 10 mol, 0.06 eq) in DMF (2 mL). Purified by MPLC on silica 
gel (petroleum ether/EtOAc, 13:7). Yield: 50 mg (44% over two steps) as colorless oil. [α]
  
D
20 
+63.1 (c 0.84, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.97 (br s, 1H, Ar-H), 7.75 (br d, J = 
7.7 Hz, 1H, Ar-H), 7.65-7.63 (m, 2H, Ar-H), 7.48 (t, J = 7.7 Hz, 1H, Ar-H), 7.43 (dd, J = 2.2, 
8.5 Hz, 1H, Ar-H), 7.23 (d, J = 8.6 Hz, 1H, Ar-H), 6.76 (t, J = 4.4 Hz, 1H, NH), 5.62 (dd, J = 
3.5, 10.0 Hz, 1H, H-3), 5.59 (d, J = 1.5 Hz, 1H, H-1), 5.55 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 
5.39 (t, J = 10.1 Hz, 1H, H-4), 4.29 (dd, J = 5.4, 12.2 Hz, 1H, H-6a), 4.19 (ddd, J = 2.1, 5.3, 
10.1 Hz, 1H, H-5), 4.15 (d, J = 4.8 Hz, 2H, NHCH2), 4.09 (dd, J = 2.1, 12.2 Hz, 1H, H-6b), 
2.20, 2.06, 2.03, 2.03 (4 s, 12H, 4 COCH3), 1.50 ppm (s, 9H, C(CH3)3); 
13C NMR (125 MHz, 
CDCl3): δ = 170.59, 170.04, 169.87 (4C, 4 CO), 169.34 (CH2CO), 167.11 (CONH), 150.98, 
139.76, 136.45, 134.78, 130.09, 129.30, 126.49, 126.04, 125.85, 124.93, 117.39 (12C, Ar-C), 
96.77 (C-1), 82.75 (C(CH3)3), 69.90 (C-5), 69.43 (C-2), 68.89 (C-3), 65.94 (C-4), 62.22 (C-
6), 42.68 (NHCH2), 28.19 (3C, C(CH3)3), 20.97, 20.81, 20.79 ppm (4C, 4 COCH3); ESI-MS: 
m/z: Calcd for C33H38ClNNaO13 [M+Na]
+: 714.19, found: 714.24. 
 
tert-Butyl 3-[4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-3-
carboxamido]-propanoate (11c). Prepared according to general procedure A from 9 (50 mg, 
0.202 mmol) and H--Ala-OtBuHCl (58 mg, 0.302 mmol, 1.5 eq) with DIPEA (103 L, 
0.604 mmol, 3.0 eq) and COMU (129 mg, 0.302 mmol, 1.5 eq) in DMF (3 mL), followed by 
reaction with 3[21] (131 mg, 0.224 mmol), K3PO4 (147 mg, 0.672 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (9.1 mg, 11.2 mol, 0.05 eq) in DMF (3 mL). Purified by MPLC on 
silica gel (petroleum ether/EtOAc, 8:2-3:7). Yield: 104 mg (66% over two steps) as colorless 
oil. [α]
  
D
20 +54.2 (c 0.81, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.93 (s, 1H, Ar-H), 7.67 
(d, J = 7.7 Hz, 1H, Ar-H), 7.63-7.61 (m, 2H, Ar-H), 7.47-7.41 (m, 2H, Ar-H), 7.22 (d, J = 8.6 
Hz, 1H, Ar-H), 7.01 (t, J = 2.1 Hz, 1H, NH), 5.61 (dd, J = 3.5, 10.0 Hz, 1H, H-3), 5.58 (d, J = 
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1.4 Hz, 1H, H-1), 5.53 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 5.38 (t, J = 10.1 Hz, 1H, H-4), 4.27 
(dd, J = 5.4, 12.2 Hz, 1H, H-6a), 4.18 (ddd, J = 2.1, 5.3, 10.0 Hz, 1H, H-5), 4.08 (dd, J = 2.1, 
12.2 Hz, 1H, H-6b), 3.68 (app q, J = 5.8 Hz, 2H, NHCH2), 2.55 (t, J = 5.9 Hz, 2H, CH2CO), 
2.19, 2.05, 2.02, 2.01 (4 s, 12H, 4 COCH3), 1.44 ppm (s, 9H, C(CH3)3); 
13C NMR (125 MHz, 
CDCl3): δ = 172.27 (CH2CO), 170.53, 170.00, 169.82 (4C, 4 CO), 167.10 (CONH), 150.92, 
139.63, 136.45, 135.38, 129.76, 129.22, 129.21, 126.40, 125.83, 125.76, 124.88, 117.35 
(12C, Ar-C), 96.73 (C-1), 81.34 (C(CH3)3), 69.86 (C-5), 69.38 (C-2), 68.84 (C-3), 65.89 (C-
4), 62.17 (C-6), 35.68 (NHCH2), 35.09 (CH2CO), 28.19 (3C, C(CH3)3), 20.92, 20.76, 20.74 
ppm (4C, 4 COCH3); HRMS: m/z: Calcd for C34H40ClNNaO13 [M+Na]
+: 728.2086, found: 
728.2081; elemental analysis: Calcd (%) for C34H40ClNO13: C 57.83, H 5.71, N 1.98 found: 
C 57.90, H 5.86, N 2.33. 
 
Ethyl 4-[4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3’-chlorobiphenyl-3-
carboxamido]-butanoate (11d). Prepared according to general procedure A from 9 (50 mg, 
0.198 mmol) and ethyl 4-aminobutyrate hydrochloride (37 mg, 0.218 mmol, 1.1 eq) with 
DIPEA (102 L, 0.594 mmol, 3.0 eq) and COMU (131 mg, 0.297 mmol, 1.5 eq) in DMF (2 
mL), followed by reaction with 3[21] (105 mg, 0.180 mmol), K3PO4 (118 mg, 0.540 mmol, 3.0 
eq) and PdCl2(dppf)CH2Cl2 (8.8 mg, 10.8 mol, 0.06 eq) in DMF (3 mL). Purified by MPLC 
on silica gel (petroleum ether/EtOAc, 1:0-0:1). Yield: 42 mg (34% over two steps) as 
colorless oil. [α]
  
D
20 +52.8 (c 1.00, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.97 (m, 1H, Ar-
H), 7.73 (br d, J = 7.7 Hz, 1H, Ar-H), 7.67 (d, J = 2.2 Hz, 1H, Ar-H), 7.63 (br d, J = 7.9 Hz, 
1H, Ar-H), 7.49-7.44 (m, 2H, Ar-H), 7.23 (d, J = 8.6 Hz, 1H, Ar-H), 6.86 (t, J = 4.9 Hz, 1H, 
NH), 5.62 (dd, J = 3.5, 10.0 Hz, 1H, H-3), 5.59 (d, J = 1.5 Hz, 1H, H-1), 5.54 (dd, J = 1.8, 
3.4 Hz, 1H, H-2), 5.39 (t, J = 10.1 Hz, 1H, H-4), 4.29 (dd, J = 5.3, 12.2 Hz, 1H, H-6a), 4.19 
(ddd, J = 2.1, 5.3, 10.1 Hz, 1H, H-5), 4.15-4.08 (m, 3H, H-6b, OCH2), 3.53 (app dd, J = 6.4, 
12.2 Hz, 2H, NHCH2), 2.46 (t, J = 6.8 Hz, 2H, CH2CO), 2.20, 2.06, 2.04, 2.03 (4 s, 12H, 4 
COCH3), 1.98 (p, J = 6.7 Hz, 2H, CH2), 1.23 ppm (t, J = 7.1 Hz, 3H, CH3); 
13C NMR (125 
MHz, CDCl3): δ = 174.23 (CH2CO), 170.60, 170.07, 169.90, 169.88 (4 CO), 167.28 
(CONH), 150.97, 139.61, 136.55, 135.34, 129.74, 129.28, 129.27, 126.46, 126.01, 125.66, 
124.94, 117.39 (12C, Ar-C), 96.80 (C-1), 69.92 (C-5), 69.44 (C-2), 68.90 (C-3), 65.95 (C-4), 
62.22 (C-6), 60.91 (OCH2), 40.51 (NHCH2), 32.34 (CH2CO), 24.29 (CH2), 20.98, 20.82, 
20.80 (4C, 4 COCH3), 14.30 ppm (CH3); HRMS: m/z: Calcd for C33H38ClNNaO13 [M+Na]
+: 
714.1929, found: 714.1926. 
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tert-Butyl [3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-3-carbonyl]-glycinate (12b). 
Prepared according to general procedure B from 11b (45 mg, 0.065 mmol) using t-BuOK (23 
mg, 0.195 mmol, 3.0 eq) in dry t-BuOH (5 mL). An additional portion of t-BuOK (3.0 eq) 
was added after 2.5 h. Purified by MPLC on silica gel (DCM/MeOH, 9:1). Yield: 18 mg 
(53%) as colorless oil. [α]
  
D
20 +68.3 (c 0.83, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.08 
(m, 1H, Ar-H), 7.82 (br d, J = 7.8 Hz, 1H, Ar-H), 7.78 (br d, J = 8.2 Hz, 1H, Ar-H), 7.74 (d, J 
= 2.2 Hz, 1H, Ar-H), 7.59 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.55 (t, J = 7.8 Hz, 1H, Ar-H), 
7.47 (d, J = 8.6 Hz, 1H, Ar-H), 5.60 (d, J = 1.4 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.2 Hz, 1H, 
H-2), 4.03 (s, 2H, NHCH2), 4.01 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-4, H-6a, 
H-6b), 3.66 (ddd, J = 2.3, 5.4, 9.7 Hz, 1H, H-5), 1.50 ppm (s, 9H, C(CH3)3); 
13C NMR (125 
MHz, CD3OD): δ = 170.69 (CH2CO), 170.32 (CONH), 153.03, 141.02, 136.72, 135.86, 
131.01, 130.33, 129.65, 127.61, 127.39, 126.65, 125.36, 118.69 (12C, Ar-C), 100.78 (C-1), 
82.94 (C(CH3)3), 75.99 (C-5), 72.40 (C-3), 71.85 (C-2), 68.23 (C-4), 62.66 (C-6), 43.36 
(NHCH2), 28.31 ppm (3C, C(CH3)3); HRMS: m/z: Calcd for C25H30ClNNaO9 [M+Na]
+: 
546.1507, found: 546.1499. 
 
tert-Butyl 3-[3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-3-carboxamido]-
propanoate (12c). Prepared according to general procedure B from 11c (87 mg, 0.123 mmol) 
using t-BuOK (46 mg, 0.370 mmol, 3.0 eq) in dry t-BuOH (10 mL). An additional portion of 
t-BuOK (3.0 eq) was added after 1.5 h. Purified by MPLC on silica gel (DCM/MeOH, 9:1). 
Yield: 28 mg (42%) as colorless oil. [α]
  
D
20 +70.8 (c 1.30, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 8.01 (t, J = 1.5 Hz, 1H, Ar-H), 7.78-7.75 (m, 2H, Ar-H), 7.73 (d, J = 2.2 Hz, 
1H, Ar-H), 7.58 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.53 (t, J = 7.8 Hz, 1H, Ar-H), 7.46 (d, J = 
8.6 Hz, 1H, Ar-H), 5.60 (d, J = 1.5 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.01 
(dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-4, H-6a, H-6b), 3.68-3.62 (m, 3H, H-5, 
NHCH2), 2.59 (t, J = 6.9 Hz, 2H, CH2CO), 1.45 ppm (s, 9H, C(CH3)3); 
13C NMR (125 MHz, 
CD3OD): δ = 172.87 (CH2CO), 169.98 (CONH), 153.01, 140.96, 136.72, 136.29, 130.81, 
130.28, 129.62, 127.59, 127.27, 126.53, 125.35, 118.68 (12C, Ar-C), 100.77 (C-1), 81.98 
(C(CH3)3), 75.98 (C-5), 72.40 (C-3), 71.85 (C-2), 68.22 (C-4), 62.65 (C-6), 37.20 (NHCH2), 
36.16 (CH2CO), 28.34 ppm (3C, C(CH3)3); HRMS: m/z: Calcd for C26H32ClNNaO9 
[M+Na]+: 560.1663, found: 560.1660. 
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Ethyl 4-[3’-chloro-4’-(-D-mannopyranosyloxy)biphenyl-3-carboxamido]-butanoate 
(12d). Prepared according to general procedure B from 11d (42 mg, 0.061 mmol) using 1 M 
EtONa/EtOH (400 L) in dry EtOH (7 mL). Purified by MPLC on silica gel (DCM/MeOH, 
9:1). Yield: 17 mg (53%) as colorless oil. [α]
  
D
20 +71.3 (c 1.07, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 8.03 (s, 1H, Ar-H), 7.80-7.74 (m, 3H, Ar-H), 7.58 (dd, J = 2.2, 8.6 Hz, 1H, Ar-
H), 7.53 (t, J = 7.8 Hz, 1H, Ar-H), 7.46 (d, J = 8.6 Hz, 1H, Ar-H), 5.60 (d, J = 1.2 Hz, 1H, H-
1), 4.13-4.09 (m, 3H, H-2, OCH2), 4.01 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-
4, H-6a, H-6b), 3.66 (ddd, J = 2.3, 5.3, 9.6 Hz, 1H, H-5), 3.45 (t, J = 6.9 Hz, 2H, NHCH2), 
2.43 (t, J = 7.3 Hz, 2H, CH2CO), 1.95 (p, J = 7.1 Hz, 2H, CH2), 1.23 ppm (t, J = 7.1 Hz, 3H, 
CH3); 
13C NMR (125 MHz, CD3OD): δ = 175.09 (CH2CO), 170.02 (CONH), 153.01, 140.96, 
136.79, 136.35, 130.75, 130.26, 129.65, 127.61, 127.30, 126.51, 125.35, 118.69 (12C, Ar-C), 
100.79 (C-1), 75.99 (C-5), 72.41 (C-3), 71.86 (C-2), 68.23 (C-4), 62.66 (C-6), 61.58 (OCH2), 
40.42 (NHCH2), 32.59 (CH2CO), 25.76 (CH2), 14.49 ppm (CH3); HRMS: m/z: Calcd for 
C25H30ClNNaO9 [M+Na]
+: 546.1507, found: 546.1501. 
 
[3’-Chloro-4’-(-D-mannopyranosyloxy)biphenyl-4-carbonyl]-glycine (2e). Prepared 
according to general procedure C from 12b (15 mg, 0.029 mmol) with 0.2 M aq. NaOH (10 
mL). The mixture was acidified with an excess of AcOH. Purified by MPLC on RP-18 
(H2O/MeOH, 19:1-1:19) followed by LC-MS (H2O/MeCN, 19:1-1:19, + 0.2% HCO2H). 
Yield: 8 mg (60%) as a white solid. [α]
  
D
20 +91.0 (c 0.80, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 8.09 (m, 1H, Ar-H), 7.84 (br d, J = 7.8 Hz, 1H, Ar-H), 7.78 (br d, J = 8.0 Hz, 
1H, Ar-H), 7.75 (d, J = 2.2 Hz, 1H, Ar-H), 7.59 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.55 (t, J = 
7.8 Hz, 1H, Ar-H), 7.47 (d, J = 8.6 Hz, 1H, Ar-H), 5.60 (d, J = 1.4 Hz, 1H, H-1), 4.13-4.11 
(m, 3H, H-2, NHCH2), 4.01 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-4, H-6a, H-
6b), 3.66 ppm (ddd, J = 2.3, 5.4, 9.7 Hz, 1H, H-5); 13C NMR (125 MHz, CD3OD): δ = 173.55 
(CO), 170.20 (CONH), 153.03, 141.00, 136.76, 135.88, 130.98, 130.29, 129.65, 127.62, 
127.42, 126.69, 125.36, 118.69 (12C, Ar-C), 100.79 (C-1), 75.99 (C-5), 72.41 (C-3), 71.86 
(C-2), 68.23 (C-4), 62.66 (C-6), 42.59 ppm (NHCH2); HRMS: m/z: Calcd for 
C21H22ClNNaO9 [M+Na]
+: 490.0881, found: 490.0874. 
 
3-[3’-Chloro-4’-(-D-mannopyranosyloxy)biphenyl-3-carboxamido]-propanoic acid 
(2g). Prepared according to general procedure C from 12c (16 mg, 0.030 mmol) with 1 M aq. 
NaOH (10 mL) in MeOH (3 mL). The mixture was acidified with an excess of AcOH. 
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Purified by MPLC on RP-18 (H2O/MeOH, 19:1-1:19, + 0.1% TFA) solvent system. Yield: 
11 mg (79%) as a white solid. [α]
  
D
20 +92.4 (c 0.40, MeOH); 1H NMR (500 MHz, CD3OD): δ 
= 8.03 (m, 1H, Ar-H), 7.79-7.74 (m, 3H, Ar-H), 7.59 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.53 (t, 
J = 7.8 Hz, 1H, Ar-H), 7.46 (d, J = 8.6 Hz, 1H, Ar-H), 5.60 (d, J = 1.4 Hz, 1H, H-1), 4.12 
(dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.01 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-4, H-
6a, H-6b), 3.68-3.64 (m, 3H, H-5, NHCH2), 2.63 ppm (t, J = 6.9 Hz, 2H, CH2CO); 
13C NMR 
(125 MHz, CD3OD): δ = 176.44 (CO), 169.95 (CONH), 153.02, 140.99, 136.83, 136.34, 
130.79, 130.26, 129.66, 127.64, 127.29, 126.54, 125.35, 118.69 (12C, Ar-C), 100.81 (C-1), 
75.99 (C-5), 72.41 (C-3), 71.87 (C-2), 68.24 (C-4), 62.66 (C-6), 37.48 (NHCH2), 35.53 ppm 
(CH2CO); HRMS: m/z: Calcd for C22H24ClNNaO9 [M+Na]
+: 504.1037, found: 504.1034. 
 
3-[3’-Chloro-4’-(-D-mannopyranosyloxy)biphenyl-3-carboxamido]-butanoic acid (2h). 
Prepared according to general procedure C from 12d (15 mg, 0.029 mmol) with 0.2 M aq. 
NaOH (10 mL). Purified by MPLC on RP-18 (H2O/MeOH, 19:1-1:19). Yield: 6 mg (43%) as 
colorless oil. [α]
  
D
20 +78.1 (c 0.60, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.04 (m, 1H, 
Ar-H), 7.80 (br d, J = 7.8 Hz, 1H, Ar-H), 7.76-7.74 (m, 2H, Ar-H), 7.59 (dd, J = 2.2, 8.6 Hz, 
1H, Ar-H), 7.53 (t, J = 7.8 Hz, 1H, Ar-H), 7.47 (d, J = 8.6 Hz, 1H, Ar-H), 5.60 (d, J = 1.3 Hz, 
1H, H-1), 4.12 (dd, J = 1.8, 3.2 Hz, 1H, H-2), 4.01 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 
(m, 3H, H-4, H-6a, H-6b), 3.66 (ddd, J = 2.3, 5.3, 9.7 Hz, 1H, H-5), 3.46 (t, J = 6.9 Hz, 2H, 
NHCH2), 2.39 (t, J = 7.2 Hz, 2H, CH2CO), 1.94 ppm (p, J = 7.1 Hz, 2H, CH2); 
13C NMR 
(125 MHz, CD3OD): δ = 177.81 (CO), 170.05 (CONH), 153.01, 140.97, 136.84, 136.41, 
130.73, 130.25, 129.66, 127.64, 127.30, 126.54, 125.35, 118.69 (12C, Ar-C), 100.80 (C-1), 
75.99 (C-5), 72.41 (C-3), 71.86 (C-2), 68.23 (C-4), 62.66 (C-6), 40.64  (NHCH2), 33.04 
(CH2CO), 26.03 ppm (CH2); HRMS: m/z: Calcd for C23H26ClNNaO9 [M+Na]
+: 518.1194, 
found: 518.1189. 
 
tert-Butyl [4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-biphenyl-3-carbonyl]-
glycinate (15b). Prepared according to general procedure A from 9 (100 mg, 0.403 mmol) 
and H-Gly-OtBuHCl (100 mg, 0.597 mmol, 1.5 eq) with DIPEA (400 L, 2.336 mmol, 5.8 
eq) and COMU (262 mg, 0.612 mmol, 1.5 eq) in DMF (2 mL), followed by reaction with 
13[21] (171 mg, 0.310 mmol), K3PO4 (204 mg, 0.930 mmol, 3.0 eq) and PdCl2(dppf)CH2Cl2 
(15.0 mg, 18.6 mol, 0.06 eq) in DMF (3 mL). Purified by MPLC on silica gel (petroleum 
ether/EtOAc, 3:2). Yield: 147 mg (72% over two steps) as colorless oil. [α]
  
D
20 +64.1 (c 1.16, 
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CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.98 (s, 1H, Ar-H), 7.71 (d, J = 7.6 Hz, 1H, Ar-H), 
7.64 (d, J = 7.7 Hz, 1H, Ar-H), 7.52 (dd, J = 8.6 Hz, 2H, Ar-H), 7.45 (t, J = 7.7 Hz, 1H, Ar-
H), 7.14 (d, J = 8.6 Hz, 2H, Ar-H), 6.81 (br s, 1H, NH), 5.57-5.55 (m, 2H, H-1, H-3), 5.45 
(dd, J = 1.7, 3.3 Hz, 1H, H-2), 5.36 (t, J = 10.0 Hz, 1H, H-4), 4.27 (dd, J = 5.1, 12.0 Hz, 1H, 
H-6a), 4.13-4.05 (m, 4H, H-5, H-6b, NHCH2), 2.19, 2.04, 2.02, 2.01 (4 s, 12H, 4 COCH3), 
1.48 ppm (s, 9H, C(CH3)3); 
13C NMR (125 MHz, CDCl3): δ = 170.58, 170.03, 170.00, 169.79 
(5C, 5 CO), 167.31 (CONH), 155.45, 140.90, 135.12, 134.58, 130.05, 129.10, 128.44, 
125.73, 125.53, 116.95 (12C, Ar-C), 95.88 (C-1), 82.60 (C(CH3)3), 69.43 (C-2), 69.31 (C-5), 
68.49 (C-3), 66.00 (C-4), 62.18 (C-6), 42.62 (NHCH2), 28.13 (3C, C(CH3)3), 20.92, 20.74 
ppm (4C, 4 COCH3); ESI-MS: m/z: Calcd for C33H39NNaO13 [M+Na]
+: 680.23, found: 
680.38. 
 
tert-Butyl [4’-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3'-trifluoromethyl-
biphenyl-3-carbonyl]-glycinate (16b). Prepared according the general procedure A from 9 
(150 mg, 0.604 mmol) and H-Gly-OtBuHCl (151 mg, 0.889 mmol, 1.5 eq) with DIPEA (609 
L, 3.557 mmol, 6.0 eq) and COMU (405 mg, 0.891 mmol, 1.5 eq) in DMF (4 mL), followed 
by reaction with 14[20] (230 mg, 0.403 mmol), K3PO4 (264 mg, 1.209 mmol, 3.0 eq) and 
PdCl2(dppf)CH2Cl2 (15.0 mg, 24.0 mol, 0.06 eq) in DMF (5 mL). Purified by MPLC on 
silica gel (petroleum ether/EtOAc, 1:0-0:1). Yield: 144 mg (49% over two steps) as colorless 
oil. [α]
  
D
20 +56.6 (c 1.10, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 7.99 (s, 1H, Ar-H), 7.82 
(d, J = 1.9 Hz, 1H, Ar-H), 7.75 (br d, J = 7.8 Hz, 1H, Ar-H), 7.70 (dd, J = 2.1, 8.7 Hz, 1H, 
Ar-H), 7.65 (br d, J = 8.0 Hz, 1H, Ar-H), 7.48 (t, J = 7.7 Hz, 1H, Ar-H), 7.32 (d, J = 8.7 Hz, 
1H, Ar-H), 6.84 (t, J = 4.7 Hz, 1H, NH), 5.67 (d, J = 1.5 Hz, 1H, H-1), 5.55 (dd, J = 3.4, 10.1 
Hz, 1H, H-3), 5.48 (dd, J = 1.9, 3.3 Hz, 1H, H-2), 5.44 (t, J = 9.9 Hz, 1H, H-4), 4.28 (dd, J = 
5.7, 12.9 Hz, 1H, H-6a), 4.14 (d, J = 4.9 Hz, 2H, NHCH2), 4.09-4.06 (m, 2H, H-5, H-6b), 
2.20, 2.05, 2.03, 2.02 (4 s, 12H, 4 COCH3), 1.49 ppm (s, 9H, C(CH3)3); 
13C NMR (125 MHz, 
CDCl3): δ = 170.53, 169.99, 169.85, 169.70 (4 CO), 169.33 (CH2CO), 167.07 (CONH), 
152.76, 139.69, 134.89, 134.82, 131.88, 130.50, 129.34, 126.09, 126.05, 125.94, 123.26 (q, J 
= 273.0 Hz), 120.52 (q, J = 31.3 Hz), 115.93 (13C, 12 Ar-C, CF3), 95.79 (C-1), 82.72 
(C(CH3)3), 69.97 (C-5), 69.24 (C-2), 68.69 (C-3), 65.67 (C-4), 62.11 (C-6), 42.64 (NHCH2), 
28.14 (3C, C(CH3)3), 20.91, 20.76, 20.75, 20.70 ppm (4 COCH3); ESI-MS: m/z: Calcd for 
C34H38F3NNaO13 [M+Na]
+: 748.22, found: 748.38. 
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tert-Butyl [4’-(-D-mannopyranosyloxy)-biphenyl-3-carbonyl]-glycinate (17b). [4’-(-D-
Mannopyranosyloxy)-biphenyl-3-carbonyl]-glycine (18e). Prepared according to general 
procedure B from 15b (109 mg, 0.166 mmol) with t-BuOK (58 mg, 0.498 mmol, 3.0 eq) in t-
BuOH (10 mL). An additional portion of t-BuOK (3.0 eq) was added after 1.5 h. The crude 
products were purified by MPLC on silica gel (DCM/MeOH, 9:1) to afford 17b (36 mg, 
44%) as colorless oil or by MPLC on silica gel (DCM/MeOH, 9:1-0:1) followed by MPLC 
on RP-18 (H2O/MeOH, 19:1-1:19, + 0.1% TFA) to afford 18e (26 mg, 36%) as colorless oil. 
17b: [α]
  
D
20 +97.3 (c 1.17, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.07 (m, 1H, Ar-H), 
7.79-7.75 (m, 2H, Ar-H), 7.61 (d, J = 8.7 Hz, 2H, Ar-H), 7.52 (t, J = 7.8 Hz, 1H, Ar-H), 7.22 
(d, J = 8.7 Hz, 2H, Ar-H), 5.54 (d, J = 1.3 Hz, 1H, H-1), 4.04-4.03 (m, 3H, H-2, NHCH2), 
3.94 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.80-3.72 (m, 3H, H-4, H-6a, H-6b), 3.63 (ddd, J = 2.5, 
5.1, 9.7 Hz, 1H, H-5), 1.49 ppm (s, 9H, C(CH3)3); 
13C NMR (125 MHz, CD3OD): δ = 170.69, 
170.53 (2 CO), 157.82, 142.34, 135.69, 135.53, 130.99, 130.13, 129.21, 126.75, 126.59, 
118.20 (12C, Ar-C), 100.15 (C-1), 82.90 (C(CH3)3), 75.43 (C-5), 72.42 (C-3), 71.97 (C-2), 
68.34 (C-4), 62.66 (C-6), 43.36 (NHCH2), 28.31 ppm (3C, C(CH3)3); HRMS: m/z: Calcd for 
C25H31ClNNaO9 [M+Na]
+: 512.1897, found: 512.1887. 
 
18e: [α]
  
D
20 +93.1 (c 0.87, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.08 (m, 1H, Ar-H), 
7.80-7.76 (m, 2H, Ar-H), 7.62 (d, J = 8.7 Hz, 2H, Ar-H), 7.52 (t, J = 7.8 Hz, 1H, Ar-H), 7.22 
(d, J = 8.7 Hz, 2H, Ar-H), 5.54 (d, J = 1.4 Hz, 1H, H-1), 4.12 (s, 2H, NHCH2), 4.04 (dd, J = 
1.8, 3.3 Hz, 1H, H-2), 3.93 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.80-3.72 (m, 3H, H-4, H-6a, H-
6b), 3.63 ppm (ddd, J = 2.5, 5.1, 9.7 Hz, 1H, H-5); 13C NMR (125 MHz, CD3OD): δ = 173.27 
(CO), 170.59 (CONH), 157.93, 142.44, 135.76, 135.65, 131.09, 130.21, 129.31, 126.88, 
126.73, 118.29 (12C, Ar-C), 100.26 (C-1), 75.53 (C-5), 72.52 (C-3), 72.08 (C-2), 68.44 (C-
4), 62.77 (C-6), 42.40 ppm (NHCH2); HRMS: m/z: Calcd for C21H23NNaO9 [M+Na]
+: 
456.1271, found: 456.1261. 
 
Methyl [4’-(-D-mannopyranosyloxy)-3'-trifluoromethyl-biphenyl-3-carbonyl]-glycinate 
(19a). Prepared according to general procedure B from 19b (20 mg, 0.036 mmol) with 1 M 
MeONa/MeOH (600 L) in MeOH (2 mL). Purified by MPLC on silica gel (DCM/MeOH, 
3:1). Yield: 12 mg (65%) as colorless oil. [α]
  
D
20 +87.3 (c 0.60, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 8.11 (m, 1H, Ar-H), 7.91-7.89 (m, 2H, Ar-H), 7.86 (m, 1H, Ar-H), 7.82 (m, 1H, 
Ar-H), 7.62-7.56 (m, 2H, Ar-H), 5.66 (d, J = 1.3 Hz, 1H, H-1), 4.15 (s, 2H, NHCH2), 4.07 
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(dd, J = 1.8, 3.2 Hz, 1H, H-2), 3.95 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.82-3.71 (m, 6H, H-4, H-
6a, H-6b, CH3), 3.60 ppm (ddd, J = 2.2, 5.6, 9.6 Hz, 1H, H-5); 
13C NMR (125 MHz, 
CD3OD): δ = 171.98 (CH2CO), 170.27 (CONH), 155.26, 141.04, 135.74, 135.21, 133.29, 
131.18, 130.44, 127.55, 126.74, 126.32 (q, J = 5.6 Hz), 120.98, 120.74, 117.82 (13C, 12 Ar-
C, CF3), 100.33 (C-1), 76.09 (C-5), 72.26 (C-3), 71.76 (C-2), 68.14 (C-4), 62.70 (C-6), 52.69 
(OCH3), 42.43 ppm (NHCH2); HRMS: m/z: Calcd for C23H24F3NNaO9 [M+Na]
+: 538.1301, 
found: 538.1288. 
 
tert-Butyl [4’-(-D-mannopyranosyloxy)-3'-trifluoromethyl-biphenyl-3-carbonyl]-
glycinate (19b). Sodium [4’-(-D-mannopyranosyloxy)-3'-trifluoromethyl-biphenyl-3-
carbonyl]-glycinate (20f). Prepared according to general procedure B from 16b (132 mg, 
0.182 mmol) with t-BuOK (64 mg, 0.546 mmol, 3.0 eq) in t-BuOH (20 mL). An additional 
portion of t-BuOK (3.0 eq) was added after 1 h. The crude products were purified by MPLC 
on silica gel (DCM/MeOH, 9:1) to afford 19b (44 mg, 44%) as colorless oil or by MPLC on 
silica gel (DCM/MeOH, 9:1-0:1), after which the intermediate was converted into the sodium 
salt with 0.5 M NaOH (3 mL) and purified by size-exclusion chromatography (P-2 gel, H2O) 
to afford 20f (29 mg, 31%) as a white solid. 
19b: [α]
  
D
20 +83.4 (c 1.10, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.12 (m, 1H, Ar-H), 
7.92-7.89 (m, 2H, Ar-H), 7.86 (br d, J = 7.8 Hz, 1H, Ar-H), 7.82 (br d, J = 8.1 Hz, 1H, Ar-
H), 7.63-7.57 (m, 2H, Ar-H), 5.68 (d, J = 1.1 Hz, 1H, H-1), 4.09 (dd, J = 1.7, 3.2 Hz, 1H, H-
2), 4.06 (s, 2H, NHCH2), 3.97 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.85-3.74 (m, 3H, H-4, H-6a, 
H-6b), 3.62 (ddd, J = 2.2, 5.6, 9.6 Hz, 1H, H-5), 1.52 ppm (s, 9H, C(CH3)3); 
13C NMR (125 
MHz, CD3OD): δ = 170.68, 170.26 (2 CO), 155.22, 140.97, 135.92, 135.18, 133.26, 131.07, 
130.41, 127.51, 126.70, 126.29 (q, J = 5.2 Hz), 125.54 (q, J = 272.7 Hz), 120.83 (q, J = 30.7 
Hz), 117.79 (13C, 12 Ar-C, CF3), 100.29 (C-1), 82.94 (C(CH3)3), 76.07 (C-5), 72.25 (C-3), 
71.75 (C-2), 68.13 (C-4), 62.68 (C-6), 43.37 (NHCH2), 28.30 ppm (3C, C(CH3)3); HRMS: 
m/z: Calcd for C26H30F3NNaO9 [M+Na]
+: 580.1770, found: 580.1763. 
20f: [α]
  
D
20 +45.7 (c 0.97, H2O); 
1H NMR (500 MHz, D2O): δ = 7.71 (m, 2H, Ar-H), 7.55 (m, 
2H, Ar-H), 7.47 (br d, J = 7.9 Hz, 1H, Ar-H), 7.41 (t, J = 7.7 Hz, 1H, Ar-H), 7.24 (d, J = 8.4 
Hz, 1H, Ar-H), 5.61 (d, J = 1.1 Hz, 1H, H-1), 4.14 (dd, J = 1.8, 3.2 Hz, 1H, H-2), 4.02 (dd, J 
= 3.4, 9.7 Hz, 1H, H-3), 3.96 (s, 2H, NHCH2), 3.81-3.76 (m, 3H, H-4, H-6a, H-6b), 3.66 ppm 
(ddd, J = 3.2, 4.6, 9.8 Hz, 1H, H-5); 13C NMR (125 MHz, D2O): δ = 176.64 (CH2CO), 169.46 
(CONH), 152.37, 138.61, 133.65, 132.91, 131.62, 129.76, 129.23, 126.03, 125.12, 124.94, 
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115.77 (13C, Ar-C, CF3), 97.34 (C-1), 73.78 (C-5), 70.31 (C-3), 69.70 (C-2), 66.34 (C-4), 
60.60 (C-6), 43.83 ppm (NHCH2); HRMS: m/z: Calcd for C22H22F3NNaO9 [M+H]
+: 
524.1144, found: 524.1141. 
 
Ethyl 1-[4-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)-3-chlorophenyl]-4-methyl-
1H-pyrrole-3-carboxylate (22). To a solution of 3[21] (400 mg, 0.684 mmol) and 21 (130 
mg, 0.821 mmol, 1.2 eq) in 1,4-dioxane (1.6 mL) were added K3PO4 (314 mg, 1.44 mmol, 
2.1 eq), CuI (6.6 mg, 34.2 mol, 0.05 eq) and trans-1,2-diaminocyclohexane (8.2 L, 0.068 
mmol, 0.1 eq) under argon. The reaction was stirred at 100 °C for 19 h, then the mixture was 
filtered through Celite, concentrated in vacuo and co-evaporated with xylene (10 mL). The 
crude product was dissolved in dry pyridine (5 mL) and Ac2O (260 L, 2.76 mmol, 4.0 eq) 
was added. The mixture was stirred at 60 °C for 2 h, then diluted with EtOAc (50 mL) and 
washed with H2O (3 x 20 mL) and brine (20 mL). The organic layer was dried over Na2SO4, 
concentrated in vacuo and co-evaporated with xylene (2 x 10 mL). The crude compound was 
purified by MPLC on silica gel (petroleum ether/EtOAc, 1:0-0:1) solvent system to give 22 
(366 mg, 88%) as colorless oil. Analytical data are in accordance with literature data.[34] 
 
1-[3-Chloro-4-(-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-carboxylic acid 
(23). A solution of 22 (366 mg, 0.600 mmol) in MeOH (10 mL) was treated with freshly 
prepared 1 M MeONa/MeOH (600 L) at rt for 1.5 h under argon. Then, 2 M aq. NaOH (20 
mL) was added and stirring was continued for 8.5 h. The reaction mixture was acidified with 
an excess of AcOH and concentrated. The crude product was purified by MPLC on RP-18 
(H2O/MeOH, 19:1-1:19) to afford 23 (65 mg, 26%) as a white solid. Analytical data are in 
accordance with literature data.[34] 
 
tert-Butyl (1-[3-chloro-4-(-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-
carbonyl)-glycinate (24b). Prepared according to general procedure D from 23 (18 mg, 
0.043 mmol) and H-Gly-OtBuHCl (15 mg, 0.087 mmol, 2.0 eq) with TEA (34 L, 0.258 
mmol, 6.0 eq) and COMU (37 mg, 0.087 mmol, 2.0 eq) in DMF (2 mL). Purified by 
preparative LC-MS (H2O/MeCN, 19:1-1:19, +0.2% HCOOH). Yield: 10 mg (45%) as 
colorless oil. [α]
  
D
20 +58.9 (c 0.90, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.63 (d, J = 2.4 
Hz, 1H, Ar-H), 7.57 (d, J = 2.7 Hz, 1H, Ar-H), 7.46 (d, J = 8.9 Hz, 1H, Ar-H), 7.39 (dd, J = 
2.7, 8.9 Hz, 1H, Ar-H), 6.97 (m, 1H, Ar-H), 5.55 (d, J = 1.5 Hz, 1H, H-1), 4.11 (dd, J = 1.8, 
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3.3 Hz, 1H, H-2), 3.99-3.96 (m, 3H, H-3, NHCH2), 3.81-3.70 (m, 3H, H-4, H-6a, H-6b), 3.65 
(ddd, J = 2.2, 5.6, 9.7 Hz, 1H, H-5), 2.29 (s, 3H, CH3), 1.49 ppm (s, 9H, C(CH3)3); 
13C NMR 
(125 MHz, CD3OD): δ = 171.17, 168.32 (2 CO), 151.62, 136.57, 125.81, 123.05, 122.78, 
120.83, 120.73, 120.41, 119.39 (10C, Ar-C), 101.09 (C-1), 82.78 (C(CH3)3), 76.07 (C-5), 
72.38 (C-3), 71.81 (C-2), 68.23 (C-4), 62.69 (C-6), 42.81 (NHCH2), 28.32 (3C, C(CH3)3), 
11.73 ppm (CH3); HRMS: m/z: Calcd for C24H31ClN2NaO9 [M+Na]
+: 549.1616, found: 
549.1617. 
 
tert-Butyl (1-[3-chloro-4-(-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-
carboxamido)-propanoate (24c). Prepared according to general procedure D from 23 (25 
mg, 0.060 mmol) and H--Ala-OtBuHCl (23 mg, 0.121 mmol, 2.0 eq) with DIPEA (62 L, 
0.360 mmol, 6.0 eq) and COMU (53 mg, 0.121 mmol, 2.0 eq) in DMF (2 mL). Purified by 
MPLC on silica gel (DCM/MeOH, 9:1) followed by preparative LC-MS (H2O/MeCN, 19:1-
1:19, + 0.2% HCOOH). Yield: 17 mg (52%) as colorless oil. [α]
  
D
20 +69.2 (c 0.85, MeOH); 1H 
NMR (500 MHz, CD3OD): δ = 7.56 (d, J = 2.4 Hz, 1H, Ar-H), 7.55 (d, J = 2.7 Hz, 1H, Ar-
H), 7.45 (d, J = 8.9 Hz, 1H, Ar-H), 7.36 (dd, J = 2.7, 8.9 Hz, 1H, Ar-H), 6.94 (m, 1H, Ar-H), 
5.54 (d, J = 1.5 Hz, 1H, H-1), 4.11 (dd, J = 1.8, 3.2 Hz, 1H, H-2), 3.97 (dd, J = 3.4, 9.5 Hz, 
1H, H-3), 3.81-3.70 (m, 3H, H-4, H-6a, H-6b), 3.64 (ddd, J = 2.2, 5.6, 9.7 Hz, 1H, H-5), 3.55 
(t, J = 6.8 Hz, 2H, NHCH2), 2.54 (t, J = 6.8 Hz, 2H, CH2CO), 2.27 (s, 3H, CH3), 1.46 ppm (s, 
9H, C(CH3)3); 
13C NMR (125 MHz, CD3OD): δ = 173.11 (CH2CO), 168.10 (CONH), 151.57, 
136.56, 125.80, 122.97, 122.79, 122.47, 121.23, 120.64, 120.34, 119.39 (10C, Ar-C), 101.08 
(C-1), 81.93 (C(CH3)3), 76.06 (C-5), 72.37 (C-3), 71.80 (C-2), 68.23 (C-4), 62.68 (C-6), 
36.44 (CH2CO, NHCH2), 28.34 (3C, C(CH3)3), 11.76 ppm (CH3); HRMS: m/z: Calcd for 
C25H33ClN2NaO9 [M+Na]
+: 563.1772, found: 563.1772. 
 
(1-[3-Chloro-4-(-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-carbonyl)-
glycine (25e). Prepared according to general procedure C from 24b (9 mg, 0.017 mmol) with 
1 M aq NaOH (1 mL) in MeOH (1 mL). The mixture was acidified with an excess of AcOH 
(120 L). Purified by preparative LC-MS (H2O/MeCN, 19:1-1:19, + 0.2% HCOOH). Yield: 
5 mg (63%) as colorless oil. [α]
  
D
20 +80.6 (c 0.50, MeOH); 1H NMR (500 MHz, CD3OD): δ = 
7.65 (m, 1H, Ar-H), 7.58 (d, J = 2.7 Hz, 1H, Ar-H), 7.46 (d, J = 8.9 Hz, 1H, Ar-H), 7.39 (dd, 
J = 2.7, 8.9 Hz, 1H, Ar-H), 6.97 (m, 1H, Ar-H), 5.55 (d, J = 1.5 Hz, 1H, H-1), 4.11 (dd, J = 
1.8, 3.3 Hz, 1H, H-2), 4.04 (br s, 2H, NHCH2), 3.98 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.70 
2.3 – Chapter 3 
106 
 
(m, 3H, H-4, H-6a, H-6b), 3.65 (ddd, J = 2.2, 5.6, 9.7 Hz, 1H, H-5), 2.29 ppm (s, 3H, CH3); 
13C NMR (125 MHz, CD3OD): δ = 173.48, 168.24 (2 CO), 151.62, 136.58, 125.81, 123.06, 
122.85, 120.72, 120.39, 119.40 (10C, Ar-C), 101.10 (C-1), 76.07 (C-5), 72.38 (C-3), 71.81 
(C-2), 68.23 (C-4), 62.69 (C-6), 41.49 (NHCH2), 11.74 ppm (CH3); HRMS: m/z: Calcd for 
C20H23ClN2NaO9 [M+Na]
+: 493.0990, found: 493.0990. 
 
(1-[3-Chloro-4-(-D-mannopyranosyloxy)phenyl]-4-methyl-1H-pyrrole-3-
carboxamido)-propanoic acid (25g). Prepared according to general procedure C from 24c 
(9 mg, 0.017 mmol) with 1 M aq NaOH (1 mL) in MeOH (1 mL). The mixture was acidified 
with an excess of AcOH (120 L). Purified by reparative LC-MS (H2O/MeCN, 19:1-1:19, + 
0.2% HCOOH). Yield: 5 mg (63%) as colorless oil. [α]
  
D
20 +84.8 (c 0.50, MeOH); 1H NMR 
(500 MHz, CD3OD): δ = 7.58 (d, J = 2.4 Hz, 1H, Ar-H), 7.56 (d, J = 2.7 Hz, 1H, Ar-H), 7.46 
(d, J = 9.0 Hz, 1H, Ar-H), 7.38 (dd, J = 2.7, 8.9 Hz, 1H, Ar-H), 6.95 (m, 1H, Ar-H), 5.54 (d, 
J = 1.5 Hz, 1H, H-1), 4.11 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 3.97 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 
3.81-3.70 (m, 3H, H-4, H-6a, H-6b), 3.64 (ddd, J = 2.3, 5.6, 9.7 Hz, 1H, H-5), 3.58 (t, J = 6.7 
Hz, 2H, NHCH2), 2.61 (t, J = 6.7 Hz, 2H, CH2CO), 2.28 ppm (s, 3H, CH3); 
13C NMR (125 
MHz, CD3OD): δ = 175.25 (CH2CO), 168.07 (CONH), 151.58, 136.59, 125.80, 122.98, 
122.83, 122.54, 121.21, 120.66, 120.32, 119.39  (10C, Ar-C), 101.10 (C-1), 76.07 (C-5), 
72.38 (C-3), 71.81 (C-2), 68.23 (C-4), 62.69 (C-6), 36.43 (2C, CH2CO, NHCH2), 11.74 ppm 
(CH3); HRMS: m/z: Calcd for C21H25ClN2NaO9 [M+Na]
+: 507.1146, found: 507.1145. 
 
3’-Chloro-N-(2-hydroxyethyl)-4’-(-D-mannopyranosyloxy)biphenyl-3-carboxamide 
(27i). Prepared according to general procedure D from 26[34] (30 mg, 0.073 mmol) and 
ethanolamine (9 L, 0.146 mmol, 2.0 eq) with TEA (31 L, 0.219 mmol, 3.0 eq) and COMU 
(63 mg, 0.146 mmol, 2.0 eq) in DMF (2 mL). Purified by preparative LC-MS (H2O/MeCN, 
19:1-1:19, + 0.2% HCOOH). Yield: 24 mg (73%) as colorless oil. [α]
  
D
20 +77.9 (c 1.20, 
MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.06 (t, J = 1.5 Hz, 1H, Ar-H), 7.81 (m, 1H, Ar-
H), 7.75-7.73 (m, 2H, Ar-H), 7.58 (dd, J = 2.3, 8.6 Hz, 1H, Ar-H), 7.52 (t, J = 7.8 Hz, 1H, 
Ar-H), 7.45 (d, J = 8.6 Hz, 1H, Ar-H), 5.60 (d, J = 1.5 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.3 
Hz, 1H, H-2), 4.01 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 5H, H-4, H-6a, H-6b, 
CH2O), 3.66 (ddd, J = 2.3, 5.3, 9.7 Hz, 1H, H-5), 3.54 ppm (t, J = 5.8 Hz 2H, NHCH2); 
13C 
NMR (125 MHz, CD3OD): δ = 170.29 (CONH), 152.98, 140.92, 136.77, 136.32, 130.75, 
130.24, 129.63, 127.60, 127.35, 126.57, 125.33, 118.66 (12C, Ar-C), 100.76 (C-1), 75.97 (C-
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5), 72.40 (C-3), 71.85 (C-2), 68.22 (C-4), 62.65 (C-6), 61.62 (CH2O), 43.63 ppm (NHCH2); 
HRMS: m/z: Calcd for C21H24ClNNaO8 [M+Na]
+: 476.1088, found: 476.1088. 
 
[3’-Chloro-4’-(-D-mannopyranosyloxy)biphenyl-3-yl](3-hydroxyazetidin-1-
yl)methanone (27j). Prepared according to general procedure D from 26[34] (20 mg, 0.049 
mmol) and 3-hydroxyazetidine hydrochloride (11 mg, 0.098 mmol, 2.0 eq) with TEA (20 L, 
0.147 mmol, 3.0 eq) and COMU (42 mg, 0.098 mmol, 2.0 eq) in DMF (2 mL). Purified by 
preparative LC-MS (H2O/MeCN, 19:1-1:19, + 0.2% HCOOH). Yield: 19 mg (83%) as 
colorless oil. [α]
  
D
20 +74.9 (c 0.95, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.82 (m, 1H, 
Ar-H), 7.73 (m, 1H, Ar-H), 7.68 (d, J = 2.2 Hz, 1H, Ar-H), 7.59 (m, 1H, Ar-H), 7.56-7.51 
(m, 2H, Ar-H), 7.46 (d, J = 7.7 Hz, 1H, Ar-H), 5.60 (d, J = 1.5 Hz, 1H, H-1), 4.63 (tt, J = 1.5 
Hz, 1H, OCH), 4.59 (m, 1H, CH2N), 4.42 (dd, J = 7.2, 10.2 Hz, 1H, CH2N), 4.16 (dd, J = 3.4, 
9.1 Hz, 1H, CH2N), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.02-3.96 (m, 2H, H-3, CH2N), 3.81-
3.71 (m, 3H, H-4, H-6a, H-6b), 3.66 ppm (ddd, J = 2.3, 5.4, 9.7 Hz, 1H, H-5); 13C NMR (125 
MHz, CD3OD): δ = 172.11 (CONH), 153.06, 141.13, 136.63, 134.98, 130.57, 130.29, 
129.60, 127.68, 127.63, 127.07, 125.37, 118.72 (12 C, Ar-C), 100.77 (C-1), 75.99 (C-5), 
72.40 (C-3), 71.84 (C-2), 68.22 (C-4), 64.15 (CH2N), 62.66 (C-6), 62.28 (OCH), 59.77 ppm 
(CH2N); HRMS: m/z: Calcd for C22H24ClNNaO8 [M+Na]
+: 488.1088, found: 488.1088. 
 
3’-Chloro-4’-(-D-mannopyranosyloxy)-N-(pyridine-4-yl)biphenyl-3-carboxamide 
(27k). Prepared according to general procedure D from 26[34] (37 mg, 0.090 mmol) and 4-
aminopyridine (17 mg, 0.180 mmol, 2.0 eq) with TEA (33 L, 0.270 mmol, 3.0 eq) and 
COMU (79 mg, 0.180 mmol, 2.0 eq) in DMF (2 mL). Purified by preparative LC-MS 
(H2O/MeCN, 19:1-1:19, + 0.2% HCOOH). Yield: 24 mg (55%) as colorless oil. [α]
  
D
20 +62.4 
(c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.48 (br s, 2H, Ar-H), 8.16 (m, 1H, Ar-
H), 7.92 (br d, J = 6.2 Hz, 3H, Ar-H), 7.83 (br d, J = 7.9 Hz, 1H, Ar-H), 7.76 (d, J = 2.2 Hz, 
1H, Ar-H), 7.61-7.58 (m, 2H, Ar-H), 7.47 (d, J = 8.6 Hz, 1H, Ar-H), 5.61 (d, J = 1.3 Hz, 1H, 
H-1), 4.13 (dd, J = 1.8, 3.2 Hz, 1H, H-2), 4.01 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.72 (m, 
3H, H-4, H-6a, H-6b), 3.66 ppm (ddd, J = 2.3, 5.4, 9.6 Hz, 1H, H-5); 13C NMR (125 MHz, 
CD3OD): δ = 168.97 (CONH), 153.09, 149.89, 149.21, 141.16, 136.51, 136.09, 131.66, 
130.45, 129.70, 127.92, 127.67, 127.05, 125.39, 118.68, 115.98 (17C, Ar-C), 100.75 (C-1), 
76.00 (C-5), 72.41 (C-3), 71.85 (C-2), 68.23 (C-4), 62.67 ppm (C-6); HRMS: m/z: Calcd for 
C24H24ClN2O7 [M+H]
+: 487.1272, found: 487.1272. 
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3’-Chloro-4’-(-D-mannopyranosyloxy)-N-(pyridine-4-ylmethyl)biphenyl-3-
carboxamide (27l). Prepared according to general procedure D from 26[34] (33 mg, 0.080 
mmol) and 4-(aminomethyl)pyridine (16 L, 0.161 mmol, 2.0 eq) with DIPEA (41 L, 0.240 
mmol, 3.0 eq) and COMU (71 mg, 0.161 mmol, 2.0 eq) in DMF (2 mL). Purified by MPLC 
on silica gel (DCM/MeOH, 9:1) followed by preparative LC-MS (H2O/MeCN, 19:1-1:19, + 
0.2% HCOOH). Yield: 25 mg (63%) as colorless oil. [α]
  
D
20 +71.9 (c 1.01, MeOH); 1H NMR 
(500 MHz, CD3OD): δ = 8.50 (br s, 2H, Ar-H), 8.11 (m, 1H, Ar-H), 7.86 (br d, J = 7.8 Hz, 
1H, Ar-H), 7.78 (br d, J = 8.0 Hz, 1H, Ar-H), 7.74 (d, J = 2.2 Hz, 1H, Ar-H), 7.59-7.54 (m, 
2H, Ar-H), 7.47-7.43 (m, 3H, Ar-H), 5.60 (d, J = 1.4 Hz, 1H, H-1), 4.65 (s, 2H, NHCH2), 
4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.01 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.71 (m, 3H, H-
4, H-6a, H-6b), 3.66 ppm (ddd, J = 2.3, 5.4, 9.7 Hz, 1H, H-5); 13C NMR (125 MHz, 
CD3OD): δ = 170.10 (CONH), 153.04, 151.04, 150.08, 141.10, 136.67, 135.80, 131.11, 
130.40, 129.66, 127.62, 127.42, 126.64, 125.36, 124.02, 118.68 (17C, Ar-C), 100.77 (C-1), 
76.00 (C-5), 72.40 (C-3), 71.85 (C-2), 68.23 (C-4), 62.66 (C-6), 43.56 ppm (NHCH2); 
HRMS: m/z: Calcd for C25H26ClN2O7 [M+H]
+: 501.1429, found: 501.1524. 
 
Competitive cell-free binding assay 
Reagents 
Bacto-Yeast extract, Bacto-Agar, and Bacto-Tryptone were purchased from Becton 
Dickinson (Basel, Switzerland). Isopropyl 1-thio--D-galactopyranoside (IPTG) was obtained 
from Applichem (Darmstadt, Germany). Polymyxin B sulfate, Hepes (4-(2-hydroxyethyl)-
piperazine-1-ethanesulfonic acid), oxalic acid, MgCl2, CaCl2, NaH2PO4, imidazole were from 
Fluka (Buchs, Switzerland). Ampicillin, bovine serum albumin (BSA) and 
ethylenediaminetetraacetic acid (EDTA), amino acids and BME vitamin mix were obtained 
from Sigma (Buchs, Switzerland). n-Heptyl -D-mannopyranoside (28) was synthesized as 
previously described[40]. The biotinylated polyacrylamide (PAA) glycopolymer Man1-
3(Man1-6)Man1-4GlcNAc1-4GlcNAc-PAA-biotin (TM-PAA) containing 20 mol% 
sugar residues and 5 mol% biotin was purchased from Lectinity (Moscow, Russia). MaxiSorp 
96-well microtiter plates were from Nunc (Roskilde, Denmark). 
 
 
Results and discussion 
109 
 
Cloning of FimH-CRD wild type and R98A mutant 
 
FimH-CRD construct linked to the thrombin cleavage site (Th), and a 6His-tag (6His) was 
generated as described previously.[35] The R98A mutantion was inserted by overlap extension 
PCR method[41] using the wild type (wt) encoding plasmid as template. The correctness of the 
construct was confirmed by DNA sequencing (Microsynth, Balgach, Switzerland). The wild 
type and R98A proteins were expressed in the protease-deficient E. coli strain HM 125[42] and 
purified by affinity chromatography on a Ni-NTA column as reported.[35] The purity of the 
proteins was verified by SDS–PAGE analysis, and the amount was determined by HPLC 
using BSA as standard.[43] The exact molecular mass was determined by LC-MS. 
 
Competitive binding assay 
  
To evaluate the affinity of the proteins a competitive binding assay described previously was 
applied.[35] Microtiter plates (F96 MaxiSorp, Nunc) were coated with 100 μL/well of a 10 
μg/mL solution of FimH-CRD in 20 mM HEPES, 150 mM NaCl and 1 mM CaCl2, pH 7.4 
(assay buffer) overnight at 4 °C. The coating solution was discarded and the wells were 
blocked with 150 μL/well of 3% BSA in assay buffer for 2 h at 4 °C. After three washing 
steps with assay buffer (150 μL/well), a serial dilution of the test compound (50 μL/well) in 
assay buffer containing 5% DMSO and streptavidin-peroxidase coupled TM-PAA polymer 
(50 μL/well of a 0.5 μg/mL solution) were added. The plates were incubated for 3 h at 25 °C 
and 350 rpm and then carefully washed four times with 150 μL/well assay buffer. After the 
addition of 100 μL/well of ABTS-substrate, the colorimetric reaction was allowed to develop 
for 4 min, then stopped by the addition of 2% aqueous oxalic acid before the optical density 
(OD) was measured at 415 nm on a microplate-reader (Spectramax 190, Molecular Devices, 
California, USA). The IC50 values of the compounds tested in duplicates were calculated with 
prism software (GraphPad Software, Inc., La Jolla, USA). The IC50 defines the molar 
concentration of the test compound that reduces the maximal specific binding of TM-PAA 
polymer to FimH-CRD by 50%. The relative IC50 (rIC50) is the ratio of the IC50 of the test 
compound to the IC50 of n-heptyl -D-mannopynoside (28). 
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Pharmacokinetic Assays 
Aqueous solubility 
Solubility was determined in a 96-well format using the µSOL Explorer solubility analyzer 
(pIon, version 3.4.0.5). For each compound, measurements were performed in triplicate at pH 
7.4 (for compounds 27k and 27l solubility at pH 3.0 was measured additionally). Six wells of 
a deep well plate, i.e. three wells per pH value, were filled with 300 µL of PRISMA HT 
universal buffer adjusted to pH 3.0 or 7.4 by adding the requested amount of NaOH (0.5 M). 
Aliquots (3 µL) of a compound stock solution (40-100 mM in DMSO) were added and 
thoroughly mixed. The final sample concentration was 0.4-1.0 mM, the residual DMSO 
concentration was 1.0% (v/v) in the buffer solutions. After 15 h, the solutions were filtrated 
(0.2 µm 96-well filter plates) using a vacuum to collect manifold (Whatman Ltd., Maidstone, 
UK) to remove any precipitates. Equal amounts of filtrate and 1-propanol were mixed and 
transferred to a 96-well plate for UV/Vis detection (190 to 500 nm, SpectraMax 190, 
Molecular Devices, Silicon Valley, CA, USA). The amount of material dissolved was 
calculated by comparison with UV/Vis spectra obtained from reference samples, which were 
prepared by dissolving compound stock solution in a 1:1 mixture of buffer and 1-propanol 
(final concentrations 0.067-0.167 mM).  
log D7.4 determination  
The in silico prediction tool ALOGPS[44] was used to estimate the log P values of the 
compounds. Depending on these values, the compounds were classified into three categories: 
hydrophilic compounds (log P below zero), moderately lipophilic compounds (log P between 
zero and one) and lipophilic compounds (log P above one). For each category, two different 
ratios (volume of 1-octanol to volume of buffer) were defined as experimental parameters 
(Table 4).  
 
Table 4. Compound classification based on estimated log P values. 
compound type log P ratios (1-octanol: buffer) 
hydrophilic  < 0 30:140, 40:130 
moderately lipophilic 0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
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Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol were mixed and shaken 
vigorously for 5 min to saturate the phases. The mixture was left until separation of the two 
phases occurred, and the buffer was retrieved. Stock solutions of the test compounds were 
diluted with buffer to a concentration of 1 µM. For each compound, six determinations, i.e. 
three determinations per 1-octanol:buffer ratio, were performed in different wells of a 96-well 
plate. The respective volumes of buffer containing analyte (1 µM) were pipetted to the wells 
and covered by saturated 1-octanol according to the chosen volume ratio. The plate was 
sealed with aluminium foil, shaken (1350 rpm, 25 °C, 2 h) on a Heidoph Titramax 1000 
plate-shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) and 
centrifuged (2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). 
The aqueous phase was transferred to a 96-well plate for analysis by liquid chromatography-
mass spectrometry (LC-MS, see below).  
The log D7.4 coefficients were calculated from the 1-octanol:buffer ratio (o:b), the initial 
concentration of the analyte in buffer (1 µM), and the concentration of the analyte in buffer 
(cB) with Equation 1:  
 
The average of the three log D7.4 values per 1-octanol:buffer ratio was calculated. If the two 
means obtained for a compound did not differ by more than 0.1 units, the results were 
accepted.  
Parallel artificial membrane permeability assay (PAMPA)  
Effective permeability (log Pe) was determined in a 96-well format with the PAMPA 
permeability assay.[38] For each compound, measurements were performed in quadruplicate at 
pH 7.4 (for compounds 27k and 27l permeability at pH 5.0 was measured additionally). For 
this purpose, wells of a deep-well plate were filled with 650 µL System Solution. Samples 
(150 µL) were withdrawn from each well to determine the blank spectra by UV-spectroscopy 
(190 to 500 nm, SpectraMax 190). Then, analyte dissolved in DMSO (10 mM) was added to 
the remaining System Solution to yield 50 µM solutions. To exclude precipitation, the optical 
density was measured at 650 nm, with 0.01 being the threshold value. Solutions exceeding 
this threshold were filtrated. Afterwards, samples (150 µL) were withdrawn to determine the 
reference spectra. Further 200 µL was transferred to each well of the donor plate of the 
PAMPA sandwich (pIon, P/N 110 163). The filter membranes at the bottom of the acceptor 
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plate were infused with 5 µL of GIT-0 Lipid Solution and 200 µL of Acceptor Sink Buffer 
was filled into each acceptor well. The sandwich was assembled, placed in the GutBoxTM, 
and left undisturbed for 16 h. Then, it was disassembled and samples (150 µL) were 
transferred from each donor and acceptor well to UV-plates. Quantification was done by 
UV/Vis-spectroscopy. Effective permeability (log Pe) was calculated from the compound 
flux deduced from the UV/Vis spectra, the filter area, and the initial sample concentration in 
the donor well with the aid of the PAMPA Explorer Software (pIon, version 3.5). 
LC-MS measurements 
Analyses were performed using a 1100/1200 Series HPLC System coupled to a 6410 Triple 
Quadrupole mass detector (Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with 
electrospray ionization. The system was controlled with the Agilent MassHunter Workstation 
Data Acquisition software (version B.01.04). The column used was an Atlantis® T3 C18 
column (2.1 x 50 mm) with a 3 µm-particle size (Waters Corp., Milford, MA, USA). The 
mobile phases (A, water; B, MeCN) contained 0.1% formic acid (v/v) and were delivered at 
0.6 ml/min. The gradient was ramped from 95% A/5% B to 5% A/95% B over 1 min, and 
then hold at 5% A/95% B for 0.1 min. The system was then brought back to 95% A/5% B, 
resulting in a total duration of 4 min. MS parameters such as fragmentor voltage, collision 
energy, polarity were optimized individually for each drug, and the molecular ion was 
followed for each compound in the multiple reaction monitoring mode. The concentrations of 
the analytes were quantified by the Agilent Mass Hunter Quantitative Analysis software 
(version B.01.04 and B.03.01). 
 
Supporting Information 
NMR spectra and HPLC traces to document purity of the test compounds. 
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2.4 Paper 4: 2-C-Branched Mannosides as a Novel Family of FimH 
Antagonists – Synthesis and Biological Evaluation 
 
This chapter describes the exploration of an unoccupied cavity located in the vicinity of the 
carbohydrate recognition domain of FimH with the derivative of n-heptyl -D-mannosides 
bearing various functional equatorial groups introduced in the 2-C position. To reveal a 
thermodynamic fingerprint of new FimH antagonists, ITC experiments with selected 
mannose-modified compounds were performed. 
 
 
 
 
 
Contribution to the project:  
Wojciech Schönemann designed and, together with the master student Marcel Lindegger, 
synthesized all new FimH antagonists reported in this chapter. Furthermore, he was 
responsible for writing of the entire chapter. Dr. Pascal Zihlmann performed ITC 
measurements of selected antagonists. 
 
 
 
 
 
This paper was published in the Perspectives in Science. 
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3. Summary and outlook 
 
The first objective of the present thesis was to optimize physicochemical and 
pharmacokinetic properties of two FimH antagonists by a prodrug approach in order 
to achieve oral bioavailability. The first one was a highly active derivative of the 
biphenyl -D-mannopyranosides containing a carboxylic acid in para-position ( 1) 
of the terminal phenyl ring. Numerous promoieties were introduced masking the polar 
character of carboxylic acid. Since aliphatic esters resulted in too low solubility, 
promoieties functionalized with oxygenated or nitrogenated substituents were studied. 
This led to prodrugs with moderate to high solubility and permeability, undergoing 
quick hydrolysis by esterases upon absorption. 
 
The second prodrug approach started from the methylsulfone bioisostere ( 2) of 
carboxylic acid derivative 3 (Figure 1). This time, promoieties were introduced at the 
C-6 hydroxyl group of the mannose moiety. It could be demonstrated that acylation of 
only one hydroxyl group of the mannose promoiety was sufficient to improve 
lipophilicity and permeability into the required range for good absorption. 
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Figure 1. Chemical structure of FimH antagonists used as a basis for the study of ester prodrug 
derivatives. 
 
In the second part of this thesis new and unexplored regions of the FimH lectin were 
studied with the aim to identify FimH antagonists with further improved affinities. 
First, for establishing a stable interaction with Arg98, a library of compounds with 
elongated substituents attached to the terminal phenyl or pyrrole ring of the biaryl 
aglycone was synthesized. Competitive binding assays with wild type FimH and the 
R98A mutant however, revealed equal affinities for both proteins, indicating that this 
approach failed. Based on additional information, which we plan to obtain from co-
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crystallized representative of this approach with the FimH lectin domain, improved 
antagonists may be designed. 
 
In a second approach, another region of the FimH lectin was explored with the goal to 
identify a new class of antagonists targeting a cavity located in the close proximity to 
the binding pocket. In order to capitalize on additional ligand-lectin contacts, 2-C-
branched -D-mannosides were synthesized. However, no significant improvement in 
affinity was observed. Noteworthy is the fact that the - and β-anomeric 2-C-
hydroxymethyl derivatives had very similar affinities. Also in this case, crystal 
structures would help to understand why promising docking results did not 
materialize in improved affinities for 2-C-branched -D-mannosides. 
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